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ABSTRACT 
 
Spinal cord injury (SCI) is a devastating condition due to the permanent neurological 
deficits it causes, and the abruptness these impairments take place. To date there is no cu-
rative therapy for SCI, therefore finding efficient treatment candidates for clinical translation 
is a compelling need. 
The deficits associated to SCI result from the disruption of the normal anatomy fol-
lowed by a complex cascade of events involving excitotoxicity, ischemia and inflammation. 
This leads to death of neurons, olygodendrocytes and demyelination. Moreover, reactive 
glial cells proliferate in the attempt to restrain the spread of damage, building up a physical 
and molecular barrier – the glial scar. However, the glial scar also represents an obstacle to 
axonal regrowth. Furthermore, in contrast to neurons in the periphery, adult central neurons 
do not normally regenerate due to an intrinsic inability to reactivate the growth machinery.  
With the purpose of promoting regeneration and functional recovery after SCI in 
adult mice, in this work we addressed different but interdependent molecular mechanisms 
to awake the intrinsic growth machinery of central neurons and to modulate the extrinsic 
environment within the injury site.  
Firstly, we performed the first systematic screening comparing epigenetic regulatory 
mechanisms between the PNS and CNS after injury. As a result, we showed that the injury-
driven retrograde signaling controls the activation of the acetyltrasferase PCAF in the dorsal 
root ganglia system. PCAF in turn leads to chromatin remodeling and activation of genes 
associated to nerve regeneration. This successful regenerative response promoted sprout-
ing of dorsal column fibers only when the SCI was preceded by a peripheral branch injury. 
Most importantly, forced expression of PCAF in dorsal root ganglia neurons led to axon 
growth after SCI, mimicking the effects of a preconditioning injury. 
It was already known that PCAF also forms a multiprotein complex with CBP/P300 
and p53, a pleiotropic factor, to drive the transcription of several regeneration associated 
genes. p53 is indeed a key orchestrator of CNS regeneration, playing a pivotal role in acti-
vating the intrinsic regenerative capacity of post-mitotic CNS neurons in addition to modu-
late the extrinsic environment. Thus, our second strategy was to manipulate p53 in order to 
enhance the p53-dependent regenerative response and improve functional recovery. By 
!!iv 
disrupting the p53 interaction with its main negative regulators MDM2 or MDM4, either by 
local Nutlin-3a inhibition or conditional deletion in SMC neurons, respectively, we enhanced 
p53 transactivation. This led in fact to increased sprouting of descending tracts and im-
proved locomotor behavior of adult mice after SCI without increasing cell death. Further-
more, we showed for the first time that these pro-regenerative effects of p53 are dependent 
on IGF1 signaling. 
In the p53 studies, Nutlin-3a, a potent MDM2 inhibitor, was employed as a drug of 
choice. Nutlin-3a is already under scrutiny in clinical trials for cancer therapy and might be 
clinically available in the near future. Therefore this work opens an exciting possibility to 
bring a new candidate for translation in the SCI clinical context. 
!!v 
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SYNOPSIS 
1 Spinal cord injury overview and rationale 
 
Injury to the spinal cord disrupts the descending or ascending pathways of the cen-
tral nervous system, often resulting in different levels of irreversible sensory, motor and/or 
autonomic deficits. These include complete or incomplete tetraplegia or paraplegia, spas-
ticity, anesthesia, paresthesia or dysesthesia; pain syndromes like neuropathic, visceral and 
musculoskeletal pain; urinary, bowel and sexual dysfunction; and life-threatening conditions 
like autonomic dysreflexia. As a result, impairments compromise daily activities and the 
overall quality of life.  
Up to 90% of the spinal cord injury (SCI) cases are traumatic in origin, usually due to 
road traffic accidents and self-harm/violence (WHO and ISCOS, 2013). The World Health 
Organization in collaboration with the International Spinal Cord Society estimated that in 
2011 236 to 4187 per million of people were living with traumatic SCI worldwide, depend-
ing upon the global region that was analyzed (Lee et al., 2014), with approximately 250.000-
500.000 new cases from traumatic and non-traumatic etiology yearly (WHO and ISCOS, 
2013). The majority of patients affected by this condition are young males (18-32 years of 
age in developing or developed countries) (Lee et al., 2014) and otherwise economically 
active people (Figure I). However, as a result of global ageing, there has been an increase in 
the incidence of SCI affecting people with 60 or more years of age, a stronger tendency in 
countries of Western Europe, where the population is older (WHO and ISCOS, 2013; Lee et 
al., 2014); falls are the main cause of SCI in this group, followed by traffic accidents and non-
traumatic causes like neoplasms, degenerative conditions of the spinal column, and vascular 
and autoimmune disorders (WHO and ISCOS, 2013).  
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Figure I. Spinal cord injury by WHO Global Regions from traumatic causes 1959–2011. (Reproduced from 
Lee B et al., page 112, Spinal Cord 2014; 52:110–116.) 
 
 During their lives, patients with SCI usually will have to deal with bladder dysfunction 
and consequently recurrent urinary tract infections, they are more prone to have pneumo-
nia, pulmonary emboli, decubitus ulcers and septicemia (Donovan, 2007). Therefore, the 
loss of working force, the reduction of life expectancy and the treatment of SCI co-
morbidities are not only a personal burden, but also incur in high costs for the society as a 
whole (Cannon, 2013; WHO and ISCOS, 2013).   
In view of the reasons mentioned above, and given that SCI is usually a sudden and 
unexpected condition with extensive disabling consequences, there is a great effort to find 
medical therapies to restore the neurological functions of the affected patients. Although 
the incidence of spinal cord injuries is considered relatively low, the financial burden for the 
long lasting care and rehabilitation of often young patients makes the discovery of strate-
gies that foster the recovery of function in SCI both ethically and financially compelling. This 
may perhaps motivate profit organizations to invest in SCI research to accelerate clinical 
translation.  
  
Asia, East
Li and Ning34,35 provided recent regional incidence data for mainland
China (60.6 TSCI per million population per year in Beijing and 23.7
in Tianjin province). As previously reported,36 land transport
accounted for 49% of TSCI in the Taiwanese population with 65%
of these accidents associated with two-wheeled vehicles.36 Falls,
particularly in Tianjin province, were higher than most developed
countries. Although work-related TSCI was reported only for Tianjin
province (0.8%), this is inaccurate as the proportion of falls that are
work-related are not included in this figure, and the number of falls in
this area is high (57%). It is important that future reports from this
region parse out the number of work-related falls. A high incidence of
TSCI in the aged with high rates of tetraplegia, predominantly due to
low falls, was found in Taiwan.36
Asia, SouthEast
We have previously comment d on high rates of land transport TSCI
in Vietnam and Thailand, in particular motorcycles and other non-
standard transport like jitneys.27,37,38 Contributing f ctors that
increase the risk of accidents include transport of heavy loads,
multiple passengers nd poor road infrastructure.
Recent unpublished data from Vietnam (2010) using ASCoN SCI
sof ware (http://www.iscos.org.uk/page.php?content=20) in s veral
spinal treatment centres, report that falls and land transport
accou ted for more than 75% of TSCI cases. Most falls occurred in
the home (51%) while doing housekeeping and house maintenance.
An addition l 46% of falls occurred in the workplace. Thirty percent
of the falls resulted in tetraplegia. Land transport continued to be the
main cause of TSCI. Motorcyclists account for 70% of the land
transport cases and 32% were complete paraplegic (highest in the
15–24-year age group). Trucks and bicycles each accounted for 10% of
the TSCI cases, violence related 4% and sports 1%. (Unpublished
data: Eric Weerts, Handicap International: ASCoN SCI registry
software).
Australasia
Australia (updated) and New Zealand12,39 have high rates of land
transport TSCI (predominantly from four-wheeled vehicles) and
growing numbers of falls, particularly in the elderly.2 Australia has
high rates of water-related TSCI (9% of all TSCI reported in 2010).
Sixty-three percent of th se injuries were to the cervical spinal
segments caused by diving into a body of water.40 In New Zealand,
as reported previously, rugby was responsible for 8% of their
sports-related injuries.
Europe, Eastern
New Estonian data are combined with regional data for Russia41–43
and show the main causes of TSCI in Estonia and Russia
(Novosibirski and Saint Petersburg) were falls (median 40%) and
land transport (median 25%).
Europe, Western
Reported rates are: Denmark (9.2 per million), Finland (13.8 per
million), France 19.4 per million, Germany 10.7 per million, Greece
33.6 per million, Greenland 26 per million, Iceland 20 per million,
Ireland 13.1 per million, Italy 19 per million, Israel 15.9 per million,
Netherlands 7.5 per million, Norway 26.3 per million, Spain 12.1 per
million, Switzerland 15 per million.2 The median calculated from
these data for the Western Europe region is 16 per million. Median
Figure 1 Spinal cord injury by WHO Global Regions from traumatic causes 1959–2011.
TSCI global epidemiology: update 2011
BB Lee et al
112
Spinal Cord
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2 Pathophysiology of SCI 
 
The neurological deficits associated with SCI result mainly from damage to spinal 
neurons and white matter tracts. This damage occurs in two phases (McDonald and 
Sadowsky, 2002). The primary injury is due to the trauma itself, because mechanical forces 
compress and pull the cord. Blood vessels are severed, axons are distracted and cell mem-
branes are ruptured. Micro-hemorrhages in the gray matter take place within minutes and 
spread out radially and axially. The spinal cord swells and ischemia occurs when swelling 
exceeds the blood pressure (McDonald and Sadowsky, 2002; Norenberg et al., 2004). Neu-
rogenic shock also contributes to the hypoperfusion. The gray matter, due to higher meta-
bolic rates, is particularly sensitive to ischemia. The hypoperfusion reaches the surrounding 
white matter, contributing to the conduction block and, therefore, to the characteristic are-
flexia or hyporeflexia of the spinal shock (Ditunno et al., 2004).  
Edema, ischemia, inflammation and a variety of factors released by ruptured cells 
trigger a secondary injury cascade. Glutamate promotes excitotoxicity by flooding the dam-
aged spinal neurons, axons and astrocytes to overexcite neighboring neurons that in turn let 
in waves of calcium ions. This calcium triggers the production of free radicals that ultimately 
kill healthy neurons and oligodendrocytes. Unsevered neurons therefore undergo demye-
lination, exacerbating the spinal shock (McDonald and Sadowsky, 2002). Nevertheless, cal-
cium is essential to mount a regenerative response, as described later.  
Moreover, within one to three days after the injury, dendrites of spinal neurons re-
tract and many synapses degenerate (Llewellyn-Smith and Weaver, 2001; Ditunno et al., 
2004). Days to weeks after the initial insult, oligodendrocytes also undergo apoptosis, af-
fecting as many as four segments from the trauma site, exacerbating the post-injury demye-
lination (Beattie et al., 2000). Interestingly, the secondary injury is actually responsible for 
most of the pathological changes seen in the human injured spinal cord (Norenberg et al., 
2004). Figure II summarizes the pathophysiological events following SCI. 
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Figure II. Pathophysiology of SCI. The primary and secondary injury mechanisms involve edema, hemorrhage, 
inflammation, apoptosis, necrosis, excitotoxicity, lipid peroxidation, electrolyte imbalance, ischemia/vasospasm, 
and blood vessel occlusion. Oligodendrocytes and neurons die, resulting in axonal demyelination and disruption 
of synaptic transmission. In the subacute and chronic phases, a fluid-filled cavity or cyst forms in the center of the 
cord, with surrounding hypertrophic astrocytes and macrophages. These and other cells secrete extracellular 
matrix and inhibitory molecules, such as chondroitin sulphate proteoglycans (CSPGs), which compose the glial 
scar, resulting in a physical and chemical barrier to regeneration. (Reproduced from Mothe and Tator, page 
3825, J Clin Invest 2012;122:3824–3834.)!!
In humans, following the areflexia/hyporeflexia phase of the spinal shock, that lasts 
for 24 hours after the injury, reflexes commence to return in days 1 to 3 as a result of dener-
vation supersensitivity to neurotransmitters. The early and late phases of hyperreflexia take 
place from 1 to 4 weeks and until 12 months after injury, respectively, as a result of neuronal 
plasticity. If there is significant spared motor descending input, sprouting can lead to func-
tional recovery. If there is minimal sparing, however, growth of segmental reflex inputs 
might instead contribute to spasticity and less voluntary motor recovery (Ditunno et al., 
2004). For the cases in which the neurological deficits are permanent, full restoration of 
science in medicine
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 11   November 2012 3825
Some perimental rat models of SCI reproduce the typical 
pathology of human SCI, i cl di g the extradural compression, 
contusion, and crush models in rats (23). SCI is classified depend-
ing on the time elapsed from the initial injury: acute, within sever-
al days of SCI; subacute, one to two weeks after injury; or chronic, 
four weeks or more after injury. As discussed below, experimental 
cell transplantation strategies have generally been more effective 
in the subacute stage compared with the acute stage or the chronic 
stage, characterized by glial scarring and other inhibitory factors.
General features of cell therapy for SCI
Cell therapy is a promising strategy for SCI, and preclinical mod-
els demonstrate that cell transplantation can ameliorate some 
secondary events thr ugh neuroprotection and also restore lost 
tissue through regeneration. Pioneering work in cell therapy 
bega  in the late 1970s when Aguayo’s group showed hat periph-
eral nerve grafts promoted regeneration of CNS axons (24) and 
Reier’s group showed that grafted fetal spinal cord supported 
regrowth of host axons (25). Since then, numerous experimental 
cell transplantation strategies have produced regeneration and 
partial recovery (2–7). Here, we describe several stem cell–based 
strategies for experimental and clinical SCI, including the use 
of ES cells, mesenchymal stem cells (MSCs) such as BM-derived 
stromal cells (BMSCs), neural stem/progenitor cells (NSPCs), 
and induced pluripotent stem cells (iPSCs) (Figure 2). Trans-
plantation of other cell types, including Schwann cells, olfactory 
ensheathing glia, genetically modified neurotrophin-expressing 
fibroblasts, and activated macrophages, have been the subject of 
other recent reviews (2–4, 7, 8).
Definition and rationale for stem cells
A stem cell, by definition, continuously proliferates and asymmet-
rically divides to self renew and generate daughter cells commit-
ted to differentiation. In contrast, progenitor cells demonstrate a 
limited proliferative capacity and differentiation potential. Several 
mechanisms for recovery have been proposed, depending on the 
cell type, including replacement of oligodendrocytes or neurons, 
remyelination of spared axons, restoration of neuronal circuitry, 
enhanced preservation of host neuronal and glial cells, increased 
expression of neurotrophins/cytokines by transplanted or host 
cells, promotion of angiogenesis, bridging of cysts or cavities, 
reduced inflammation or gliosis, stimulation of endogenous pre-
cursor cells, and creation of a favorable environment for plastic-
ity and axonal regeneration (Figure 3). In most studies, the exact 
mechanisms of i provement were not completely defined.
ES cells
ES cells are pluripotent cells derived from the inner cell mass of 
developing blastocyst embryos that can differentiate into nearly 
all cell types (26). Human ES cells are typically obtained from pre-
implantation or blastocyst-stage embryos created during in vitro 
fertilizatio  procedures and can also be generated by somatic cell 
nuclear transfer or parthenogenetic activation of eggs. Trans-
planted ES cells will form teratomas, and thus, ES cells must be 
predifferentiated prior to grafting. Protocols have been developed 
to differentiate ES cells into neural precursors (27–30) and spe-
cific neuronal (30–32) and glial lineages (33, 34). Predifferentiated 
mouse ES cells transplanted into the injured rat spinal cord dif-
ferentiated into neuro s and glia and showed partial functional 
recovery (35). As noted above, SCI causes extensive demyelination 
and oligodendrocytes re particularly vulnerable to apoptosis. 
ES cells predifferentiated into oligodendrocyte progenitor cells 
(OPCs) remyelinated spared axons and improved recovery when 
transplanted subacutely into the injured rat spinal cord (36, 37).
The advantage of ES cells is that they can be propagated in 
vitro almost indefinitely, since they retain high telomerase activ-
ity. However, it has been difficult to generate high-purity lineage-
Figure 1
Pathophysiology of SCI. The diagram shows a composite of patho-
physiological events occurring after SCI, including the acute (e.g., 
edema and hemorrhage), subacute (e.g., inflammation), and chronic 
(e.g., cavitation) phases. The primary and secondary injury mecha-
nisms involve edema, hemorrhage, inflammation, apoptosis, necrosis, 
excitotoxicity, lipid peroxidation, electrolyte imbalance, ischemia/vaso-
spasm, and blood vessel occlusion. Oligodendrocytes and neurons die, 
resulting in axonal demyelination and disruption of synaptic transmis-
sion. In the subacute and chronic phases, a fluid-filled lentiform-shaped 
cavity or cyst forms in the center of the cord, with surrounding hyper-
trophic astrocytes and macrophages. These and other cells secrete 
extracellular matrix and inhibitory molecules, such as chondroitin sul-
fate proteoglycans (CSPG), which compose the glial scar, resulting in 
a physical and chemical barrier to regeneration.
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functions would not only imply sprouting, but also regeneration of severed axons to rein-
nervate their original or novel targets.  
In contrast to the peripheral nervous system (PNS), however, axons of the central 
nervous system (CNS) have a very limited regenerative response. It was initially thought that 
this inability to mount an efficient regenerative response relied on extrinsic cues pertaining 
to the CNS environment, since ground-breaking work from Aguayo and colleagues 
(Richardson et al., 1980, 1984; Aguayo et al., 1981) demonstrated that axons could grow 
into peripheral nerve grafts bridging the injury site in the spinal cord of rodents. Indeed, a 
robust endogenous regeneration response occurs solely in about 30% of dorsal column 
transected axons 6-24 hours after injury in mice, but the axons fail to grow back to or be-
yond the lesion scar (Kerschensteiner et al., 2005). !
Notwithstanding, experimental blockade of extrinsic inhibitory activities has so far 
failed to achieve the expected axonal regeneration, pointing to an intrinsic inability of neu-
rons to activate a regrowth program (Fournier et al., 2003; Sivasankaran et al., 2004; Zheng 
et al., 2005). Moreover, not all types of neurons are able to grow into peripheral nerve 
grafts, with the cortiscopinal tract (CST) axons showing the greatest refractoriness to exper-
imental interventions (Richardson et al., 1984; Bregman et al., 1989). These extrinsic and 
intrinsic properties of the CNS will be briefly reviewed in order to contextualize the original 
contributions of this work. Even though they were examined separately, they are in fact in-
terdependent, since the transcriptional growth machinery is active in the permissive adult 
PNS, but not in the adult CNS (Lindner et al., 2013). 
 
2.1 THE ROLE OF THE EXTRINSIC ENVIRONMENT IN THE CNS REGENERATIVE FAILURE 
 
In order to restore the blood brain barrier (BBB) and avoid the spread of damage to 
the remaining fragile central nervous system tissue, a glial scar is formed to wall off zones of 
intense inflammation within the injury site (Faulkner et al., 2004). Nevertheless, it also repre-
sents a physical and molecular barrier to axonal regeneration.  
The glial reaction to injury results in the recruitment of microglia, oligodendrocyte 
progenitor cells (OPCs), meningeal cells and astrocytes to the lesion site (Yiu and He, 2006). 
Perivascular fibroblasts deposit fibronectin in the injury site (Zhu et al., 2015), while astro-
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cytes proliferate around this fibronectin-positive epicenter (Camand et al., 2004). These re-
active astrocytes upregulate the production of tenascin, semaphorin 3, ephrin-B2, slit pro-
teins, and CSPGs (Fitch and Silver, 2008). A large fluid-filled cavity or cyst forms in the cen-
ter of the cord, surrounded by a subpial rim containing some preserved axons, many of 
which are demyelinated (Figure II), a scar morphology that is often observed in humans 
(Bunge et al., 1993) and rats (Sroga et al., 2003) after SCI. By contrast, in mice a dense fi-
brotic tissue without cavitation predominates (Sroga et al., 2003).   
Aggrecan, brevican, neurocan, versican, phosphacan and NG2 belong to the CSPG 
class of extracellular matrix molecules. Proteoglycans are upregulated in areas of gliosis fol-
lowing traumatic injuries in the brain and spinal cord. They are typically enhanced in regions 
of BBB breakdown (Fitch and Silver, 1997) and at high concentration in the lesion center 
that gradually diminishes into the penumbra, forming an inhibitory gradient to axonal 
growth (Yiu and He, 2006). The protein tyrosine phosphatase σ (PTPσ) (Shen et al., 2009), 
the phosphatase leukocyte common antigen-related (LAR) (Fisher et al., 2011) and the Nogo 
receptors (NgR) 1 and 3 (Dickendesher et al., 2012) are receptors for the inhibitory glycosyl-
ated side chains of CSPGs. It has been recently shown that PTPσ is implicated in converting 
growth cones into a dystrophic state by stabilizing them within CSPG-rich substrates (Lang 
et al., 2014). Severed axons also interact with NG2+-OPCs at the lesion core, which entrap 
their dystrophic ends, and though counteracting dieback, prevent their elongation (Busch et 
al., 2010). Moreover, there is enhanced CSPGs production within the perineuronal nets, 
which has been implicated in reactive glial changes by denervated target regions distant 
from the lesion site, thus limiting potential plasticity from surviving inputs (Massey et al., 
2006).  
The myelin also contributes to the growth inhibitory environment of the CNS. Dam-
aged axons are initially exposed to various myelin-associated inhibitors from oligodendro-
cytes and myelin debris. These inhibitors include the Nogo member of the reticulon family 
of proteins and its isoforms Nogo-A, -B, -C (Prinjha et al., 2000), the myelin-associated gly-
coprotein (MAG) (McKerracher et al., 1994), the oligodendrocyte-myelin glycoprotein 
(OMgp) (Wang et al., 2002b), the transmembrane semaphorin 4D (Sema4D/CD100) 
(Moreau-Fauvarque et al., 2003) and ephrin B3 (Benson et al., 2005). All the three Nogo 
isoforms have a common 66 amino acid loop (Nogo-66) (Prinjha et al., 2000), which is rec-
ognized by NgR (Fournier et al., 2001), a receptor that is expressed in many types of CNS 
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neurons and can also bind with high affinity to MAG (Liu et al., 2002) and OMgp (Wang et 
al., 2002b). Nogo-A is highly expressed in oligodendrocytes (Huber et al., 2002) and pro-
motes growth cone collapse through the binding of Nogo-66 to NgR1 (Fournier et al., 
2001). NgR1 forms a complex with the trasmembrane proteins LINGO-1 (Mi et al., 2004), 
p75 (Wang et al., 2002a) or TROY (Park et al., 2005), that are present in the growth cone of 
the nerve cell (Schwab, 2010). This triggers the activation of RhoA and ROCK (Niederöst et 
al., 2002), leading to the phosphorylation of cofilin by LIM kinase to destabilize the actin 
cytoskeleton of damaged axons, culminating in growth cone collapse (Hsieh et al., 2006). 
Moreover, Sema4D/CD100 is expressed by oligodendrocytes, can be induced by injury and 
triggers growth cone collapse (Moreau-Fauvarque et al., 2003).  
The inflammatory response may also contribute to the regenerative failure in the 
CNS. Like astrocytes, resident microglia respond rapidly to injury, extending cellular pro-
cesses or migrating toward the lesion site, where they take part in the scar formation 
(Davalos et al., 2005). Within 30 minutes, they form a dense border to seal the lesion and 
avoid the spread of damage (Davalos et al., 2005). Approximately 2 days after the injury, 
blood monocytes migrate into the lesion (Pineau et al., 2010) where they differentiate into 
tissue macrophages (Mawhinney et al., 2012). Both monocyte-derived macrophages and 
fully activated microglia express high levels of CD45, therefore are no longer distinguishable 
and are referred as microglia/macrophages (David and Kroner, 2011).  
The role of microglia/macrophages to the regeneration failure is rather controversial. 
While they act as scavengers, cleaning debris at the injury site, and helping to restrain the 
damage, they also produce pro-inflammatory cytokines, proteases and other factors that are 
cytotoxic (David and Kroner, 2011) and contribute to delayed axonal dieback (Evans et al., 
2014). Different types of macrophage activation may explain this dual modus operandi. The 
“classically” activated or M1 phenotype of macrophages is driven by exposure to interferon-
or tumor necrosis factor-α and display a neurotoxic phenotype (Gordon and Taylor, 2005; 
Kigerl et al., 2009), although in some circumstances (e.g. via zymosan or LPS inflammatory 
induction) it may also enhance axonal regeneration in the lesioned PNS or CNS (Yin et al., 
2003; Boivin et al., 2007). The “alternatively activated” or M2 is induced by interleukins 4 or 
13 and downregulates the expression of pro-inflammatory cytokines, promotes more robust 
neurite outgrowth and stimulates remyelination (Gordon and Taylor, 2005; Miron et al., 
2013). The M1 phenotype predominates after SCI, while M2 markers are only transiently 
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expressed (Kigerl et al., 2009; Gensel and Zhang, 2015). M2 is indeed the phenotype of 
resting microglia in the uninjured CNS (Ponomarev et al., 2007). 
Taken together, the environment of the lesioned spinal cord site is not permissive to 
axonal regeneration. Whilst the severed axon tip struggles to advance a new growth cone, 
myelin-derived inhibitory factors promotes its collapse, CSPGs turn it into a dystrophic state, 
and in the sequence it suffers the attack of M1 macrophages, which were paradoxally sup-
posed to clean the harmful debris in first place (Silver et al., 2015) (Figures II and III). 
!
Figure III. Schematic representation of the injury site following CNS trauma. The lesion cavity expands as 
inflammatory cells interact with the surrounding reactive astrocytes and other reactive glial cells. This intense 
inflammatory response leads to a cascade of secondary damage to axons initially spared from direct trauma, and 
demyelination of adjacent axons. The gradient of inhibitory molecules upregulated in the areas of intense in-
flammation provides an environment that is non-permissive for regeneration, and dystrophic neurons develop 
the classically described sterile end-balls with clubbed endings that are characteristic of abortive attempts at 
regeneration. If experimental interventions render the scar environment more permissive and/or reactivate the 
intrinsic neuronal growth program, axons may eventually sprout or regenerate past the lesion site. (Adapted 
from Fitch MT and Silver J, page 298, Exp Neurol 2008;209:294-301.) !
2.2 NEURONAL INTRINSIC MECHANISMS OF CNS REGENERATION FAILURE 
 
At the beginning of last century, Ramon Y Cajal proposed that injured adult central 
axons were not capable of regeneration. In his own words: “(…) In adult centres, the nerve 
paths are something fixed, ended, immutable. Everything may die, nothing may be regen-
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erated. (…)” (Page 750, Ramón y Cajal, 1928). In fact, after injury to the adult mammalian 
CNS, most of the axons retract from the injury site. In mice, thirty minutes after the SCI, the 
proximal and distal segments of severed dorsal column axons undergo dieback by acute 
axonal degeneration, followed by later (>30 hours) Wallerian degeneration of the distal 
stump (Kerschensteiner et al., 2005). Only the minority of the remaining proximal axonal 
segments are able to sprout, doing so by a millimeter or less, and terminating in dystrophic 
growth cones that halt elongation (Bradke et al., 2012). Today we know that experimental 
interventions are able to awaken the intrinsic growth machinery of adult neurons after CNS 
injury. Even though much progress has been done in unraveling this machinery, especially 
by studying injury models in the PNS, the nervous system in development and of lower in-
vertebrates, there is still lack of information on how signaling pathways are activated or inac-
tivated, and how they interact to promote restoration of the CNS, therefore hindering con-
crete clinical translation. 
In order to mount an effective regenerative response, an injured neuron has to sense 
that the damage has happened, inform its nucleus what and where it has occurred, in turn 
the nucleus has to alter gene transcription to ultimately assemble a new competent growth 
cone and promote axonal elongation toward its original targets. While these events are well 
orchestrated in the PNS, where regeneration does take place, many signaling pathways ap-
pear to be defective in the CNS (Tedeschi, 2012).  
The differences between the PNS and CNS responses to injury have been extensive-
ly studied in the dorsal root ganglia (DRG) system. DRG neurons are pseudo-unipolar cells 
with a peripheral branch bringing in sensory input and a central branch travelling into the 
dorsal columns to relay the sensory information to higher centers. This anatomy provides a 
unique opportunity to track changes to central or peripheral injuries converging in the same 
nucleus. Indeed, injuries to the peripheral but not the central branch are able to trigger a 
regenerative response (Schreyer and Skene, 1991). Of special interest, a previous injury to 
the peripheral branch, the so-called “preconditioning injury”, primes the cell to a regenera-
tive state, consequently improving regeneration after a subsequent peripheral injury, and 
even promoting axonal outgrowth after a central injury (Richardson and Issa, 1984; 
Neumann and Woolf, 1999).  
In the present work, specific intrinsic mechanisms involving gene expression were un-
raveled and experimentally manipulated to achieve axonal outgrowth and functional recov-
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ery after SCI. Briefly, we discovered that the acetylation of lysine 9 of histone H3 (H3K9Ac) 
by a specific histone acetyltransferase (HAT), the P300/CBP-associated factor (PCAF), drives 
the expression of regeneration associated genes (RAGs) after PNS injury. RAGs are genes 
differentially induced between the regenerating PNS and the non-regenerating CNS, whose 
protein products include transcription factors such as c-JUN, CREB, STAT3, ATF3, RAR, 
and p53; cytoskeleton and growth cone associated proteins such as α-tubulin, Coronin 1b 
and Rab13, MAP-1, GAP-43, CAP-23; cell adhesion molecules like NCAM, L1CAM, and 
TAG1; cytokines and extracellular matrix components, including SNAP-25, CPG15/neuritin, 
Galectin-1, Galanin and SPRR1; and the neurotrophin brain-derived neurotrophic factor 
(BDNF) (Di Giovanni, 2009).  More importantly, forcing the expression of PCAF in DRG neu-
rons promoted growth of dorsal column axons after SCI, mimicking a preconditioning injury 
(Puttagunta and Tedeschi et al., 2014). Our work provided the first systematic screening 
comparing epigenetic regulatory mechanisms between the PNS and CNS after injury. 
Moreover, we showed that the retrograde signaling is implicated in the modulation of the 
chromatin landscape following injury. 
In another set of experiments aiming to promote functional recovery following SCI, 
we released the transcription factor p53 of its constitutively inhibition by the ubiquitin ligas-
es mouse double minute 2 and 4 (MDM2 and MDM4). For the first time, we demonstrated 
that enhancing p53 transactivation leads to sprouting of serotoninergic (5-HT) and cortico-
spinal fibers and functional recovery in mice. Furthermore, we provided a novel mechanistic 
insight on CNS regeneration, by showing that these pro-regenerative p53 effects depend 
upon the insulin-like growth factor 1 receptor (IGF-1R) signaling (Joshi and Sória et al., 
2015).  
Next, I will summarize the main events known so far to prompt an intrinsic regenera-
tive response in injured neurons, focusing on the mechanisms that I contributed to discover-
ing. 
 
2.2.1 How does the cell body sense the injury?  
 
Axotomy provokes depolarization of the cell membrane that is sufficient to activate 
voltage-gated calcium channels, leading to calcium influx in the neuron and propagation of 
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the response to the soma via activation of voltage-dependent sodium channels. The spiking 
activity causes a sodium load, activation of transient calcium currents, and inversion of the 
sodium–calcium exchanger, providing an additional mean of entry for calcium (Mandolesi et 
al., 2004). The calcium current propagates along the axon reaching the cell body, therefore 
constituting rapid retrograde signaling (Rishal and Fainzilber, 2010), and is essential to seal 
the cut axonal membrane (Spira et al., 1993), to drive cytoskeletal changes necessary for the 
formation of a new growth cone (Ziv and Spira, 1997; Spira et al., 2003), to activate the 
long-range retrograde molecular signaling (Perlson et al., 2005) and local protein translation 
(Yudin et al., 2008).  
The successful assembly of a new growth cone is crucial to drive axonal regenera-
tion. In fact, severed CNS axons are only able to produce retraction bulbs, which are dys-
trophic growth cones, pointing to an intrinsic regenerative failure already in the initial steps 
(Bradke et al., 2012). This is probably a result of the characteristic microtubule depolymeri-
zation that occurs at the CNS-injured axonal stump and consequently impairs the advance-
ment of the growth cone (Ertürk et al., 2007). 
The fast signaling calcium wave leads to export of histone deacetylase 5 (HDAC5) 
from the nucleus in a protein kinase Cµ dependent matter (Cho et al., 2013). Nuclear export 
of HDAC5 increases acetylation of histones to help in the activation of a pro-regenerative 
gene expression program. Moreover, it seems to prime the neuronal cell body to receive a 
second slower signaling wave of information, that rely on retrograde transport of molecular 
motors along the axon microtubules (Cho et al., 2013; Doron-Mandel et al., 2015). In the 
uninjured neuron, neurotrophic factors are constantly retrograde transported (Bronfman et 
al., 2007), and the drastic reduction in the amount of these factors arriving to the soma after 
axonal injury may inform the cell body about the damage (Rishal and Fainzilber, 2010).  
 Active retrograde transported is mediated by the dynein complex from plus to mi-
nus ends of microtubules (Cosker et al., 2008). Importin  and  are major components of 
the nuclear import complex. Some of the local signals produced at the injury site contain a 
nuclear localization signal (NLS). NLS-bearing proteins are bound to importin α/β heterodi-
mers and the complex is attached to dynein to be transported to the nucleus (Yudin et al., 
2008). One such cargo is the type III intermediate filament vimentin, which is locally trans-
lated after injury, and cleaved by the calcium-activated protease calpain. The vimentin pro-
teolysis products bind to both phosphorylated extracellular-signal-regulated kinases (pErks) 
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and importin 1, therefore linking pErks to the dynein retrograde motor (Perlson et al., 
2005). Other cargo involved in alerting the soma to initiate a regeneration response include 
the c-Jun N-terminal kinase (JNK)-Sunday Driver (Syd) complex (Cavalli et al., 2005).  
Once these signals arrive at the soma, they need to reach the nucleus to alter gene 
transcription. However, accessibility to gene promoters additionally requires chromatin re-
modeling to be in a more relaxed state.  
 
2.2.2 How the epigenetic landscape influences the growth machinery? The role of PCAF. 
  
 Epigenetic modifications initiate the regulatory changes to drive or repress transcrip-
tion depending on the environmental context. They are essential during embryological de-
velopment, when strict temporal and spatial regulation of gene expression is required 
(Lindner et al., 2013). Furthermore, it has been shown that chromatin modifications play a 
fundamental role in adult neurogenesis, cognition, vision, learning and memory, neuro-
degenerative and psychiatric disorders (Feng and Fan, 2009; Day and Sweatt, 2010; Ma et 
al., 2010). More recent experimental data suggest that epigenetic modifications regulate 
axonal outgrowth and regeneration in post-mitotic adult CNS neurons (Gaub et al., 2010, 
2011; Iskandar et al., 2010; Trakhtenberg and Goldberg, 2012; Cho et al., 2013; Cho and 
Cavalli, 2014).  
 The classical components of the epigenome include DNA methylation and histone 
post-translational modifications (PTMs). DNA methylation is mediated by DNA methyltrans-
ferase enzymes, which catalyze the covalent binding of the methyl group to the C5 position 
of the cytosine residue of CpG dinucleotides (Feng and Fan, 2009). The canonical methylat-
ed CpG (5mCgG) serves as an attachment site for members of the family of methylated 
CpG binding domain (MBD) proteins. The binding of MBD proteins to methylated DNA 
sites in gene promoters leads to the recruitment of histone-modifying enzymes, deacetyla-
tion of histone protein tails, and chromatin condensation around the gene promoter result-
ing in transcriptional repression (Sharma et al., 2005). On the other hand, histone PTMs are 
mostly regulated by histone acetyltransferases (HATs), histone deacetylases (HDACs), his-
tone methyltransferases, and histone lysine demethylases, which form large multiprotein 
complexes in the proximity of gene regulatory regions (Yang and Seto, 2007).  
  Sória MG !
!- 13 - 
Specific combinations of acetylated and methylated sites (i.e. the “histone code”) 
are associated with “open” or “closed” chromatin formations. This “code” mediates pro-
tein-protein interactions contributing to short- and long-term regulation of transcription, 
representing a specific form of cellular memory (Sharma et al., 2005). Transcriptionally active 
chromatin predominates in early embryogenesis and in the growth-active developing nerv-
ous system (Reik, 2007), whereas global DNA methylation levels are higher in the adult brain 
than in comparison to other tissues (Goto et al., 1994). 
Acetylated histone H3 at lysine residues 9, 14, 18 and 27 (H3K9/14/18/27 ac) and 
acetylated H4 are often associated to active promoter regions and close to transcription 
start sites. Moreover, not only does histone acetylation imply a more relaxed chromatin 
state at gene promoters, but also so does methylation of histone H3-K4 and K36 
(Kouzarides, 2007). The acetylation of lysines is highly dynamic and regulated by the oppos-
ing action of histone acetyltransferases (HATs) and histone deacetylases (HDACs) (Bannister 
and Kouzarides, 2011). Type A members compose the largest family of HATs, they are nu-
clear enzymes usually found in multiprotein complexes and can be classified in three cate-
gories: GCN5-related N-acetyltransferases (GNATs), MYST, and CREB-binding protein 
(CBP)/P300 families (Hodawadekar and Marmorstein, 2007; Bannister and Kouzarides, 
2011). Of these, well characterized are PCAF, which belongs to the GNATs family, and the 
complex CBP/P300. PCAF acetylates the core histones H3 at lysines 9, 14 and 18, and H4, 
whereby it is the primary HAT for H3K9. Its transcriptional activation repertoire also includes 
acetylation of transcription factors as a co-activator (Jin et al., 2011). 
 In Puttagunta and Tedeschi et al. (2014), we sought to find an epigenetic “orches-
trator of gene regulation” linking the retrograde signaling to the transcription of RAGs. For 
that, we performed equidistant PNS and CNS injuries in mice, respectively by sciatic nerve 
crush (SNA) and dorsal column axotomy (DCA), and submitted L4-L6 DRG from both condi-
tions to DNA methylation arrays and screening of histone modifications at the proximal 
promoters of RAGs by quantitative chromatin immunoprecipitation (ChiP) assays.  
We found no differences in DNA methylation of RAGs between SNA and DCA, thus 
promoter and CGI DNA methylation are probably not essential to the differential regenera-
tive response between the PNS and CNS. Of the histone modifications related to activation 
of gene transcription (H3K9ac, H3K18ac and H3K4me2) or gene repression (H3K9me2 and 
H3K27me3) (Wang et al., 2008), only H3K9ac and H3K9me2 were differentially enriched at 
  Sória MG !
!- 14 - 
the promoters of the specific upregulated RAGs GAP-43, Galanin and BDNF following 1-7 
days after SNA in the mouse. Moreover, PCAF was also enriched at these promoters, which 
is with H3K9ac usually found in the proximity of transcription start sites of active transcribing 
genes (Wang et al., 2008). Conversely, H3K9me2 was reduced at the same promoters after 
SNA, but increased after DCA. Furthermore, the nuclear expression of H3K9ac and PCAF 
was increased in SNA in comparison to DCA (Figure 3, Puttagunta and Tedeschi et al., 
2014, reproduced below as Figure IV). Taken together, these histones modifications portray 
an active expression state of specific essential upregulated RAGs after SNA, whilst a repres-
sive state is depicted after DCA (Figure 1a,b,c; Puttagunta and Tedeschi et al., 2014).  
 
!
Figure IV. Increased nuclear PCAF and H3K9ac following SNA but not DCA. (a) IHC co-staining with PCAF 
and H3K9ac of L4-L6 DRG following Sham/SNA or Sham/DCA. Insert shows high nuclear expression of PCAF 
and H3K9ac after SNA. Scale bar, 50 µm. (b) IHC intensity density analysis reveals an increase in nuclear PCAF 
following SNA/Sham but not DCA/Sham. (c) Intensity density analysis of IHC stained with H3K9ac reveals a sig-
nificant fold increase following SNA but not DCA when compared with respective Sham. Student’s t-test, error 
bars, s.e., *P<0.05, ***P<0.001, N = 3 per group, performed in triplicate. (Reproduced from Puttagunta and 
Tedeschi et al., page 5, Nat Commun 2014;5:3527.) 
 
To address how the activation of PCAF might occur after PNS injury, we postulated 
that retrograde signaling could be implicated. For that, we exposed adult primary DRG neu-
(AAV, Supplementary Fig. 6a–c) could also drive neurite
outgrowth. Indeed, neurite outgrowth increased on laminin and
myelin by PCAF overexpression in DRG (Fig. 5a,b) as well as
another CNS primary culture, cerebellar granule neurones (CGN,
Supplementary Fig. 7a). In CGN (employed for its ease of culture
and greater cell numbe fo use in immun bloting, ChIP nd
transfections for luciferase assays) there was a significant decrease
in H3K9ac when plated on myelin (Supplementary Fig. 7b,c) and
a reduction of H3K9ac at select promoters, which was reverted to
permissive levels with overexpression of PCAF (Supplementary
Fig. 7d). Likewise, PCAF overexpression reversed myelin
repression of select genes in DRGs (Fig. 5c). Furthermore, the
drug Garcinol (5 mM), which inhibits PCAF acetyltransferase
activity29, reduced neurite outgrowth in DRG (Fig. 5d,e)
and CGN (Supplementary Fig. 7e,f), decreased the luciferase
expression of a GAP-43 promoter luciferase construct in CGN
(Supplementary Fig. 7g) and decreased select gene expression
in DRG (Fig. 5f). In ex vivo experiments, the inhibition of
PCAF activity by Garcinol was able to significantly limit neurite
outgrowth on both laminin and myelin as well as repress H3K9ac
induced by SNA (Fig. 5g–i). Correspondingly, PCAF! /! mice
provided full abolishment of neurite outgrowth induced by SNA
in ex vivo cultured DRG neurones (Fig. 5j,k). Additionally,
SNA-dependent neurite outgrowth in ex vivo cultured DRG
neurones was blocked by ERK inhibition via delivery of PD at the
nerve stump (Fig. 6a–c), phenocopying PCAF loss of function
experiments.
Thus far our data suggest that PCAF is integral to the signalling
involved following PNS injury leading to regeneration by altering
the epigenetic landscape and stimulating intrinsic competence
through crucial gene expression. To validate these observations
in vivo, we studied regeneration of ascending sensory fibres
following a preconditioning lesion (SNA 7 days before DCA) in
the absence of PCAF and found that PCAF is required for
regeneration induced by a conditioning lesion and for the
expression of GAP-43, Galanin and BDNF in DRG (Fig. 7a–g).
Importantly, axonal tracing in SCI experiments in a cohort of
PCAF-/- mice and strain-matched controls showed that PCAF-/-
mice did not display any abnormalities or overt phenotype in
axonal tracing or r garding the lesion site (Fig. 7a).
Next, we wondered whether PCAF overexpression alone would
mimic regeneration induced by a conditioning lesion and
enhance regeneration of ascending sensory fibres in the spinal
cord following dorsal column lesion. Indeed, similar to that
previously reported for a preconditioning lesion7,30, PCAF
overexpression (Supplementary Fig. 8) significantly increased
the number of regenerating fibres across the lesion and up to a
distance of 1mm rostral of the lesion site (Fig. 8a–c and
Supplementary Fig. 9). Important to note, the depth of the lesion
(Supplementary Fig. 10) and lack of tracing rostral to the lesion
site (Supplementary Fig. 11) allowed excluding the presence
of spared fibres. Furthermore, the introduction of the AAV
directly into the sciatic nerve is in and of itself a PNS injury
that does induce minimal sprouting towards the lesion in the
GFP control.
Discussion
Our work demonstrates that PCAF is required for conditioning-
dependent spinal regeneration and that PCAF overexpression
alone is able to promote regeneration of sensory fibres across the
injured spinal cord and beyond similarly to previously established
conditioning paradigms. Furthermore, PCAF-induced regenera-
tion correlated with a significant increase in the expression of
H3K9ac, GAP-43, Galanin and BDNF in the L4-L6 DRG. The
definition of regeneration-associated genes (RAGs) is genes
differentially induced between the regenerating PNS and non-
regenerating CNS systems; however, this does not validate the
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ronal cultures to nerve growth factor (NGF) or to NGF together with PD98059 (PD), the Erk 
kinase (MEK) inhibitor. NGF is a neurotrophin that is induced after sciatic nerve injury (Rush, 
1995); it activates the Erk signaling and promotes neurite outgrowth (Averill et al., 2001); 
and induces PCAF nuclear localization and activation of its acetyltransferase activity in PC12 
cells (Wong et al., 2004). NGF increased the expression of pErk, nuclear PCAF and H3K9ac, 
while PD abrogated their induction. Similar results were obtained in vivo, with SNA promot-
ing an Erk-activation-dependent raise in pErk expression, acetylation of H3K9, and PCAF 
nuclear translocation in DRG neurons. Inhibition of Erk activation also led to decrease in 
gene expression of GAP-43, Galanin and BDNF as well as reduced PCAF and H3K9ac pro-
moter occupancy for these genes (Figure 4, Puttagunta and Tedeschi et al., 2014, 
reproduced below as Figure V).  
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Figure V. ERK retrograde signalling controls PCAF activation. (a,b) NGF stimulates pERK, PCAF and H3K9ac 
expressions in adult DRG cultures after 3-h treatment, which is abrogated by the ERK kinase inhibitor PD98059 
(PD), ICC (a) and fold change analysis of intensity density (b). Scale bar, 20 mm, N = 3 per group, performed in 
triplicate. (c,d) Nuclear PCAF immunoprecipitation from in vivo L4-L6 DRG 24 h following Sham or SNA reveals 
an increase in PCAF expression and threonine phosphorylation following SNA but not serine phosphorylation, 
immunoblot (c) and fold change of density analysis (d). N = 5 per group, performed in triplicate. (e–i) In L4-L6 
DRG, 24 h following SNA we observe an increase in pERK (e,f), PCAF (g,h) and H3K9ac (g,i) expression, which is 
significantly decreased by ERK inhibition with PD at the nerve stump. Insert shows high nuclear expression of 
PCAF and H3K9ac after SNA. Scale bars, 75 µm, N = 3 per group, performed in triplicate. (j–l) PD also inhibits 
gene expression (Q-PCR, N = 3 per group) (j) as well as H3K9ac (k) and PCAF (l) at the promoters of GAP-43, 
Galanin and BDNF 24 h following SNA (ChIPs). N = 6 per group, performed in triplicate. Error bars, s.e. (b,f,h,i), 
P<0.0001, ANOVA, Bonferroni post hoc tests, **P<0.001 and ***P<0.001, (d,j–l) Student’s t-test, *P<0.05, 
**P<0.001 and ***P<0.001. Original immunoblot images are shown in Supplementary Fig. 12. (Reproduced from 
Puttagunta and Tedeschi et al., page 6, Nat Commun 2014;5:3527.) 
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Figure 4 | ERK retrograde signalling controls PCAF activation. (a,b) NGF stimulates pERK, PCAF and H3K9ac expressions in adult DRG cultures
after 3-h treatment, which is abrogated by the ERK kinase inhibitor PD98059 (PD), ICC (a) and fold change analysis of intensity density (b).
Scale bar, 20mm, N¼ 3 per group, performed in triplicate. (c,d) Nuclear PCAF immunoprecipitation from in vivo L4-L6 DRG 24 h following Sham
or SNA reveals an increase in PCAF expression and threonine phosphorylation following SNA but not serine phosphorylation, immunoblot (c) and
fold change of density analysis (d). N¼ 5 per group, performed in triplicate. (e–i) In L4-L6 DRG, 24 h following SNA we observe an increase in pERK (e,f),
PCAF (g,h) and H3K9ac (g,i) expression, which is significantly decreased by ERK inhibition with PD at the nerve stump. Insert shows high nuclear
expression of PCAF and H3K9ac after SNA. Scale bars, 75mm, N¼ 3 per group, performed in triplicate. (j–l) PD also inhibits gene expression (Q-PCR,
N¼ 3 per group) (j) as well as H3K9ac (k) and PCAF (l) at the promoters of GAP-43, Galanin and BDNF 24h following SNA (ChIPs). N¼6 per group,
performed in triplicate. Error bars, s.e. (b,f,h,i) Po0.0001, ANOVA, Bonferroni post hoc tests, **Po0.001 and ***Po0.001, (d,j–l) Student’s t-test,
*Po0.05, **Po0.001 and ***Po0.001. Original immunoblot images are shown in Supplementary Fig. 12.
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Interestingly, a preconditioning injury (i.e. SNA 7 days before DCA) led to an in-
crease in GAP-43, Galanin and BDNF expression and promoter occupancy by PCAF in the 
L4-L6 DRG 24 hours after DCA (Figure 1d,e, Puttagunta and Tedeschi et al., 2014). This ob-
servation motivated us to test whether PCAF overexpression in DRG could mimic the pre-
conditioning injury. Indeed, PCAF overexpression increased neurite outgrowth in permissive 
and non-permissive substrates (Figure 5, Puttagunta and Tedeschi et al., 2014). In ex vivo 
experiments, pharmacological inhibition of PCAF and PCAF-/- repressed H3K9ac and abol-
ished neurite outgrowth following SNA, respectively, and inhibition of Erk phenocopied the 
loss of PCAF (Figures 5 and 6, Puttagunta and Tedeschi et al., 2014). In the in vivo setting, 
preconditioning-injured PCAF-/- mice showed reduced sprouting of dorsal columns after 
DCA in a way that they resembled non-conditioned wild-type mice, and reduced expression 
of GAP-43, Galanin and BDNF in DRG following SCI (Figure 7, Puttagunta and Tedeschi et 
al., reproduced below as Figure VI). Strikingly, overexpression of PCAF in the DRG of wild 
type mice enhanced regeneration of the dorsal columns across and up to 1 mm rostral to 
the DCA site mimicking the enhancement of the growth potential following a precondition-
ing injury (Figure 8, Puttagunta and Tedeschi et al., 2014, reproduced below as Figure VII). 
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Figure VI. PCAF is required for conditioning-dependent axonal regrowth after SCI. (a) MicroRuby tracing of 
the dorsal columns shows regenerating fibres invading into and past the lesion site (upper) in WT but not in 
PCAF-/- (lower) after conditioning injury (SNA followed by DCA; left panels). The red dotted lines indicate the 
lesion site. Insets (1 and 2) show higher magnification of regenerating axons. D-R-C-V: anatomical coordinates, 
dorsal-rostral-caudal-ventral. Right panels show the lesion site. Arrows indicate axonal sprouts. Scale bar, 100 
µm. (b) Amira 3D reconstruction of regenerating dorsal column axons and glial scar in a sagittal projection (~25 
µm) of the lesion site from WT and PCAF-/- mice. (c) Quantification of regenerating axons, N = 6 (WT), N = 6 
(PCAF-/-), Welch’s t-test, *P<0.05 and ***P<0.001. (d,e) Lack of CNS regeneration correlates with a significant 
decrease in H3K9ac expression in L4-L6 PCAF-/- traced DRG neurons when compared with WT, IHC (d), bar 
graphs (e). Inset shows high nuclear expression of H3K9ac in WT but not PCAF-/- traced DRG neurons. Student’s 
t-test, error bars, s.e., ***P<0.001, N = 6, performed in triplicate. (f,g) IHC and 3,3’-Diaminobenzidine (DAB) 
intensity analysis of L4-6 DRG neurons shows a decrease in GAP-43, BDNF and Galanin expression in PCAF-/- 
DRG neurons when compared with WT after SNA followed by SCI. Scale bar, 25 µm. Student’s t-test, 
***P<0.001, N = 4 per group, performed in triplicate. (Reproduced from Puttagunta and Tedeschi et al., page 9, 
Nat Commun 2014;5:3527.) 
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Figure VII. PCAF overexpression induces spinal axonal regeneration. (a) MicroRuby tracing of the dorsal 
columns shows regenerating fibres invading into and past the lesion site after AAV-PCAF overexpression (upper 
right) versus a control AAV-GFP virus (upper left). Insets show higher magnification of regenerating axons. D-R-C-
V: anatomical coordinates, dorsal-rostral-caudal-ventral. cc: central canal. Scale bar, 250 µm. (b) Quantification of 
regenerating axons, N = 9 (AAV-GFP), N = 7 (AAV-PCAF). (c) Quantification of longest regenerating axon per 
animal. (d–f) Overexpression of AAV-PCAF in the SCI study promotes H3K9ac (8 weeks post infection; arrow-
heads) as shown by IHC (d). Nuclear intensity density analysis of H3K9ac (e) and PCAF (f) show enhanced PCAF 
and H3K9ac after PCAF overexpression. (g,h) GAP-43, Galanin and BDNF IHC analysis of corresponding L4-L6 
DRG from infected AAV-PCAF and AAV-GFP animals show an increase in GAP-43, Galanin and BDNF expres-
sion, IHC (g) and DAB intensity analysis (h). Scale bars, 25 µm. Error bars, s.e., (b) Welch’s t-test, *P<0.05, 
**P<0.01 and ***P<0.001. (c,h) P<0.0001, ANOVA, Bonferroni post hoc tests, **P<0.01 and ***P<0.001, (e,f) 
Student’s t-test, ***P<0.001, N = 3, performed in triplicate. (Reproduced from Puttagunta and Tedeschi et al., 
page 10, Nat Commun 2014;5:3527.) 
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Figure 8 | PCAF overexpression induces spinal axonal regeneration. (a) MicroRuby tracing of the dorsal columns shows regenerating fibres invading
into and past the lesion site after AAV-PCAF verexpression (u per right) versus a control AAV-GFP virus (upper left). Insets show higher magnification
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In conclusion, we discovered that PCAF is an essential “orchestrator of gene expres-
sion” after PNS injury, linking the Erk dependent retrograde signaling to expression of spe-
cific RAGs (GAP-43, Galanin and BDNF) via changes in the chromatin landscape (acetylation 
of H3K9). Moreover, we showed that PCAF is essential for the activation of the CNS regen-
eration program following a preconditioning injury, therefore providing a potential mecha-
nism to be explored in SCI translational medicine.  
In Puttagunta and Tedeschi et al. (2014), I performed several surgical procedures 
(SNA and DCA), including applying PD or vehicle onto sciatic nerves. Moreover, I worked on 
the fixation and frozen-sectioning of DRG; performed and developed several protocols for 
DRG staining: fluorescent immunohistochemistry for PCAF, H3K9ac, pErk 1/2 and Tuj1 (Fig-
ures 3a, 4e,g and 8d,g); and DAB staining for GAP-43, BDNF and Galanin (Figures 7f and 
8d,g).  
Furthermore, I created a method to specifically quantify the nuclear intensity density 
(ID) of H3K9ac, PCAF and pErk in DRG-stained sections. For that, photomicrographs were 
taken with an Axio Imager.Z1/ Apotome (Zeiss) microscope as 0,800 mm Z-stacks at x40 
magnification and processed with the software AxioVision (Zeiss). In order to determine the 
nuclear ID of pixels, Image J (Fiji) was used. First of all, the Z-stack that contained the high-
est intensity of pixels was chosen for analysis. After that, each neuronal nuclear area was 
selected in the DAPI channel (about 25 nuclei/picture). The same selection was then used to 
delineate the nuclei in the other channels. The threshold of the nuclear area was set for each 
different channel, and based on that the pixel ID of the nucleus was determined and divided 
by its nuclear area. Triplicates of each treatment were analyzed. The respective quantifica-
tions are shown in bar graphs of Figures 3b,c, 4f,h,i and 8e,f.  
Moreover, I worked in all steps of on the NGF/PD in vitro assay, including DRG cul-
tures, NGF or NGF+PD administration, fixation, fluorescent immunocytochemistry for PCAF, 
H3K9ac and pErk and respective intensity density quantifications (Figure 4a,b). Finally, I ac-
quired and arranged the representative pictures of my experiments that were published in 
Figures 3, 4, 7 and 8 of Puttagunta et al. (2014).  
Having demonstrated how the chromatin environment has to be prepared to allow 
gene expression in the injured neuron, and knowing that histone modifiers like PCAF and 
CBP/P300 work in multiprotein complexes, I will next explore some of the other players in 
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transcriptional complexes that are necessary to activate the intrinsic neuronal regenerative 
capacity, focusing on the transcription factor p53.  
 
2.2.3 How transcription factors drive the regenerative response? Letting p53 work. 
 
During development, the axons of nervous cells elongate for long distances thanks 
to an active growth program related to gene transcription, that couple cytoskeletal changes 
to extrinsic cues. Once these cells reach their post-synaptic partners, however, the growth 
cone differentiates into a pre-synaptic terminal and the growth program is switched off 
(Caroni and Becker, 1992). Accordingly, through developmental stages of the CNS, there is 
a gradual decline in the expression of factors that promote axon growth, such as the B-cell 
CLL/lymphoma 2 (Bcl-2) (Chen et al., 1997) and the mammalian target of rapamycin (mTOR) 
(Park et al., 2008; Liu et al., 2010), while growth repressive factors like the Kruppel-like fac-
tors (KLFs) 4 and 9 increase (Moore et al., 2009), highlighting the loss of regenerating capac-
ity of the CNS.  
In the injured adult PNS, an intrinsic successful regenerative response is mounted by 
means of transcription activation or repression associated to key signaling pathways, while 
in the CNS negative regulators of growth pathways predominate (Liu et al., 2011). Gene 
transcription is a tightly regulated process, in which transcription factors and co-factors work 
together to recruit RNA polymerase to specific DNA regulatory regions upstream to the 
transcription start site (Tedeschi, 2012). 
Intuitively, many factors involved in PNS regeneration and in the preconditioning ef-
fect have been experimentally manipulated in CNS injury models with the purpose to repli-
cate the PNS successful regenerative response. These factors and their related pathways will 
now be briefly considered. 
In the PNS, axon growth is dependent on neurotrophins (NTs), which include NGF, 
BDNF, NT-3 and NT-4 acting on correspondingly tyrosine kinase receptors (TrkA for NFG, 
TrkB for BDNF and NT-4, and TrkC for NT-3) or on the common receptor p75 (Reichardt, 
2006). While the reduction of retrograde transported neurotrophins after injury functions as 
a damage alarm, Schwann cells increase their production and release to support the regen-
erative response (Seijffers and Benowitz, 2008). The binding of neurotrophins to their recep-
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tors triggers various intracellular pathways. The most important ones for axon growth are 
the phosphoinositide 3-kinases (PI3K)/serine/threonine/protein kinase B (AKT) and the Ras-
activated rapidly accelerated fibrosarcoma (RAF)/Erk kinase cascade. The PI3K/AKT path-
ways seem to regulate the cytoskeleton (Kimpinski and Mearow, 2001), while Erk not only 
mediates the PCAF-dependent chromatin remodeling, but also activates many transcription 
factors necessary for regeneration, such as CREB and STAT3, and exerts local effects on 
microtubule assembly (Gao et al., 2004; Goold and Gordon-Weeks, 2005; Qiu et al., 2005). 
Following PNS injury, cyclic AMP (cAMP) levels increase activating the protein kinase 
A, which phosphorylates the cAMP response element-binding protein (CREB). CREB partici-
pates in axon growth by upregulating the expression of Arginase I, which synthesizes poly-
amines that may interact with cytoskeletal elements and overexpression of CREB promotes 
regeneration of the dorsal columns after SCI (Gao et al., 2004). Nevertheless, the effects of 
cAMP elevation are only partially responsible for the potency of conditioning lesions on cen-
tral axonal regeneration. Compared to cAMP modulation, conditioning lesions initiate far 
more extensive regenerative responses in DRG neurons, leading to long-lasting changes in 
gene expression and superior axonal regeneration in vivo (Blesch et al., 2012). Indeed, we 
showed that cAMP signaling in adult DRG neuronal cultures did not induce nuclear PCAF 
translocation as opposed by a preconditioning lesion (Puttagunta and Tedeschi et al., 2014, 
Supplementary Figure 5). 
After peripheral injury, local release of neuropoietic cytokines, such as leukemia in-
hibitory factor (Banner and Patterson, 1994), interleukin-6 (Cao et al., 2006) and ciliary neu-
rotrophic factor (Xu et al., 2009), activates the JAK/STAT3 pathway. JAKs phosphorylate 
STAT3, which is then retrograde transported to the nucleus (Liu et al., 2005), complexes 
with CBP/P300 (Paulson et al., 1999) and drives the expression of RAGs like GAP-43 and 
SPRR1A (Qiu et al., 2005; Wu et al., 2007). Sustained STAT3 delivery results in sprouting in 
injured dorsal columns (Bareyre et al., 2011). 
Other factors induced after PNS injury include the members of the BMP4/Smad1, 
JNK/c-Jun and the ATF-3 transcription pathways, which provide another point of crosstalk of 
signaling pathways (Tedeschi, 2012). While forced activation of the Smad1-dependent BMP 
signaling promoted dorsal column regeneration (Parikh et al., 2011), the induction of the 
JNK/c-Jun (Carulli et al., 2002) and ATF-3 (Seijffers et al., 2007) pathways was not able to 
overcome the intrinsic CNS inhibition for axon outgrowth. 
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Some factors have been directly studied in the CNS, such as KLF4, suppressor of cy-
tokine signaling 3 (SOCS3) and phosphatase and tensin homolog (PTEN) signaling pathways 
(Liu et al., 2011). Inhibition of these factors promoted regeneration in specific subsets of 
CNS neurons. KLF4 is a potent inhibitory gene for axon growth of embryonic hippocampal 
neurons and retinal ganglion cells (RGCs) (Moore et al., 2009). SOCS3 is a negative regula-
tor of the JAK/STAT pathway and its deletion promoted robust optic nerve regeneration in 
adult mice (Smith et al., 2009).  
In 2008, Park and colleagues had a remarkable discovery. They injected adeno-
associated viruses expressing Cre (AAV-Cre) or a control virus into the vitreous body of dif-
ferent adult floxed mice (Rbf/f, p53f/f, Smad4f/f, Dicerf/f, LKB1f/f or PTENf/f) and performed op-
tic nerve crush (ONC) at later time points. Using this approach, they were able to condition-
ally and individually delete these genes and observe their effects on retinal ganglion cells 
(RGCs) regeneration. Among the mouse lines studied, those that had deletion of PTEN ex-
hibited the largest effects on both neuronal survival and axon regeneration of RGCs, with 
some regenerating fibers reaching the optic chiasm 4 weeks after injury (Park et al., 2008).  
Nevertheless, such regrowth tapered off within 2 weeks after injury, a similar out-
come observed after SOCS3 deletion (Park et al., 2008; Smith et al., 2009). Simultaneous 
PTEN and SOCS3 deletion in RGCs, however, enabled robust (more than tenfold increase in 
the number of regenerating axons compared with deletion of either gene alone) and sus-
tained axon regeneration after optic nerve injury (up to 4 weeks when the double-deletion 
was performed before the injury, or up to 3 weeks when the double-deletion was performed 
after injury) (Sun et al., 2011). Gene expression profiling revealed that PTEN/SOCS3 double 
deletion triggers differential expression of several pro-regeneration genes, among which 
two encode critical positive mTOR regulators, namely small GTPase Rheb and insulin-like 
growth factor 1 (IGF1) (Sun et al., 2011). Sustained regeneration would be critical in the clin-
ical setting, in which regenerating axons would need to surpass the hurdle of much greater 
distances imposed by adult organisms to reinnervate their original targets.  
Investigators also tested whether neonatal PTEN conditional deletion in neurons of 
the sensorimotor cortex (SMC) would also promote CST regeneration following unilateral 
piramidotomy, T8 dorsal hemisection or T8 complete crush in the adult (Liu et al., 2010). In 
fact, this resulted in extensive trans-midline sprouting from the intact CST into the denervat-
ed (pyramidotomized) site, and unprecedented regeneration of adult CST axons in both SCI 
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models up to 3 mm caudal to the injury site (Liu et al., 2010). These regenerating CST axons 
were able to form synapsis caudal to the lesion (Liu et al., 2010), but functional recovery was 
unexpectedly only modest, as reported in another cohort of experiments, in which short-
hairpin RNA (shRNA) was employed to suppress PTEN expression (Zukor et al., 2013). PTEN 
is an antagonist of PI3K activity, and PTEN deletion leads to AKT activation, consequently 
triggering mTOR, which controls cell growth and size by regulating cap-dependent protein 
translation initiation (Guertin and Sabatini, 2007; Park et al., 2010), therefore it is likely that 
neuronal growth competence is dependent on the capability of new protein synthesis, 
which provides building blocks for axonal regrowth. 
 In the past decade, other factor that emerged as a prominent candidate for control-
ling axon regeneration pathways is the transcription factor p53. p53 is at the hub of numer-
ous signaling pathways that are triggered in response to particular stresses, all of which can 
leave their mark on p53 by way of diverse post-translational modifications (phosphorylation, 
acetylation, sumoylation and neddylation) and interactions with cofactors. The precise com-
bination of these marks dictates the behavior of p53 in any given situation (Murray-
Zmijewski et al., 2008).  
p53 is activated mainly after genotoxic and oxidative stress and depending upon the 
level of DNA damage, it determines cell fate. Moderate damage leads to p53-dependent 
G1 cell cycle arrest to repair the DNA (Sengupta and Harris, 2005; Okorokov, 2014), where-
as high dose damage inflicts apoptosis to restrain tumor formation (Okorokov, 2014). p53-
downstream effectors of these responses are p21 and GADD45 for cell cycle arrest (Taylor 
and Stark, 2001), or pro-death genes including BAX, NOXA, PUMA, FAS, DR5 and APAF-1 
(Harms et al., 2004; Murray-Zmijewski et al., 2008). Therefore, p53 is recognized as the ge-
nome gatekeeper and has been widely explored in cancer medicine for its tumor suppressor 
properties.  
But p53 is a pleiotropic factor that governs many other aspects of the cell life, includ-
ing angiogenesis, senescence and cell growth (Green and Chipuk, 2006; Riley et al., 2008). 
In the nervous system, it was demonstrated that p53 is involved in cell survival, proliferation 
and differentiation of the developing CNS (Armesilla-Diaz et al., 2009; Tedeschi and Di 
Giovanni, 2009; Quadrato and Di Giovanni, 2012). And as demonstrated by key experi-
ments summarized in the next paragraphs, it also plays a definite role in the regeneration of 
the nervous system. In fact, the p53-dependent decision-making process that results either 
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in neuronal death or survival during development is similar to the one that drives axonal 
retraction or outgrowth in the injured adult nervous system (Tedeschi and Di Giovanni, 
2009). Again, post-translational modifications of p53 are at the forefront of this decisive pro-
cess, with phosphorylation of specific serine and threonine residues being often associated 
with increased neuronal death following genotoxic stress, while acetylation of specific lysine 
residues are implicated in outgrowth and differentiation of neural cells (Figure VIII) (Tedeschi 
and Di Giovanni, 2009).  
 
!
Figure VIII. p53-mediated decision-making processes in neurons. p53 PTMs and related target genes in-
volved in cell death or survival/outgrowth/regeneration after lesion in the adult nervous system. (Adapted from 
Tedeschi and Di Giovanni, page 579, EMBO Rep 2009;!10(6):576-83.) 
 
By employing temporal gene expression profile after SCI, Di Giovanni and col-
leagues (Di Giovanni et al., 2005) identified a cluster of induced genes whose proteins pro-
mote neurite outgrowth, including the actin-binding protein Coronin 1b and the small 
GTPase Rab13. They also showed that these proteins are co-expressed with GAP-43 in ax-
ons in the spinal cord after injury. By investigating a possible common transcription factor 
driving the expression of these genes, they found that Coronin 1b and Rab13 share multiple 
p53 transcription binding sites (Di Giovanni et al., 2006). In fact, they showed that p53 is 
required for neurite outgrowth in cultured cells including primary neurons as well as for ax-
onal regeneration after facial axotomy in mice (Di Giovanni et al., 2006).  
Furthermore, a specific PTM in p53, the acetylation of lysine 320 (K320), provokes 
the binding of p53 to Coronin 1b and Rab13 promoters to drive their expression, and p53 
also induced the expression of the pro-regenerative protein GAP-43 (Di Giovanni et al., 
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been linked to the acetylation of a single residue—Lys 320—located 
within a flexible linker domain near the oligomerization domain, 
which also contains a nuclear localization signal (Brooks & Gu, 
2003). Importantly, these kinase and acetyltransferase pathways 
are activated downstream from NGF and brain-derived nerve 
growth factor (BDNF) signalling during neuronal differentiation and 
axon outgrowth. Interesting y, the acetylation of p53 at Lys 320 by 
P/CAF and the highly homologous acetyltransferase CGN5 leads to 
increased transcriptional activation of the p21 promoter, which trig-
gers G1/S arrest and promotes neuronal differentiation in PC12 cells 
(Wong et al, 2004). P/CAF and CGN5 are activated upon the phos-
phorylation of specific serine and threonine residues within their HAT 
domains—which is mediated by the kinases PI(3)K, Rsk2 and MSK1 
(Fig 2). This observation clearly shows the presence of cross-talk 
between the phosphorylation and acetylation cascades. It is unclear 
whether these p53-dependent molecular pathways are representative 
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Fig 1 | p53-mediated decision-making processes in neural progenitor cells and neurons. (A) The self-renewal and differentiation of NSCs is dependent on p53. 
In its absence (the p53-null condition), NSC self-renewal and the number of differentiated neurons increases. Furthermore, in the absence of both p53 and Pten 
(the p53/Pten-null condition), NSCs show a higher renewal and neuronal differentiation potential. The genes with altered expression in p53-null and p53/Pten-
null mice are indicated in brackets. (B) p53 PTMs and related target genes involved in cell death or survival/outgrowth/regeneration after lesion in the adult 
nervous system. APAF1, apoptotic protease-activating factor 1; Bax, BCl-2-associated X protein; GADD45, growth arrest and DNA damage; GAP43, growth 
associated protein 43; NSC, neural stem cell; Pten, phosphatase and tensin homologue; PTM, post-translation modification; Puma, p53-upregulated modulator 
of apoptosis; Rab13, Ras-associated protein 13.
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2006). Interestingly, PCAF specifically acetylates p53 at K320 (Knights et al., 2006), and 
overexpression of PCAF increased the binding of acetylated p53 to the promoters of Coro-
nin 1b and Rab13 (Di Giovanni et al., 2006). Therefore, a new function was added to the 
vast p53 repertoire, showing that it was able to coordinate the regenerative response of 
adult neural cells. In fact, p53 can be activated by NGF (Eizenberg et al., 1996), which lead 
to PTMs in p53 via the kinases Erk1/2 and 2, p38MAPK, JNK1-2 and the acetyltransferase 
PCAF (Di Giovanni and Rathore, 2012), evidencing the crosstalk of p53 with other estab-
lished intrinsic neuroregenerative pathways. 
Further investigation of the interaction between p53 and GAP-43, a prototypical pro-
tein for axon growth, which is highly expressed in the developing nervous system and in the 
PNS and CNS following injury, revealed that p53 forms a transcriptional complex with 
CBP/P300 in a chromatin environment. This complex specifically acetylates p53 at lysines 
372, 373 and 382 (K372-3-82) and is then recruited to the GAP-43 promoter to drive the 
expression of GAP-43 (Tedeschi et al., 2009a). This was also demonstrated in vivo, where 
both CBP and p53 K372-3-82 were induced following facial motor neurons axotomy and the 
p53/GAP-43 transcriptional module was essential to promote facial nerve regeneration 
(Tedeschi et al., 2009a).  
p53 also drives the expression of the cGMP-dependent protein kinase type I (cGKI) 
during neuronal maturation, which counteracts Semaphorin 3A-induced growth cone col-
lapse (Tedeschi et al., 2009b). Moreover, it has been shown that p53 is present in the 
growth cones of primary hippocampal neurons, where it prevents their collapse by inhibiting 
the Rho kinase activity (Qin et al., 2009). Furthermore, Semaphorin 3A-mediated growth 
cone collapse results partially from calpain-mediated truncation of phosphorylated p53, 
leading to Rho kinase activation and cytoskeleton reorganization (Qin et al., 2010), while 
Semaphorin 3F downregulates p53 expression to promote growth cone collapse (Yang et 
al., 2012). These findings indicate that p53 operates either by transcriptional activation of 
specific RAGs or locally at the growth cone, the structure that is crucial for successful axon 
regeneration and proper synaptic formation.  
In line with the previous mentioned p53 studies in neural regeneration based on 
chromatin remodeling and formation of transcription complexes, in vitro hyperacetylation 
driven by HDAC inhibition enhanced the acetylation of CBP/P300 and PCAF promoter, 
forming a positive feedback loop to increase the expression of these HATs, which led to 
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H3K9 acetylation to relax the chromatin environment and facilitate p53 occupancy of specif-
ic promoters. In its turn, p53 acetylation activated the transcription of RAGs, thereby pro-
moting neurite outgrowth and preventing growth cone collapse of cerebellar granule neu-
rons not only in permissive, but also in non-permissive substrates. Interestingly, in untreated 
(normally acetylated) cells the expression of CBP/P300 and PCAF was reduced by exposure 
to myelin (Gaub et al., 2010), linking extrinsic cues to the intrinsic machinery failure of cen-
tral neurons to reactivate a pro-growth program. In an in vivo paradigm, HDAC inhibition 
induced CBP expression and retinal ganglion cells (RGCs) survival but not regeneration fol-
lowing optic nerve crush (ONC) in adult rats. Overexpression of P300, however, was able to 
promote axon regeneration after ONC as a result of H3 acetylation-dependent chromatin 
remodeling and acetylation of the pro-growth transcription factors p53 and C/EBP, direct 
promoter acetylation and occupancy of GAP-43, CORO1B and SPRR1A, and transcription 
activation of several other RAGs (Gaub et al., 2011).  
In vivo studies in spinal cord injured-adult p53-/- mice showed that in the absence of 
p53 corticospinal spinal axons had increased dieback, greater number of retraction bulbs 
and less sprouting in comparison to wild type animals. Reduced sprouting was also ob-
served in serotoninergic fibers (Floriddia et al., 2012). Strikingly, p53-/- mice also exhibited 
an enhanced scarring reaction at the lesion site, as evidenced by increased areas of fibron-
ectin deposition and reactive GFAP+ astrocytes. Moreover, these mice showed a greater 
number of active microglia/macrophages, but the M1/M2 ratio was similar between p53 null 
and wild-type mice at the injury site, with M1 cells predominating in both genetic back-
grounds. Coupled with these findings, p53-/- mice displayed less functional recovery in lo-
comotor tests (Floriddia et al., 2012). Gain of function experiments were able to rescue CST 
sprouting above the lesion and neurite outgrowth of primary cortical neurons in vitro 
(Floriddia et al., 2012).  
These results indicate that p53 is a key orchestrator of CNS regeneration, playing a 
pivotal role in activating the intrinsic regenerative capacity of post-mitotic CNS neurons in 
addition to modulate the extrinsic environment where these neurons lie in, thus motivating 
us to test whether enhancing p53 activation would increase regeneration and functional 
recovery after SCI. The first strategy was to force p53 expression in the layer V neurons of 
the mouse sensorimotor cortex, which gives rise to the CST, using viral vectors carrying p53 
constructs that mimic p53 acetylation at lysines K320-72-3-82 in its C-terminus (K320-72-3-
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82Q), which had already proven to be efficient to promote neurite outgrowth in vitro on a 
non-permissive substrate (Gaub et al., 2010). However, p53 overexpression did not enhance 
CST sprouting (Simone Di Giovanni’s personal communication), suggesting that other mo-
lecular players were probably compensating the p53 overexpression to hinder its activity. 
After all, p53 regulates cell survival and death decisions, therefore its levels and acti-
vation must be tightly regulated to maintain tissue homeostasis. This is achieved by a num-
ber of ubiquitin ligases, including MDM2 (Momand et al., 1992), MDM4 (also known as 
MDMX) (Shvarts et al., 1996), ARF-BP1/Mule (Chen et al., 2005), COP1 (Dornan et al., 2004) 
and Pirh2 (Leng et al., 2003), that control p53 protein levels and subcellular compartmentali-
zation. Particularly, MDM2 and MDM4 are partners of a sophisticated feedback system to 
keep p53 in check. In a resting cell, p53 is kept at low levels owing to the E3 ubiquitin-ligase 
activity of MDM2, which catalyzes p53 polyubiquitylation that targets it for proteasomal 
degradation, while MDM4 inactivates p53 by occluding its transactivation domain (Toledo 
and Wahl, 2006). In this scenario, MDM2-dependent monoubiquitylation of p53 also pro-
motes the translocation of p53 from the nucleus to cytoplasm (Wade et al., 2010). Further-
more, both MDM2 and MDM4 are able to inhibit CBP/P300-mediated p53 acetylation 
(Sabbatini and McCormick, 2002). Upon stress, MDM2 and MDM4 are degraded to transi-
ently allow p53 transactivation, but once the stress is relieved, they accumulate to inactivate 
and reduce p53 back to its low basal levels (Figure IX) (Toledo and Wahl, 2006; Wade et al., 
2010). Specifically, MDM4 inhibits p53 transactivation in overexpression studies (Shvarts et 
al., 1996), which may explain why overexpression of wild type p53 in the sensorimotor cor-
tex, in the eye, or in the spinal cord after axonal injury did not result in reactivation of the 
axonal growth program (not shown, data from Simone Di Giovanni’s laboratory). 
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Figure IX. Control of p53 stability by Mdm2 homo-oligomers and Mdm2–Mdmx hetero-oligomers. Basal 
p53 levels are regulated by both Mdm2 homo-oligomers and Mdm2/Mdmx hetero-oligomers. Immediately 
following DNA damage, during the early activation phase, Mdm2 is destabilized, and phosphorylated at residues 
outside the RING domain, destabilizing Mdm2 oligomers, leading to increased p53 levels. At the peak activation 
phase, Mdm2 degrades itself and Mdmx, which removes Mdm2–Mdm2 and Mdm2–Mdmx oligomers, leading to 
maximal p53 accumulation. During the activation phase, p53 also transactivates the Mdm2 gene (dashed arrow). 
The attenuation phase begins when DNA damage signaling abates. Kinase inhibition and phosphatase activation 
removes the pool of phosphorylated Mdm2 and Mdmx, leading to their stabilization. As a result, the homo- and 
hetero-oligomers regain p53 ubiquitin ligase activity, reducing p53 to basal levels. In addition to regulation of 
Mdm2 and Mdmx, phosphorylation of p53 during the damage response also contributes to p53 activation by 
decreasing the affinity for negative regulators, and increasing the affinity for transcriptional co-factors. (Adapted 
from Wade et al., page 303, Trends Cell Biol 2010; 20(5):299-309.) 
 
We therefore decided to experimentally disturb the interaction of p53 with MDM2 or 
MDM4 to enhance p53 transactivation in two models of CNS injury in mice, SCI and ONC, 
as we recently reported in Joshi and Sória et al. (2015). For this work, I performed all the SCI 
and behavioral experiments, while my colleague Y. Joshi was in charge of the ONC model. 
Firstly, we tested whether the conditional genetic deletion of MDM4 in corticospinal neu-
rons would aid in p53 transactivation to stimulate the growth program after CST transection. 
For that, we used homozygous adult MDM4 floxed mice (MDM4f/f), in which MDM4 is 
flanked by loxP sites and can be excised by Cre recombinase. To delete MDM4 specifically 
in neurons giving rise to the CST, I stereotaxically injected in layer V neurons of the SMC an 
adeno-associated virus type I (AAV1), which is the optimal serotype to infect corticospinal 
circumstances, as recently reviewed by Lee andGu [44]. In
addition to modulation of substrate choice, deubiquityla-
tion is also use to stabiliz Mdm2, Mdmx and p53. For
example, HAUSP is a deubiquitylase (DUB) that binds to
and stabilizes Mdm2 and Mdmx preferentially under
normal growth conditions [45,46]. This might explain
why Mdm2-bound Mdmx is not constitutiv ly degraded
in the absence of stress. In addition, HAUSP-dependent
stabilization of Mdm2 d Mdmx might enh nce degra-
dation of p53 by the Mdm2–Mdmx heterodimer. More
recently a s cond DUB, Usp2a, has been reported to
deubiquitylate both Mdm2 and Mdmx [47,48] and lead
to p53 desta iliz tion. Thus, targeting DUBs might be of
potential therapeutic benefit for p53 reactivation in
tumors. However, most DUBs, including HAUSP, have
additional cellular targets, raising the possibility that
DUB inhibition could lead to mechanism-based toxicity
in normal tissues.
Regulation of Mdm2 and Mdmx phosphorylation
In addition to ubiquitylation, Mdm2 and Mdmx are also
subjected to phosphorylation at several sites. A bewilder-
ing array of phosphorylation-induced changes has been
reported (Figure 3), but the biological effects predictably
segregate into those that activate or inhibit p53 (eg
[49,50]). Owing to the combinatorial nature of phosphoryl-
ation, it is extremely challe ging to determine the precise
physiological impact of single phospho-mutants. However,
some general conclusions can be drawn from the literature.
To date, two classes of kinases are known tomediateMdm2
and Mdmx phosphorylations: those activated by DNA
amage, and o hers involved in mediation of cell growth
and survival signals.
Genotoxic stress triggers a signaling cascade of multiple
nuclear kinases (including ataxia telangiectasia mutated,
checkpoint kina e-1 and -2, and DNA-dependent protein
kinase) that is required to inhibit replication and cell cycle
progres ion. If damage is repaired, these kinases are inac-
tivated and proliferation is resumed. Otherwise, these
kinases can contribute to permanent cell cycle arrest or
apoptosis. Given the critical role of p53 in these latter
processes, it is not surprising that p53 and its negative
regulators are targets of damage-activated kinases [51].
DNA damage-induced phosphorylation of N-terminal resi-
dues of Mdm2 at Ser17 by DNA-PK [52] or Mdmx at Tyr99
by c-abl [53] have been reported to disrupt binding to p53 in
vitro. These modifications might contribute in part to
activation of p53-dependent transcription. Additionally,
phosphorylation of Mdm2 and Mdmx at serine residues
close to the RING domain by ATM or ATM-dependent
Figure 2. Control of p53 stability by Mdm2 homo-oligomers and Mdm2–Mdmx hetero-oligomers. Basal p53 levels are regulated by both Mdm2 homo-oligomers and
Mdm2/Mdmx hetero-oligomers. In vitro data suggests the hetero-oligomer is a more effective p53 ligase in the absence of stress, and that Mdmx contributes significantly to
p53 basal activity, but evidence for the regulatory importance of hetero-oligomers is limited. Immediately following DNA damage, during the early activation phase, Mdm2
is destabilized, and phosphorylated at residues outside the RING domain, destabilizing Mdm2 oligomers, leading to increased p53 levels. At the peak activation phase,
Mdm2 degrades itself and Mdmx, which removes Mdm2–Mdm2 and Mdm2–Mdmx oligomers, leading to maximal p53 accumulation. During the activation phase, p53 also
transactivates the Mdm2 gene (dashed arrow). The attenuation phase begins when DNA damage signaling abates. Kinase inhibition and phosphatase activation removes
the pool of phosphorylated Mdm2 andMdmx, leading to their stabiliz tion. As a result, the homo- and hetero-oligomers regain p53 ubiquitin ligase activity, reducing p53 to
basal levels. Although Mdmx degradation is clearly Mdm2-dependent and therefore requires hetero-oligomerization, the existence and ubiquitin ligase activity of
phosphorylated Mdm2–Mdmx hetero-oligomers (early activation phase) is curently speculative. In addition to regulation of Mdm2 and Mdmx, phosphorylation of p53
during the da age response also contributes to p53 ctivation by decreasing the affinity for negative regulators, and increasing th affinity for transcriptio al co-factors.
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neurons (Hutson et al., 2012), encoding a green fluorescent protein (GFP)/Cre recombinase 
fusion protein (AAV1-CreGFP), or AAV1-GFP in controls. Infected cells express GFP, there-
fore infection can be ascertain by immunohistochemistry. I monitored the infection specifici-
ty of layer V cortical neurons by co-staining GFP with Ctip2 (Supplementary Figure 4, Joshi 
and Sória et al., 2015, reproduced below as Figure X), a marker expressed by layer V and VI 
neurons (Lickiss et al., 2012). 
  
!
Figure X. Infection and labeling of SMC layer-V neurons. (a) Shown are GFP and BDA labeling of the sen-
sorimotor cortex after stereotaxic delivery of AAV-GFP or BDA. Inset shows layer V in the sensorimotor cortex. 
Scale bar 500 μm. (b) Shown are cre-positive cells after anti-cre immunostaining in proximity of the injection site 
(asterix) of AAV-cre in the sensorimotor cortex. Scale bar 50 μm. (c) Immunostaining for GFP and CTIP2 (layer V 
neurons marker) show AAV-GFP infection of layer V neurons in the sensorimotor cortex. Scale bar 20 μm. (Re-
produced from Joshi and Sória et al., Brain 2015;138(Pt 7):1843-62.) 
 
Five weeks after the viral injections, at the time when the AAV1 infection rate should 
be close to peak levels (Mason et al., 2010), I performed T9 spinal cord dorsal hemisections 
for both groups, a lesion that transects the dorsal and lateral CSTs. Two weeks later, the 
CST fibers were traced with fluorescent biotin dextran tetramethylrhodamine (BDA). Com-
parative stereological analysis of the corticospinal axons showed that in animals injected 
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with AAV1-CreGFP there was a significant increase of sprouting not only rostral, but also 
caudal to the lesion site extending up to 1 centimeter (Figure 2, reproduced below as Fig-
ure XI, and Supplementary Figure 5, Joshi and Sória et al., 2015). These results showed that 
releasing p53 of the MDM4 inhibitory influence allowed p53 to enhance the regenerative 
capacity of the otherwise refractory CST axons. 
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Figure XI. Conditional deletion of MDM4 in the sensorimotorcortex enhances corticospinal tract sprout-
ingfollowing T9 dorsal hemisection in MDM4f/f mice. (A and B) Schematic diagrams summarizing the experi-
mental design. AAV-CreGFP/AAV-GFP particles were injected in the sensorimotor cortex of adult MDM4f/f mice 5 
weeks before T9 dorsal hemisection. BDA for corticospinal tract labelling was injected 14 days before sacrificing 
the animal. (C) Representative images of sagittal sections from MDM4f/f mice after cortical AAV-GFP/AAV-
CreGFP infection. The corticospinal tract was traced by BDA injection (red) in the cortex. Spinal cord sections 
were also stained with DAPI (blue). High magnification images (insets) show the sprouting axons past the lesion 
site, in the AAV-CreGFP infected mice. Scale bar = 500 µm. (D) Quantification of the BDA-labelled sprouting 
corticospinal tract in the spinal cord rostral and distal to the lesion site. (Mann Whitney test, **P<0.001, N = 10 
for AAV-GFP and N = 9 for AAV-CreGFP, number of cords analyzed). (E) Coronal section of a spinal cord 15 mm 
caudal to the lesion site showing completeness of the lesion with lack of BDA positive corticospinal tract label-
ling after AAV-Cre infection in the sensorimotor cortex of MDM4f/f mice (5 weeks post-spinal cord injury). Scale 
bar = 500 µm. (Reproduced from Joshi and Sória et al., page 1851, Brain 2015;138(Pt 7):1843-62.) 
 
Next, we decided to test whether inhibiting MDM2 would also enhance regeneration 
after SCI. This time, instead of employing genetic manipulation, we decided to use a more 
clinical applicable approach by inhibiting the MDM2-p53 interaction pharmacologically. The 
drug of choice was Nutlin-3a, the most potent enantiomer of Nutlin-3, which belongs to a 
class of selective small-molecule antagonists of MDM2. These compounds are cis-
imidazoline analogs that bind MDM2 in the p53 binding pocket and activate the p53 path-
way in cancer cells (Vassilev et al., 2004). One of the Nutlin compounds, RG7112, is current-
ly in Phase II clinical trials for cancer therapy (Biswas et al., 2014), and therefore is a real 
candidate for future clinical application.  
For the experiments with Nutlin-3a, we employed adult C57BL/6 wild type mice. I 
delivered the drug or vehicle via osmotic minipump (model 2002, Alzet, USA) connected to 
an intrathecal catheter, and performed the T9 spinal cord dorsal hemisection during the 
same surgical procedure for implantation of the minipump/catheter system. In the day pre-
ceding the surgeries, the minipumps were primed, i.e. incubated overnight in saline at 37 ºC 
to assure immediate drug or vehicle delivery after implantation, as indicated by the manu-
facturer. I placed the catheter in a way to have its tip just caudal to the lesion site (Figure 
XII). With this system, 4 µM/day of Nutlin-3a diluted in 8,6% ethanol/PBS or homologous 
vehicle were delivered at 0,43 µl/hour at the injury site (for details on the mathematic calcu-
lations, please refer to the Appendix). 
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Figure XII. Schematic illustration of the osmotic minipump/intrathecal catheter system. After exposing the 
spinal processes from T8 until T12, laminectomies at the T9 and T11 vertebral levels exposed the spinal cord 
underneath. A polyethylene 32 G intrathecal catheter (external diameter of 0,025 ± 0,0038 cm) was subdurally 
inserted at T11 and driven until T9. Its caudal extremity was fixed at T12 with a cyanoacrylate glue and attached 
to the flow moderator of the pump. The pump was lodged in the subcutaneous tissue of the back of the animal. 
In order to strength the fixation, a muscular “tunnel” involving the catheter was created by suturing the cut ex-
tremities of the superficial muscle layers (in light rose, right panel) at the midline on top of the catheter (from T10 
until T12, not shown). With the catheter tied in place, the dorsal hemisection was performed at T9, in a way that 
the upper extremity of the catheter was just apposed to the injury site. Finally, the above muscles and skin were 
sutured. (Original illustration by Sória MG, 2015.)  
 
Three days later, in animals receiving Nutlin-3a, immunobloting of the spinal cord 
comprising the injury site and two adjacent vertebral segments, one above and other below, 
revealed that acetylated p53 and its prototypic target p21 were induced, while not increas-
ing cleaved caspase-3, a classic apoptotic marker (Supplementary Figure 10, Joshi and Sória 
et al., 2015, reproduced below as Figure XIII), suggesting that Nutlin-3a was de facto lead-
ing to p53 transactivation. Furthermore, in cultured cerebellar granular neurons Nutlin-3a 
induced several axon growth associated and p53 target genes, without leading to apoptosis 
(Supplementary Figure 8, Joshi and Sória et al., 2015).  
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Figure XIII. Spinal cord immunoblotting after Nutlin-3 or vehicle delivery. (a) Representative immunoblotting 
from a spinal cord 72 hours after Nutlin-3 or vehicle delivery with osmotic minipump and spinal cord T9 hemisec-
tion. Shown is enhancement of active acetylated p53 (p53ac) and of the prototypical p53 target gene p21 after 
Nutlin-3 versus vehicle. Classical cell death pathways were also not induced by Nutlin-3 as shown by cl-caspase 3 
expression. (b) Bar graphs show densitometry analysis (arbitrary units) expressed as fold change of Nutlin3 versus 
vehicle. N = 3. Student's unpaired two-tailed t-test **P< 0.01 or ***P<0.001. (Reproduced from Joshi and Sória 
et al., Brain 2015;138(Pt 7):1843-62.) 
  
Having confirmed the effectiveness of Nutlin-3a delivery and activity in our tissue, we 
extended the drug or vehicle delivery further to 2 weeks after SCI, and assessed the loco-
motor behavior weekly until 35 days after injury. During this period, treatment and control 
groups did not show differences in health outcomes, and Nutlin-3a seemed to be well toler-
ated. We employed two tests for behavioral assessment, the Basso Mouse Scale (BMS) and 
the grid walk. The BMS was specifically developed to evaluate mice that suffered a 
midthoracic SCI at T9 (Basso et al., 2006). It assesses features of locomotion that should be 
progressively reacquired by injured mice during their recovery period, if the injury type or 
the treatment provided permit recovery from paraplegia at all. Initially, mice reacquire ankle 
movements, followed by an intermediate phase when they recover the weight support of 
the hindlimbs evolving to stepping. In the late phase of recovery, fine details of locomotion 
are assessed, including forelimb-hindlimb coordination, paw position during stance, and the 
extent of trunk stability. The BMS main score consists of 9 points, ranging from no ankle 
movement (0) to normal or nearest normal behavior (9), while the BMS subscore is also cu-
mulative (from 0 to 11) and is useful to discriminate differences in the fine details of locomo-
tion that may not be apparent in the main score (Basso et al., 2006).  
The grid walk is a more challenging behavioral task and thereby more sensitive to re-
sidual deficits (Bresnahan et al., 1987), therefore only animals able to frequently or consist-
ently plantar step (BMS ≥ 5) were tested in this modality. To perform well on this examina-
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tion, the animals must demonstrate normal limb coordination, which is mediated by ven-
trolateral tracts, have an intact reticulospinal system for initiation of stepping rhythm, and 
possess voluntary motor control, which is mediated by corticospinal and rubrospinal systems 
(Metz et al., 2000).  
In our experiments, animals treated with Nutlin-3a performed better in both behav-
ioral modalities in comparison to controls, having significantly higher punctuations on the 
BMS main and subscores as of the second week (Figure 7, Joshi and Sória et al., 2015, 
reproduced below as Figure XIV). In the grid walk, Nutlin-3a-treated mice also missed signif-
icantly fewer steps than controls from the third week on. Moreover, the majority of the ani-
mals showing enough recovery for grid walk assessment belonged to the Nutlin-3a group 
for all time points after injury (Figure 7, Joshi and Sória et al., 2015, reproduced below as 
Figure XIV). After the last behavioral tests (35 days after SCI), BDA was injected in the right 
SMC of the animals to trace the CST. Ten days later they were sacrificed and the spinal 
cords processed for histology. Stereological analysis revealed a significant increase of CST 
sprouting above and below the lesion in Nutlin-3a-treated animals in comparison to controls 
(Figure 7, Joshi and Sória et al., 2015, reproduced below as Figure XIV). These animals also 
displayed increased sprouting of serotonergic fibers below the lesion (Figure 8, Joshi and 
Sória et al., 2015, reproduced below as Figure XV). 
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Figure XIV. MDM2/p53 inhibition via Nutlin-3 delivery enhances neurological recovery and corticospinal 
tract regeneration following T9 dorsal hemisection. (A) Basso Mouse Scale score and subscore (B) show sig-
nificant improvement in locomotion in Nutlin-3 treated mice (Nutlin-3 or vehicle were delivered via osmotic min-
ipump connected to an intrathecal catheter in proximity of a T9 dorsal hemisection for 14 days post-injury). (C) 
Percentage of mice able to walk on a gridwalk is much higher after Nutlin-3 treatment versus vehicle. (D) Per-
centage of mice with a Basso Mouse Scale score ≥ 5 from 14 days after injury. (E) Number of missteps on a 
gridwalk is significantly reduced by Nutlin-3 treatment (two-way ANOVA with Sidak’s multiple comparisons, ***P 
< 0.001; **P < 0.01; *P < 0.05, N = 13 (vehicle), N = 13 (Nutlin). (F) Schematic diagram summarizing the experi-
mental design. BDA for corticospinal tract labelling was injected 10 days before sacrifice. SCI = spinal cord inju-
ry. (G) Representative images of sagittal cord sections of mice treated with Nutlin-3 or vehicle. The corticospinal 
tracts were traced by BDA injection (red) in the cortex. Spinal cord sections were also stained with DAPI (blue). 
Visible are sprouting axons past the lesion site in the Nutlin-3 treated mice. Scale bar = 500 µm. Inset (i) showing 
sprouting corticospinal tract fibers at higher power. (H) Quantification of the BDA labelled sprouting corticospi-
nal tract axons in the spinal cord rostral and distal to the lesion site. (Mann Whitney test, **P < 0.01, N = 7). 
(Reproduced from Joshi and Sória et al., page 1859, Brain 2015;138(Pt 7):1843-62.) !
!
Figure XV. MDM2/p53 inhibition via Nutlin-3 delivery enhances 5-HT axonal sprouting and functional 
recovery via IGF1 following T9 dorsal hemisection. (A) Representative images of sagittal cord sections of mice 
treated with Nutlin-3 or vehicle (Nutlin-3 or vehicle were delivered via osmotic minipump connected to an in-
trathecal catheter in proximity of a T9 dorsal hemisection for 14 days post-injury). Raphe-spinal fibres were la-
belled with an anti-5-HT antibody (immunoperoxidase). Visible are parasagittal cord sections with numerous 
sprouting axons past the lesion site in the Nutlin-3 treated mice (45 days post-injury). (i and iii) Scale bar = 2,5 
mm. (ii and iv) Scale bar = 750 µm. Inset (v): sprouting fibers at higher power. Scale bar = 50 µm. (B) Quantifica-
tion of the 5-HT-positive fibers in the spinal cord distal to the lesion site. (Unpaired Student’s t-test, ***P < 0.001; 
**P < 0.01, N = 7). (C) Representative images of sagittal cord sections of mice treated with Nutlin-3 via osmotic 
mini-pump and intraperitoneal delivery of picropodophyllin (PPP) or vehicle (for 14 days post-spinal injury). Ra-
phe-spinal fibers were labelled with an anti-5-HT antibody (immunoperoxidase). Visible are parasagittal cord 
sections with numerous sprouting axons past the lesion site in the Nutlin-3 and vehicle treated mice, while only a 
few are visible after picropodophyllin (35 days post-injury). (i and iv) Scale bar = 2,5 mm; (ii and v) Scale bar = 
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750 µm; (iii and vi) Sprouting fibres at high power. Scale bar = 60 µm. (D) Quantification of the 5-HT positive 
fibres in the spinal cord distal to the lesion site. (Unpaired Student’s t-test, ***P < 0.001; **P < 0.01, N = 7). (E) 
Basso Mouse Scale score shows significant reduction in locomotion performance in Nutlin-3 and picropodophyl-
lin treated mice versus Nutlin-3 and vehicle (two-way ANOVA with Sidak’s multiple comparisions, *P < 0.05 N = 
10). (Reproduced from Joshi and Sória et al., page 1860, Brain 2015;138(Pt 7):1843-62.) 
 
At the injury site, Nutlin-3a-treated animals displayed less fibronectin deposition and 
decreased number of activated microglia/macrophages (Figure XVI).  
 
!
Figure XVI. Nutlin-3 reduces the size of the fibronectin-positive core scar area and the density of CD11b+ 
cells at the injury site. (A) Representative photomicrographs of spinal cord injury sections of vehicle- or Nutlin-
3-treated animals 45 days after T9 dorsal hemisection stained for fibronectin or CD11b. The pictures depict the 
injury site (R, rostral; C, caudal; D, dorsal; V, ventral; cc, central canal), scale bar 350 µm. (B) In Nutlin-3 samples, 
there was a significant reduction in the fibronectin core scar area (unpaired two-tailed Student’s t-test, ***P < 
0,001, N = 12 for Nutlin-3 and N = 5 for vehicle, performed in triplicate), while the scar depth was similar be-
tween groups (C), an evidence that the surgeon could consistently reproduce the lesion between animals and 
groups. (D) Nutlin-3 samples also exhibited significantly fewer activated microglia/macrophages (i.e. CD11b+ 
cells) at the injury site (unpaired two-tailed Student’s t-test, **P < 0,01, N = 7 for Nutlin-3 and N = 5 for vehicle, 
performed in triplicate).  
 
Altogether, these results show that increasing p53 transactivation by disrupting the 
MDM2-p53 interaction enhances the intrinsic regenerative capacity of CNS neurons, as 
demonstrated by the increased sprouting of corticospinal and serotonergic axons, as well as 
contributes to modifying the scarring process to render the extrinsic environment more 
permissive to axonal outgrowth. The amelioration observed in the behavioral tests likely 
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resulted from p53-dependent modulation of both intrinsic and extrinsic cues, most probably 
as a local effect at the injury site and vicinity. Even though it is conjecturable that Nutlin-3a 
was transported through the CSF and reached the brain parenchyma to transactivate p53 in 
the cell bodies, in the praxis the redistribution of intrathecal drugs throughout the neural 
axis has proven uneven (Hayek and Hanes, 2014). Specifically with slow infusion rates involv-
ing an intrathecal catheter system, it seems that the delivered agents tend to stay close to 
the site of infusion (Loomis et al., 1987; Bernards, 2006). Therefore, I postulate that the in-
creased CST and 5-HT sprouting observed in Nutlin-3a-treated animals probably resulted 
from local p53 transactivation counteracting growth cone collapse, allied to nuclear transac-
tivation in second-order neurons and interneurons to enhance local plasticity. 
 Next, we wanted to check what could possibly be the molecular signature of the 
MDM4-MDM2/p53 complex disruption. Genome wide analysis of FACS sorted RGCs after 
optic nerve crush revealed that MDM4 conditional deletion was associated with the en-
hancement of transcripts involved in cytoskeleton remodeling, axonal development and 
signaling, including genes involved in neuronal maturation, supporting the reactivation of 
the growth program also in the SCI model. Of special interest was the induction of the insu-
lin growth factor-1 (IGF-1) and receptor signaling pathways in MDM4 deleted cells (Figure 4, 
Joshi and Sória et al., 2015). Insulin and insulin-like growth factors stimulate neurite initiation 
and elongation in DRG neurons and augment the effects of NGF when administered to-
gether (Fernyhough et al., 1993). IGF-1 is a critical positive mTOR regulator that is triggered 
by SOCS3/PTEN co-deletion in RGCs (Sun et al., 2011), and activation of IGF-1 receptor 
signaling is also necessary for regeneration of RGCs (Dupraz et al., 2013). Downstream tar-
gets of IGF1-receptor activation are PI3K (Bondy and Cheng, 2004) and JAK/STAT3 (Staerk 
et al., 2005), which are essential for axonal regeneration, as discussed above. 
Finally, to address the role of the IGF-1 signaling in our SCI model, we antagonized 
the IGF-1 receptor by employing picropodophyllin (PPP), a specific IGF-1R inhibitor (Girnita 
et al., 2004). For that, we conducted experiments in which mice receiving Nutlin-3a via os-
motic minipump/intrathecal catheter were concurrently injected for 2 weeks with PPP (20 
mg/Kg, 12/12 hours, intraperitoneal route) or vehicle. As a result, in animals co-treated with 
PPP sprouting of serotonergic fibers was reduced and they displayed impaired functional 
recovery (Figure 8, Joshi and Sória et al., 2015, reproduced above as Figure XV), thus con-
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firming the dependency of p53 transactivation on IGF-1 signaling to promote axon out-
growth after SCI. !
3 Considerations on neuroplasticity to promote functional recovery after SCI  
 
Even though much effort has been concentrated in promoting growth of axons to 
rewire interrupted pathways after SCI, experimental data have shown that this may not be 
enough to provide functional recovery, as prolific regeneration of CST fibers driven by PTEN 
inhibition, which formed synaptic contacts below the lesion, was not associated with func-
tional improvement (Zukor et al., 2013). It has already been recognized that mechanisms 
underlying beneficial functional outcomes in single-treatment approaches might, in fact, 
include spontaneous rearrangements of spared axons rather than regeneration of lesioned 
axons (Blesch and Tuszynski, 2009). Moreover, it is likely that several studies reporting “re-
generation” of lesioned axons of adult CNS are in reality eliciting axonal sprouting (Blesch 
and Tuszynski, 2009), since the distinction of types of axon growth may be misleading 
(Tuszynski and Steward, 2012). 
 As a matter of fact, several other reports have demonstrated that sprouting of CST 
fibers (Weidner et al., 2001; Bareyre et al., 2004) and other descending motor tracts, like the 
rubrospinal (Weishaupt et al., 2013), reticulospinal (Ballermann and Fouad, 2006) and sero-
tonergic tracts (Perrin et al., 2010), do correlate with amelioration of neurological motor 
functions. Moreover, when as little as 1–2% of the CST was spared in adult rats that under-
went electrolytic lesions of the spinal cord, the animals exhibited recovery in the perfor-
mance of a forepaw reaching task (Li et al., 1997), while as little as 10% of spinal white mat-
ter tracts were sufficient to permit spontaneous walking without support in adult cats 
(Windle et al., 1958). In humans patients that had large portions of spinal tracts transected 
owing to intractable cancer pain, transection of more than 50% of the spinal cord resulted in 
only weak or transitory effects on locomotion (Nathan, 1994). Altogether, these observations 
imply that regeneration of a small percentage of axons could potentially lead to a significant 
recovery of function. Therefore, the relatively modest growth of CST and 5-HT fibers in-
duced by Nutlin-3a might have aided in the observed functional recovery of the animals in 
our experiments.  
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This phenomenon may be explained by synaptic plasticity, that are modifications in 
synapsis strength in pre-existing pathways, and by anatomical plasticity, which refers to the 
formation of new circuits of damaged or spared fibers through sprouting and anatomical 
reorganization, including growth of axonal branches and dendrites. Synaptic and anatomic 
plasticity may contribute to the limited functional improvement frequently experienced by 
subjects with incomplete SCI (Raineteau and Schwab, 2001), which is the type of lesion of 
the majority of spinal cord injured-patients. Even when the injury is neurologically consid-
ered complete, there is usually about 1-10% of spared white matter bridging the lesion gap 
in humans (Kakulas, 1999). The reorganization processes might occur at cortical and subcor-
tical motor centers, in the spinal cord below the lesion, and in the spared fiber tracts that 
connect these centers. Nevertheless, the information that passes through these new con-
nections is usually fragmentary and distorted, leading to additional dysfunctions, such as 
chronic pain and spasticity (Raineteau and Schwab, 2001). Most importantly, spontaneous 
plasticity can be potentiated by activity, as well as by specific experimental manipulations. 
The challenge is to direct these new connections properly to propitiate meaningful func-
tional recovery and, at the same time, to avoid detrimental effects.  
Theoretically, to mediate functional recovery, sprouting of transected descending 
supraspinal tract systems like the CST must fulfill 2 requirements: (1) transected CST fibers 
must contact spared intraspinal neuronal tracts that bridge the lesion; (2) these intraspinal 
neurons must form synaptic contacts on the original targets of the transected CST (Figure 
XVII) (Bareyre et al., 2004). Bareyre et al. (2004) demonstrated that these processes indeed 
take place after midthoracic dorsal hemisection in adult rats. They showed that hindlimb 
CST collaterals spontaneously sprouted into the cervical gray matter where they contact 
descending propriospinal neurons (PSNs). Long PSNs arborized on lumbar motor neurons, 
creating a new and functional intraspinal circuit relaying cortical input to its original spinal 
targets, which was responsible for the partial locomotor recovery experienced by the ani-
mals, as CST re-lesion significantly decreased the hindlimb placing response (Bareyre et al., 
2004). Even though spontaneous reorganization does occur, strategies that take advantage 
of this phenomenon and potentiate sprouting of transected tracts are usually paralleled by 
enhancement of functional recovery in comparison to the more limited recovery observed in 
control groups, as demonstrated by several experimental interventions (reviewed by Onifer 
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et al., 2011; Ruff et al., 2012; Burnside and Bradbury, 2014; Fujita and Yamashita, 2014; 
Schwab and Strittmatter, 2014), including our work (Joshi and Sória et al., 2015). 
Perhaps the most striking experiments showing that plasticity is fundamental for 
functional recovery are the ones involving functional training, which seems to be the most 
effective approach to direct and enhance plasticity as a means to recover motor function 
(Dietz and Fouad, 2014). More than 30 years ago, classical experiments demonstrated that 
the mammalian spinal cord can generate locomotor output in the absence of input from the 
brain by central pattern generation (Grillner and Zangger, 1979). Adult cats with complete 
transection of the spinal cord (spinalized cats) could stand and step when sensory input (e.g. 
standing on a moving treadmill) was provided to the lumbosacral pattern generator circuitry 
(de Leon et al., 1998). In adult paralyzed rats as a result of complete spinal cord transec-
tions, combinations of serotonergic agonists and epidural electrical stimulation were able to 
acutely transform spinal networks from nonfunctional to highly functional and adaptive 
states as early as 1 week after injury, which enabled full weight-bearing treadmill locomotion 
that was almost indistinguishable from voluntary stepping (Courtine et al., 2009). These re-
sults show that neuronal circuits for locomotion in the spinal cord can “learn” by training 
independently of the connection to the brain (Dietz and Fouad, 2014), leading to functional 
recovery of stepping, and that the spinal cord contains circuits that can produce stereo-
typed locomotor patterns. The mechanisms underlying this training-induced plasticity in-
clude the adaptation of neurotransmitter systems within the spinal cord, the upregulation of 
BDNF and enhanced collateral sprouting (Fouad and Tetzlaff, 2012).  
But the restoration of supraspinal control in this context can be even more beneficial, 
as elegantly demonstrated by the Courtine group (van den Brand et al., 2012). In their ex-
periments, adult rats received a left lateral over-hemisection at T7 and a right lateral hemi-
section at T10, which completely abolished hindlimb function, but left an intervening gap of 
intact tissue in order to simulate a clinically complete human SCI. In addition to systemic 
administration of serotonin and dopamine receptor agonists, epidural stimulation over L1 
and S2 spinal segments and treadmill training, animals aided by a robotic postural interface 
were encouraged to perform active overground locomotion. As a result, these animals were 
capable of initiating and sustaining full weight-bearing bipedal locomotion, sprinting up 
stairs and avoiding obstacles, which was paralleled by anatomical and synaptic plasticity in 
cortex- and brainstem-derived axonal systems. In contrast, rats that received treadmill-
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restricted step training under electrochemically enabled states failed to initiate overground 
locomotion and did not exhibit remodeling of descending pathways (van den Brand et al., 
2012).   
Promising results related to functional training and electrical stimulation were already 
reported in humans. In patients with neurologically complete spinal cord injuries, treadmill 
training led to the return of rhythmic locomotor muscle activation patterns and a decrease in 
spasticity (Dietz et al., 1994). In another cohort with incomplete para- and tetraplegic pa-
tients, the locomotor improvement resulting from treadmill training allowed 92% of these 
subjects to become independent walkers, in contrast to only 50% of the ones treated with 
conventional therapy (Wernig et al., 1995), with follow-up studies showing that the capabil-
ity of walking persisted or further improved 6 months to 6 years in initially acute patients 
(Wernig et al., 1998). More recently, 4 young adult chronic spinal cord-injured patients, in-
cluding 2 with complete SCI, were implanted with a 16-electrode array epidural stimulator 
over the L1-S1 cord segments and received intensive rehabilitation (including weight-
supported treadmill and standing training) before and after implantation (Harkema et al., 
2011; Angeli et al., 2014). With continuous stimulation, they were able to stand inde-
pendently with full weight-bearing for several minutes and move their legs, and some pa-
tients even regained partial autonomic control; unlike motor function, these autonomic im-
provements became independent of stimulation (Harkema et al., 2011; Angeli et al., 2014).  
Although these results may provoke enthusiasm, it is still too early for generaliza-
tions. The mechanisms underlying plasticity after SCI are still poorly understood and the 
recovery of functions associated to this phenomenon is still limited. Nevertheless, these 
studies encourage further investigation to potential clinical translation. Finally, it is likely that 
treatments that promote anatomical and synaptic plasticity may be potentiated by function-
al training, since newly formed projections might be fine tuned and stabilized by activity-
dependent mechanisms. 
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Figure XVII. Restoration of function after spinal cord injury might arise from anatomical plasticity of dam-
aged or spared connections. (a) Collateral sprouts (illustrated in red) might form from long descending path-
ways that bypass the lesion site and activate spinal circuits more effectively or activate novel circuits, or from 
damaged or intact descending projections that activate local propriospinal neurons that bypass the injury site 
and form a novel descending system. (b) Ascending sensory projections might also form collateral sprouts, which 
activate spinal circuits more effectively. CPG, central pattern generator. (Reproduced from Bradbury and Mac-
Mahon, page 649, Nat Rev Neurosc 2006;7(8):644-53) 
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extent to which this plasticity is responsible 
for functional improvement has not been 
established in most studies.
Chondroitin sulphate proteoglycans 
(CSPGs) also contribute to the inhibitory 
environment of the CNS, particularly after 
injury 44. CSPGs are increasingly being seen 
as molecules that regulate plasticity in the 
adult CNS (for a review, see REF. 45). Key 
evidence first came from studies in the brain; 
for example, high levels of CSPGs are present 
in perineuronal nets46, and disruption of 
these using ChABC can restore synaptic 
plasticity in the visual cortex of adult rats to 
a level normally seen only during develop-
ment 47. Degradation of CSPGs by ChABC 
treatment also leads to sprouting of intact 
Purkinje axons in the cerebellum48 and pro-
motes sprouting of undamaged retinal affer-
ents into the denervated superior colliculus 
following a partial retinal lesion injury 49.
Recent evidence shows that CSPGs can 
also regulate plasticity in the spinal cord. In 
recent work from our laboratories, we have 
observed sprouting of both intact and injured 
descending pathways as well as intact sensory 
afferents following SCI and treatment with 
ChABC (A. W. Barritt et al., unpublished 
observations). In all cases, sprouting fibres 
were observed in aberrant locations close 
to the SCI (within one or two segments) in 
areas of degeneration and CSPG degradation. 
Although these data provide evidence that 
CSPGs are important for restricting the plas-
ticity of adult spinal systems, the functional 
role of these sprouting fibres is less clear. 
However, a recent study has demonstrated 
functional collateral sprouting of forelimb 
sensory afferents into partially denervated 
brainstem nuclei following ChABC injec-
tions50. This study combined anatomical 
tracing techniques with receptive field 
mapping to demonstrate sprouting of intact 
afferents and an expansion of receptive fields 
after CSPG degradation. However, it did not 
determine whether such sprouting could 
affect forelimb function. By contrast, we have 
found that terminal field expansion within 
the spinal cord following ChABC treatment 
can result in a remarkable recovery of fore-
limb function following denervation51. In a 
spared-root injury model (in which all the 
dorsal roots from C5–T1 are rhizotomized, 
with the exception of C7), little activity was 
recorded in the C7 spinal cord following 
stimulation of the C7 dorsal root (deter-
mined by recording cord dorsum potentials, 
focal field potentials and single units in the 
dorsal horn). A single intraspinal injection of 
ChABC restored postsynaptic responses to 
levels that were indistinguishable from those 
observed in uninjured control animals and 
led to a complete recovery on several tests of 
sensory function of the denervated forelimb. 
These data provide robust evidence that 
degrading CSPGs within the spinal cord can 
lead to a functional reorganization of dorsal 
horn input, and that novel connections are 
organized in a functionally meaningful way.
The results of these studies suggest that 
CSPGs have a similar role to myelin inhibi-
tors in suppressing sprouting responses 
of injured and intact systems after injury. 
Targeting both myelin and CSPG inhibitors 
might be a future strategy to consider for 
maximizing the potential for sprouting or 
plasticity after SCI.
It should be noted that in addition to 
having beneficial effects, increased sprouting 
can also lead to abnormal connections being 
made, with potentially detrimental conse-
quences. For example, increased primary 
afferent sprouting in the spinal cord of experi-
mental animals has been associated with 
pain and autonomic dysreflexia52,53. In one 
study, the beneficial effects on motor function 
observed following neural stem cell trans-
plants were limited by the development of 
allodynia, which was associated with aberrant 
sprouting54. The outcome was improved by 
differentiating the cells prior to transplanta-
tion, but this study highlights the importance 
of balancing potentially opposing influences. 
Pain, autonomic dysreflexia and spasticity are 
common symptoms in  patients with SCI 55–59 
that could potentially be increased if abnor-
mal connections were formed. Therefore, 
targeted treatments aimed at minimizing 
detrimental sprouting and optimizing ben-
eficial sprouting will be a future goal for the 
treatment of patients with SCI.
Other mechanisms
Although there is some (albeit limited) evi-
dence that regeneration and anatomical plasti-
city of connections contribute to functional 
recovery after SCI, there are several less 
well-explored, but entirely plausible, putative 
processes that might also contribute to repair. 
If these, or indeed any other mechanisms, 
can contribute to functional recovery from 
SCI, there is a self-evident value in optimiz-
ing their effects. Establishing that some or 
all of them do not contribute to functional 
improvement might also be important in 
removing experimental confounds. Some of 
these alternative mechanisms are discussed 
below and illustrated in FIG. 4.
Functional reorganization of spinal circuits. 
After complete spinal cord transection 
at thoracic levels, all voluntary control of 
hindlimb locomotion is lost. However, 
Figure 3 | Restoration of function after spinal cord injury might arise from anatomical plasti-
city of damaged or spared connections. a | Collateral sprouts (illustrated in red) ight form from 
long des e ding pathw ys that bypass the lesion site an  activate spinal circuits more effectively or 
activ te novel circuit , or from damag d or inta t descending projections that activate l cal proprio-
spinal neuron  that bypass the injury site and form a novel descending system. b | Ascending sensory 
projections might also form collateral sprouts, which activate spinal circuits m re effectively. CPG, 
central pattern generator.
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4 Conclusion remarks and perspectives  
 
For millennia SCI was considered an “ailment not to treat”. The first scientific known 
records of spinal cord injuries date to approximately 2.500 B.C. in the Ancient Egypt, as 
revealed by the Edwin Smith Surgical Papyrus in 1930 (Hughes, 1988). The papyrus contains 
six cases of injuries involving the cervical spine, two of them are clearly spinal cord injuries. 
For these two cases, the author states that no treatment could be provided (Hughes, 1988; 
Donovan, 2007). This nihilism toward SCI prevailed until last century, when pioneers of the 
rehabilitative approach for spinal cord-injured patients decided to establish the first SCI care 
units. Together with the latest advances in surgical and clinical medicine and neuroimaging 
it was possible to improve the quality of life and reduce the mortality of these patients 
(Donovan, 2007). Nevertheless, treatments to provide recovery of the neurological functions 
are still very limited. Most of them are at the bench side, but some hold the promise for 
clinical translation in the near future.   
Ramer et al. (2014) classified the strategies to treat SCI according to the clinical tar-
get in three categories: Rescue, Reactivate and Rewire. Rescue encompasses early interven-
tions that prevent the spread of damage beyond the initial site of injury, like surgical de-
compression, cooling or hypothermia, and interventions targeting a specific biological event 
(e.g. inflammation). Reactivate refers to how spared systems, which are nearly always pre-
sent in clinical SCI, can be exploited through rehabilitation, pharmacological or electrical 
stimulation of spinal networks, or remyelination of denuded axons. Finally, rewire aims the 
regrowth of injured axons or re-purposing of spared ones, with strategies targeting the in-
trinsic growth capacity of injured neurons or reducing inhibitors of axon growth (Ramer et 
al., 2014). 
In this setting, our proposal to treat SCI by pharmacological transactivation of p53 
may target these three fronts simultaneously. We showed that p53 is able to positively 
modulate the extrinsic environment, reducing inflammation and scar extension, thus reduc-
ing the spread of damage. p53 may also foster the reactivation of spared systems to in-
crease compensatory sprouting and, in the same line, help transected axons to grow to re-
wire lost connections, without increasing apoptosis. These actions represent a solid substra-
tum to explain the amelioration in locomotor recovery experienced by the mice in our ex-
periments.  
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As a pleiotropic factor, p53 may exert its positive actions by fine tuning various mo-
lecular pathways rather than introducing drastic changes in the components that produce 
the SCI pathological picture. In this way, p53 may shift the balance to a reparative state at 
the injury site. Radical interventions targeting single components of the injury milieu may 
indeed be harmful. As an example, the attempt to reduce the glial scar by depleting prolif-
erating astrocytes results in impaired BBB repair, decreased remyelination, increased leuko-
cyte infiltration, neuronal degeneration, and increased motor deficits (White and Jakeman, 
2008). Similarly, selective ablation of proliferative microglial cells exacerbates lesion pathol-
ogy and decreases IGF-1 levels (Lalancette-Hébert et al., 2007).  
In accordance to our observations with p53 transactivation, other interventions rein-
force the importance of modulation of glial cells to enhance functional recovery after SCI. 
For instance, systemic minocycline administration after SCI in adult rats resulted in reduced 
density of activated microglia/macrophages remote as well as at the lesion site, which was 
associated to both diminished CST dieback and lesion size, and improved functional out-
come (Stirling et al., 2004). In the same line, studies with transplantation of different types of 
neuroprotective glial cells at the injury site also reported varied degrees of success in pro-
moting functional recovery. When transplanted into adult acutely spinal cord injured-rats, 
human embryonic stem cell-derived oligodendrocyte progenitor cells enhance remye-
lination and promote substantial amelioration in locomotor ability (Keirstead et al., 2005). 
Grafting of Schwann cells (SCs), which are required for PNS regeneration, results in reduc-
tion of lesion cavities, as well as abundant sensory and propriospinal axon growth across the 
SC-filled lesion and substantial myelination of axons, but supraspinal axons fail to penetrate 
SC grafts. In animal models of SCI, functional recovery and improvement in axon growth can 
only be achieved if SCs grafts are combined with other factors (chondroitinase ABC, neuro-
trophins or cAMP) (Bunge and Wood, 2012). Olfactory ensheating cells (OECs), unique glia 
found only in the olfactory system that retain exceptional plasticity and support olfactory 
neurogenesis, have already been tested in different models of acute and chronic SCI. These 
cells can stimulate tissue sparing and neuroprotection, enhance sprouting of descending 
tracts, activate angiogenesis, change the response status of endogenous glia after lesion, 
remyelinate axons and promote functional recovery (Richter and Roskams, 2008). 
At the molecular level, in this work we addressed the molecular mechanisms that link 
the retrograde signaling to PCAF-dependent chromatin remodeling, a HAT that is known to 
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form a multiprotein complex with CBP/P300 and p53 itself. This complex activates gene 
transcription via a multifunctional effector, the protein p53, that drives the transcription of 
several RAGs. Furthermore, disrupting the negative regulation of MDM2 and MDM4 in-
creases p53 transactivation, which we showed to depend on IGF-1 signaling to exert its pro-
growth effects. In this setting, a further step to be tested would be a combinatorial ap-
proach by simultaneous promoting PCAF induction and p53 nuclear transactivation in cen-
tral neurons. This may perhaps lead to greater functional recovery after SCI.  
 Overall, this work opens an exciting possibility to bring a new candidate for SCI 
treatment. A pharmacological approach holds the potential for faster clinical translation, an 
urgent need in the spinal cord clinical context, in comparison to other more complexes 
strategies like cell therapy. Nutlin-3a is already under scrutiny in clinical trials for cancer 
therapy and therefore may be clinically available in the near future. 
However, care has to be taken to extrapolate the results obtained in mice to humans. 
For example, while corticospinal connections are highly important for motor control in hu-
mans, they probably play a minor role in the initiation of limb movement in non-primate 
mammals (Sengul and Watson, 2012). To address this question, experiments with Nutlin-3a 
should be repeated in other animal models that are more similar to humans in terms of le-
sion morphology and neurophysiology. Additional experiments should also try to elucidate 
the exact mechanism of interaction of p53 and IGF1 signaling. Since both molecules govern 
several signaling pathways, knowing how they influence each other may reveal more details 
on how nerve regeneration is orchestrated and pave the way to more specific molecular 
manipulation. At last but not the least, Nutlin-3a should be tested in combination with other 
potential therapies for SCI. The spinal cord involves complex systems and multiplicity of 
cells, therefore successful recovery of functions will probably be achieved with combinatorial 
strategies targeting different aspects of this milieu. 
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The MDM4/MDM2-p53-IGF1 axis controls
axonal regeneration, sprouting and functional
recovery after CNS injury
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Regeneration of injured central nervous system axons is highly restricted, causing neurological impairment. To date, although the
lack of intrinsic regenerative potential is well described, a key regulatory molecular mechanism for the enhancement of both axonal
regrowth and functional recovery after central nervous system injury remains elusive. While ubiquitin ligases coordinate neuronal
morphogenesis and connectivity during development as well as after axonal injury, their role specifically in axonal regeneration is
unknown. Following a bioinformatics network analysis combining ubiquitin ligases with previously defined axonal regenerative
proteins, we found a triad composed of the ubiquitin ligases MDM4, MDM2 and the transcription factor p53 (encoded by TP53)
as a putative central signalling complex restricting the regeneration program. Indeed, conditional deletion of MDM4 or pharma-
cological inhibition of MDM2/p53 interaction in the eye and spinal cord promote axonal regeneration and sprouting of the optic
nerve after crush and of supraspinal tracts after spinal cord injury. The double conditional deletion of MDM4-p53 as well as
MDM2 inhibition in p53-deficient mice blocks this regenerative phenotype, showing its dependence upon p53. Genome-wide gene
expression analysis from ex vivo fluorescence-activated cell sorting in MDM4-deficient retinal ganglion cells identifies the down-
stream target IGF1R, whose activity and expression was found to be required for the regeneration elicited by MDM4 deletion.
Importantly, we demonstrate that pharmacological enhancement of the MDM2/p53-IGF1R axis enhances axonal sprouting as well
as functional recovery after spinal cord injury. Thus, our results show MDM4-MDM2/p53-IGF1R as an original regulatory
mechanism for CNS regeneration and offer novel targets to enhance neurological recovery.
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Introduction
The adult mammalian CNS is unable to regenerate follow-
ing axonal injury due to the presence of glial inhibitory
environment as well as the lack of a neuronal intrinsic re-
generative potential. Research over the past two decades
has elucidated several key molecular mechanisms and
pathways that limit axonal sprouting and regeneration fol-
lowing CNS axonal injury, including myelin or proteogly-
can-dependent inhibitory signalling (Yiu and He, 2006;
Giovanni, 2009; Bradke et al., 2012). More recently, accu-
mulating evidence suggests that the modulation of the neur-
onal intrinsic potential via the manipulation of selected
genes in specific neuronal populations may enhance
axonal regeneration in the injured CNS (Park et al.,
2008; Moore et al., 2009; Smith et al., 2009; Sun et al.,
2011). More often, these are developmentally regulated
pathways that contribute to locking the adult CNS neurons
in a non-regenerative mode. Remarkably, deletion of phos-
phatase and tensin homolog (PTEN) in retinal ganglion
cells (RGCs) or in corticospinal tract axons enhances
mTOR activity and leads to robust axonal regeneration
after optic nerve or corticospinal tract injury, respectively
(Park et al., 2008; Liu et al., 2010), which is further
enhanced with conditional co-deletion of SOCS3 (Sun
et al., 2011). Furthermore, modifications of the develop-
mentally regulated neuronal transcriptional program can
lead to increased axonal regeneration after optic nerve
crush or spinal cord injury as demonstrated by the deletion
of kruppel-like factor 4 (KLF4), the overexpression of p300
(encoded by EP300) in RGCs (Moore et al., 2009; Gaub
et al., 2011) as well as the overexpression of KLF7
(Blackmore et al., 2012) or retinoic acid receptor beta
(RARB) in corticospinal neurons (Puttagunta and Di
Giovanni, 2011; Puttagunta et al., 2011).
Ubiquitin ligases and ubiquitin ligase-like proteins,
including neuronal precursor cell-expressed developmen-
tally downregulated protein (NEDDs), Smad ubiquitin
regulatory factor (SMURFs) and murine double minute 2
and 4 (MDM2 and MDM4), coordinate neuronal morpho-
genesis and connectivity both during development and after
axonal injury. Moreover, they regulate the turnover, local-
ization and activity of a number of proteins and transcrip-
tion factors involved in the axonal regeneration program,
including PTEN, p300, KLFs, Smads, p21 and p53
(Yamada et al., 2013). Ubiquitin ligases and ubiquitin
ligase-like proteins may therefore represent a regulatory
hub controlling the regenerative neuronal response
following injury. However, their role in axonal regener-
ation remains unaddressed. Therefore, to functionally
rank ubiquitin ligase dependent control of the regeneration
programme, we systematically analysed protein networks
using the STRING bioinformatic tool including proteins
previously described to be involved in axonal regeneration
and sprouting in the CNS and the corresponding ubiquitin
ligases. This had the goal to identify central protein net-
works that control the regeneration program that may have
positive implications for functional recovery.
This analysis showed that MDM4, in association with
MDM2, and p53 constitutes a central regulatory complex,
potentially involved in repressing axonal regeneration. The
ubiquitin ligase-like MDM4 and MDM2 can form inhibi-
tory protein complexes with at least four key proteins
involved in axonal outgrowth: SMAD1/2, p300, p53
(Kadakia et al., 2002; Markey, 2011). Strikingly, MDM4
and MDM2 expression is developmentally regulated in the
retina reaching its maximal levels in adulthood (Vuong
et al., 2012), potentially keeping the post-injury RGC
growth program in check. Therefore, MDM4 and
MDM2 appear to be strong candidates for limiting
axonal regeneration in the CNS, particularly in the injured
optic nerve.
We investigated whether disruption of MDM4 and
MDM2-dependent regulation would affect the axonal re-
generation program. Indeed, we found that MDM4 and
MDM2 restrict axonal regeneration after optic nerve
crush. In fact, conditional MDM4 deletion in RGCs leads
to axonal regeneration and sprouting of RGC axons fol-
lowing optic nerve crush. Additionally, conditional co-
deletion of MDM4 and its target protein p53 in RGCs
after optic nerve crush blocks nerve regeneration elicited
by MDM4 deletion alone. Similarly, pharmacological in-
hibition of the interaction between the MDM4 co-factor
MDM2 and p53 via the MDM2/p53 antagonist Nutlin-
3a also enables regeneration after optic nerve crush,
which is abolished in p53 deficient mice. Further,
genome-wide gene expression analysis from a pure RGC
population after conditional deletion of MDM4 showed
enhancement of IGF1R expression suggesting IGF1 signal-
ling as a downstream effector of the MDM4 deletion.
Indeed, co-inhibition of MDM4 and IGF1 signalling after
optic nerve crush via a specific IGF1R antagonist impairs
axonal regeneration, while viral overexpression of IGF1 in
the eye enhances it. Finally, we demonstrate that MDM4/2-
p53-IGF1 regulation is critical for axonal sprouting and
neurological recovery after spinal cord injury. Both condi-
tional deletion of MDM4 and Nutlin-3 delivery after spinal
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cord dorsal hemisection in mice enhance axonal sprouting
of supraspinal descending fibres and functional recovery,
which is blocked when IGF1R signalling is inhibited.
Together, this work portrays the MDM4-MDM2/p53-
IGF1R axis as a novel molecular target for axonal regen-
eration and neurological recovery after spinal injury.
Materials and methods
Mice
All experimental procedures were performed according to the
animal protocols approved by the Regierungspra¨sidium
Tu¨bingen. Mice were housed in a colony maintained at 24!C
with a 12 h dark/light cycle and ad libitum food and water.
For all surgeries, mice were anaesthetized with xylazine
(10mg/kg of body weight) and ketamine (100mg/kg of body-
weight), and eye ointment bepanthen was applied to protect
corneas during surgery.
Intravitreal injections
For intravitreal injections, pulled glass capillaries attached to a
Hamilton syringe via a connector were inserted into the per-
ipheral retina. A volume of vitreal fluid equal to the volume to
be injected was removed to avoid intravitreal pressure eleva-
tion. The micropipette was deliberately angled in a way to
avoid lens injury. Fundoscopic inspection was done after
every intravitreal injection to check for any damage to the
lens. Animals with lens injury were excluded from the study.
For performing the optic nerve injury, the left optic nerve was
exposed intraorbitally and crushed for 10 s, 1mm from the
optic disc with forceps (Dumont 5, FST). Care was taken
not to injure the ophthalmic artery to avoid retinal ischaemia.
Animals with injury to the ophthalmic artery were excluded
from the study. For anterograde tracing of the RGC axons,
1 ml cholera subunit B (CtB) conjugated to Alexa Fluor! 555
(Invitrogen) was injected intravitreally at least 2 days before
sacrificing the mice. Mice were killed with a lethal dose of
anaesthesia and transcardially perfused with ice cold 0.1M
phosphate-buffered saline (PBS) followed by 4% paraformal-
dehyde. Optic nerves and eyes were dissected and post fixed
for 1 h at 4!C, before cryoprotecting them with 30% sucrose
solution.
AAV-cre in MDM4f/f mice and
Nutlin-3a administration
MDM4f/f mice were a gift from the J.C.M lab and were
produced as described previously (Grier et al., 2006).
Primers used for genotyping of the MDM4 mice were: a- (for-
ward) - 5’-ggtgtccttgaacttgctgtgtagaa-3’; b-(exon2 reverse) - 5’-
ctgggccgaggtggaatgtgatgt-3’; c-(reverse) - 5’-tatccagtgtcctcttct
ggctt-3’. One microlitre of the adeno-associated virus express-
ing GFP (AAV GFP) or AAV CreGFP were intravitreally in-
jected in male mice aged postnatal Day 21 and optic nerve
crush was performed 14 days later (at postnatal Day 35).
Twenty-six days post-optic nerve crush, CtB (Invitrogen, 2mg/
ul) was intravitreally injected in the eye, 2 days before sacrifice
by transcardial perfusion (28 days). One microlitre of 100 nm
Nutlin-3a or vehicle were intravitreally injected in C57/BL6
(Charles River) male mice aged postnatal Day 35 and optic
nerve crush was performed on the same day. Another intravi-
treal dose of Nutlin-3a was given 7 days post-optic nerve
crush. Twenty-six days later, CtB (Invitrogen, 2 mg/ml) was
intravitreally injected, and mice were sacrificed by transcardial
perfusion 28 days post-optic nerve crush. Both wild-type and
p53" / + mice were used for Nutlin-3a experiments.
Experiments with MDM4f/f/p53f/f mice
MDM4f/f were crossed with P53f/f mice (Strain name:
B6.129P2-Trp53tm1Brn/J, Stock Number: 008462, Jackson
Labs) to generate MDM4f/f/p53f/f mice. The same experimental
design including AAV delivery and optic nerve crush was con-
ducted in MDM4f/f/p53f/f as in MDM4f/f.
Adeno-associated virus preparation
and purification
Details about production of adeno-associated virus 2 (AAV2-
GFP/AAV2-CreGFP) has been described elsewhere (Berton
et al., 2006; Grieger et al., 2006). Plasmid vector for AAV-
GFP and AAV-CreGFP production were a gift from Dr Eric J.
Nestler. Briefly, GFP (control) or an N terminal fusion of GFP
to Cre were cloned into a recombinant AAV-2 vector contain-
ing the human immediate early cytomegalovirus promoter with
a splice donor acceptor sequence and polyadenylation signal
from the human-globin gene. Cloning of the AAV-2 vector
carrying a human IGF1 cDNA sequence was previously
described (PMID 22160392). The vector was produced using
a triple-transfection, helper-free method. The final purified
virus was stored at "80!C. The titre was evaluated after in-
fection in HeLa cells and successful infection was also tested
in vivo. AAV used were in the range of 1–3 # 1013 vector
genomes (vg)/ml.
Immunoprecipitation
Whole retinas were collected 72 h after sham or optic nerve
crush surgeries and flash frozen in liquid nitrogen. Upon thaw-
ing, total proteins were extracted with RIPA lysis buffer
(Thermo Inc.) plus protease and phosphatase inhibitors cock-
tails (Roche). Ten micrograms of protein were diluted in 200 ml
of RIPA buffer, and 5 mg of anti-MDM4 antibody (Sigma-
Aldrich) was added and incubated for 1 h on a rotating
wheel at room temperature. Mouse normal IgG (Santa Cruz)
was used as negative control. The immunocomplexes were col-
lected by adding 40 ml of protein G magnetic beads (Cell
Signaling), and incubated for 15min on a rotating wheel at
room temperature. Beads were collected with a magnetic sep-
aration rack (Cell Signaling), and washed three times with
500 ml of RIPA buffer. Proteins were then eluted with 10 ml
of 4# loading buffer (Tris HCl 0.25M, SDS 4%, glycerol
40%, 0.5% Bromphenol blue, 1# reducing agent) and
heated for 5’ at 96!C. Beads were separated with the magnetic
separation rack, and supernatants onto 4% stacking/10%
separating SDS polyacrylamide gels. The proteins were electro-
phoretically transferred onto nitrocellullose membranes,
blocked with PBST + 5% non-fat dried milk, and subsequently
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incubated overnight at 4!C with antibodies against p53
(rabbit, 1:1000, Santa Cruz) or MDM2 (mouse, 1:1000,
Novus). The proteins were detected by horseradish peroxid-
ase-conjugated secondary antibodies (Thermo) and visualized
by chemiluminescence reagents provided with the ECL kit
(Thermo) and exposure onto hyperfilm (GE Healthcare).
Whole mount retinal staining
After perfusion, uninjured and injured eyes were dissected and
post-fixed for 1 h in paraformaldehyde. Flat retinae were
plated on a dish in PBS and then stained for Tuj1 to detect
surviving RGCs and with DAPI to detect nuclei. The uninjured
retinae were used as a control. The retinae were mounted with
single coverslips with mounting medium (Dako). At least 10
fields were imaged at #25 oil magnification specifically from
the retinal ganglion cell layer using Zeiss Apotome. The
number of Tuj1 + cells was counted with the help of ImageJ.
RGCs were quantified by an observer blind to the treatment.
At least 15 high magnification images were taken from differ-
ent parts of each retina and the total viable RGC number was
obtained by multiplying the average number per field of
Tuj1 + cells in the ganglion cell layer by the retinal area.
Immunostaining of retina sections
Post-fixed and cryoprotected eyes were snap frozen and then
cryosectioned longitudinally (10 mm). Standard immunostain-
ing procedures were followed. Antibody specificity was con-
firmed by using secondary antibody alone for each staining.
The details of the antibodies are as follows: anti-p53 (1:200,
Leica); anti-MDM4 (1:50, Sigma); anti-MDM2 (1:200, Novus
Biologicals); anti-Cre (1:500, Novus Biologicals); anti-Tuj1
(1:1000, Covance and Promega), anti-GFP (1:500, Abcam);
anti-p53ac 373 (1:200, Millipore), anti-GFAP (1:1000,
Millipore). Detailed protocols are available upon request.
Retinal ganglion cell densitometry
analysis
A high-resolution image was obtained at #400 magnification
using the Zeiss Axioplan Microscope (Axiovert 200, Zeiss
Inc.). Images for the same antigen groups were processed
with the same exposure time. Assessment of fluorescence in-
tensity was performed using AlphaEaseFC 4.0.1 software by
measuring the intensities specifically from retinal ganglion
cells. Care was taken that the area analysed for each cell
was the same for each set, 100 cells from at least six sections
per condition were quantified. The intensity values of each cell
were normalized to the 4’,6’-diamidino-2-phenylindole signal
and mean values of intensities were calculated for each animal
(at least three animals per condition) (Gaub et al., 2011).
Evaluation of optic nerve
regenerating axons
Regenerating axons were counted as described previously
(Leon et al., 2000; Park et al., 2008). Longitudinal sections
of nerves were mounted and imaged at #400. Every fourth
section and at least four sections per animal were quantified by
drawing lines perpendicular to the crush site at a distance of
200, 300, 500, 750, 1000 and 1500 mm from the crush site.
CtB + axons between these sections were counted and the
cross-sectional width of every nerve was also measured. An
observer blind to the treatment counted the regenerating
fibres. The number of axons per millimetre was calculated
and averaged over all the sections !ad, the total number of
axons extending distance d in a nerve having a radius of r, was
estimated by summing over all sections having a thickness t
(10 mm) !ad = !r2 # [average axons / mm] / t.
Cerebellar granule neuron culture
Cerebellar granule neurons were prepared from cerebella of
post-natal Day 7 MDM4f/f mice as described previously
(Gaub et al., 2010; Bradke et al., 2012). Briefly, the minced
cerebella were incubated for 15min at 37!C in an ionic
medium with 0.025% trypsin and 0.05% DNase I (Sigma).
Then trypsin inhibitor (0.04%, Sigma) was added followed
by centrifugation. The pellet was triturated, centrifuged and
suspended in the growth medium [basal Eagle’s medium sup-
plemented with 10% bovine calf serum, 25mM KCl, 4mM
glutamine and gentamycin (100 ng/ml)]. Cells were plated at a
density of 105 cells on PDL/myelin (4 mg/cm2) coated plates
followed by infection with adenovirus 5 (AV5)-GFP/AV5-Cre
(2 # 1010 vg/ml). Cells were then fixed with 4% paraformal-
dehyde 24 h later followed by staining with anti-Tuj1 and anti-
Cre. At least 100 single transduced cells per condition (n = 4)
were traced manually with Neurolucida software.
Viral injections into the sensorimotor
cortex
Four-week-old MDM4f/f mice were anaesthetized with keta-
mine and xylazine and then placed on a stereotactic frame.
To infect layer V neurons, AAV1-GFP or AAV1-CreGFP
under CMV promoter were injected with a 5 ml Hamilton syr-
inge in the right sensorimotor cortex 5 weeks before spinal
cord injury. The viruses were injected after craniotomy in a
total of four sites [0.8 ml/site of AAV1-GFP or AAV1-CreGFP
(3.1 # 109 vg/ml) (SignaGen)]. The coordinates used were
1.0mm lateral, 0.6mm deep, and + 0.5, "0.2, "0.7, and
"1mm with respect to bregma (Steward et al., 2008).
Quantitative reverse transcriptase
polymerase chain reaction
Total RNA was extracted from cerebellar granule neuron cells
24 h after transduction with TRIzol! Reagent (Invitrogen).
Complementary DNA was synthesized from 1 mg of RNA
using oligo dT and SuperScript! II Reverse Transcriptase kit
(Invitrogen). Complementary DNA (1 ml of 1:5 dilution) was
used in a reverse transcriptase PCR (RT-PCR) using Master
Mix (Invitrogen) and for quantitative RT-PCR, SYBR!
GreenERTM (ThermoScientific) was used. Rpl13a or 18 S
RNA were used as controls. Melting curve analysis ensured
single amplified products. Primers sequences have been sum-
marized in Supplementary Table 5.
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Retinal ganglion cell culture
Dissociated retinal ganglion cell culture has been described
previously (Gaub et al., 2011). Briefly, post-natal Day 7 eyes
were dissected, and retinae were incubated in Dulbecco’s mod-
ified Eagle’s medium with Papain (Worthington) and L-cysteine
(Sigma) for 40min. After incubation, retinae were dissociated
in Dulbecco’s modified Eagle’s medium with B27 (Life
Technologies) and penicillin/streptomycin (Sigma). Cells were
plates at a density of 106 cells per 2 cm2. Plated cells were
immediately infected with AV-GFP and AV-Cre at 100 multi-
plicity of infection. Following incubation, cells were fixed with
4% paraformaldehyde for 20min. Cells were then blocked
with 8% bovine serum albumin, 0.1% TritonTM X-100 in
PBS and finally incubated with the primary antibodies over-
night at 4!C: mouse anti-Tuj1 (1:1000, Promega). Cells were
then washed with PBS and incubated with appropriate second-
ary antibodies (1:1000, Invitrogen) for 1 h at room tempera-
ture. At least 10 images taken at #200 magnification with
Axioplan inverted microscope (Zeiss) were automated analysed
for neurite outgrowth with ImageJ, NeuriteTrace plugin.
Immunoblotting
For immunoblotting, entire retinae were collected 6 h after
Nutlin-3a injection and optic nerve crush and flash frozen or
72 h after sham surgery or optic nerve crush. For spinal cord
tissue, spinal cord segments corresponding to the injury site
(3mm rostral and 3mm caudal to the lesion) were harvested
and flesh frozen in liquid nitrogen. On thawing, proteins were
extracted with RIPA buffer (50 mMTris., 150mM NaCl,
2mM EDTA, 1% NP-40, 0.1% SDS, 0.1mM PMSF, 1#
Protease inhibitor (Roche), 1# PhosphoStop (Roche). A por-
tion of the lysate (30–50mg of protein) was then fractionated
by SDS-polyacrylamide gel electrophoresis, and the separated
proteins were transferred to a nitrocellulose membrane and
following blocking, probed for different antigens, as follows:
rabbit anti-p53 (1:1000, Santa-Cruz), mouse anti-MDM4
(1:1000, Sigma), rabbit anti-MDM2 (1:1000, Novus); rabbit
anti-acetylated p53 (lysine 373) (1:500, Millipore), rabbit anti-
cleaved caspase-3 (1:1000, Cell Signaling) or rabbit anti-p21
(1:500, Abcam). Mouse anti-b-actin (1:5000, Sigma) was used
as a loading and transfer control. Immune complexes were
detected with appropriate secondary antibodies (goat anti-
rabbit IgG, goat anti-mouse IgG, label with horseradish per-
oxidase (Thermo Scientific) and chemiluminescence reagents
(Pierce ECL Western blotting Substrate).
Retrograde labelling of retinal gang-
lion cells for FACS and Affymetrix
gene expression analysis
DiI (Molecular Probes, Invitrogen, 2% in dimethyl formamide)
was injected in the superior colliculus of post-natal Day 28
mice. Anaesthetized mice were placed in a stereotaxic holder
and $2 ml DiI was then injected directly into the superficial
superior colliculus (4.5mm caudal to Bregma, 0.5mm lateral
to sagittal suture and 1–2mm deep to brain surface) using
a 10 ml gas tight syringe (Hamilton) connected to an
automated nano-injector. Seven days after superior colliculus
injection, the optic nerve crush was performed. Three days
(72 h) after crush, retinae were dissected and incubated in di-
gestion solution (20 U/ml papain, Worthington; 1mM L-cyst-
eine HCl; 0.004% DNase; 0.5mM EDTA in Neurobasal!) for
25–40min at 37!C, with gentle shaking every 5min. Digestion
was stopped by adding Ovomucoid solution before trituration.
Retinae were then passed through a 40 mm filter. The obtained
suspensions of the retinae were then processed using fluores-
cence-activated cell sorting (FACS). For microarray, total RNA
was isolated from the FACS sorted RGCs using PureLink RNA
micro kit (Invitrogen) according to manufacturer’s instructions.
Affymetrix Mouse Genome 430 2.0 Array from triplicate
samples was performed at the Microarray Genechip Facility
at Universita¨tsklinikum, Tu¨bingen. Data processing and ana-
lysis was performed according to standard procedures (GC-
RMA, RMA, MAS5). Genes differentially expressed were
selected based upon a 2-fold change cut-off and significant
statistical difference (ANOVA with Bonferroni correction).
The microarray data analysis was carried out by Ingenuity
Pathway Analysis software (Ingenuity System Inc). Cluster
analysis for selected probe sets was performed in R 3.0.1.
Signal intensities were scaled and centred and the distance be-
tween two expression profiles was calculated using Euclidian
distance measure. Hierarchical cluster analysis was performed
with average linkage for genes. Heat maps were generated
with the Bioconductor package gplots.
Drugs
Nutlin-3a (Cayman) was diluted in 8.6% ethanol in DPBS
(vehicle). Before use in osmotic mini-pumps. Picropodophyllin
(Medkoo Biosciences) was diluted in 1:10 dimethyl sulphox-
ide:cottonseed oil (vehicle). The oil was dry-heat sterilized at
150!C for 1 h, before use for i.p. (intraperitoneal) delivery.
Spinal cord injury surgical procedure,
BDA tracing and postoperative care
The experimental procedure followed for spinal cord injury has
been described previously (Floriddia et al., 2012).
Briefly, anaesthetized wild-type or Mdm4f/f mice (ketamine/xyla-
zine) were kept on a heating pad to maintain the body tempera-
ture at 37!C during the whole procedure. An incision was made
on the thoracic area after shaving and cleaning with Softasep! N
(Braun). Muscle tissue right below the incision was dissected to
expose laminae T8–T10. A dorsal hemisection at T9 until the
central canal was performed with a microknife (FST).
To ensure that the lesion was complete, the microknife
was passed throughout the dorsal part of the spinal cord several
times. This kind of injury damages the dorsal and lateral corti-
cospinal tract, the dorsal columns, the rubrospinal, the dorsal
and lateral raphe-spinal, and part of the reticulospinal tracts.
For spinal surgeries with Nutlin-3 delivery by osmotic
minipumps (Alzet 2002) 12-week-old C57BL/6 mice (Charles
River, Germany) mice were used. A customized 32G-poly-
ethylene IT catheter (ReCathCo) was placed subdurally until
T9. Once placed, the caudal tip of the catheter was glued to
the T12 bone with a drop of cyanoacrylate glue (Cyano
Veneer, Hager&Werken). The pump was placed in the
subcutaneous space on the back of the animal caudal to the
surgical incision. All the surgical procedures were performed
in an unbiased blind fashion, i.e. the surgeon did not know
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the content of the pumps (vehicle versus drug). After 2 weeks
pumps were removed under 2% isoflurane/0.8% O2 and mice
were injected with the non-steroidal anti-inflammatory
carprofen (Carprieve, Norbrook, 5mg/kg subcutaneously).
The pump was freed from the subcutaneous tissue and
removed. The IT catheter, however, was left in place to
avoid a secondary injury to the spinal cord. The skin was
closed with suture clips. During the surgical procedure,
animals were kept warm at 37!C.
After surgery, mice were placed back in their cages and
warmed up with an infrared light to prevent hypothermia.
Mice underwent daily check for general health, mobility
within the cage, wounds, swelling, infections, or autophagy
of the toes throughout the experiment. They were injected
subcutaneously with 1ml of 0.9% saline twice daily for
3 days and once daily from Days 4 to 7 after surgery. Pain
was managed with injections of 0.05–0.1 mg/kg subcutaneous
buprenorphine twice daily (12/12 h) for the first 3 days after
the spinal cord injury surgery and 5 mg/kg/day subcutaneous
of carprofen for Days 4–7. To prevent urinary infection,
enrofloxacin was injected at 5 mg/kg once daily in the first 5
days after surgery. If the animal developed signs of urinary
infection in the chronic phase, it received enrofloxacin
10 mg/kg/day subcutaneously for 14 days, and 1 ml of 0.9%
saline solution subcutaneously daily until the urine was clear.
Animals also received Nutrical as food supplement after the
spinal cord injury surgery. Bladders were manually expressed
twice daily until needed. Ten to 14 days before sacrifice, the
animals were injected with 1.4 ml of a 10% (w/v) solution of
BDA (fluorescent biotin dextran tetramethylrhodamine;
10 000MW, Molecular Probes, 10% w/v in PBS) into four
injection sites of the right sensorimotor cortex of the hind
limb region to trace the corticospinal tract as previously
described (Simonen et al., 2003).
Quantification of corticospinal tract
sprouting
Two weeks following tracer injection mice were perfused
transcardially with 0.1M PBS, pH 7.4, and 4% paraformalde-
hyde in PBS, pH 7.4 under deep anaesthesia. For each animal,
at least three consecutive most medial parasagittal cryosections
(18 mm) using the central canal as landmark were chosen
and analysed with the software Stereo-Investigator 7 (MBF
Bioscience) to count axons and sprouts. The quantification
of the sprouting index of the dorsomedial corticospinal tract
was performed proximal to the lesion site at rostral and caudal
level. For each section, the BDA-labelled sprouts and axons
were counted live. The sum of the total number of labelled
axons and axon sprouts was normalized to the total number
of labelled axons above the lesion site counted in all the
analysed sections for each animal, obtaining an inter-animal
comparable ratio considering the individual tracing variability
(Schnell and Schwab, 1993; Steward et al., 2008). Sprouts
and regrowing fibres were defined following the anatomical
reported criteria (Joosten and Bar, 1999; Steward et al.,
2003; Hill et al., 2004; Erturk et al., 2007). Cords
showing spared fibres were excluded by monitoring
BDA labelling in coronal sections from 15mm below the
lesion site.
Immunohistochemistry of brain and
spinal cord sections
Animals were intracardially perfused with cold 0.1M PBS, pH
7.4, followed by fixation with cold 4% paraformaldehyde in
0.1M PBS, pH 7.4. The spinal cords and brains were dissected
and post-fixed with 4% paraformaldehyde for 2 h in ice, then
cryoprotected in 30% saccharose and kept at 4!C. After 5–7
days, the tissues were frozen in liquid nitrogen and kept at
"80!C until sectioning. The spinal cords and the brains
were embedded in Tissue-Tek O.C.T. compound. The cords
were sectioned in the sagittal plane at 18 mm thickness, includ-
ing the injury site. Coronal sections of the cords 1.0 cm rostral
and 1.5 cm caudal to the injury site were also included. Brains
were sectioned at 40 mm in the coronal plane and the sections
were collected in cryoprotectant solution. The tissues were
kept at "20!C until staining. For all the stainings performed,
the antibody specificity was tested by incubating samples only
with the secondary antibody. Primary antibodies for spinal
cord sections: anti-fibronectin (1:500, Sigma), anti-GFAP
(1:500, Millipore). Coronal sections from brains (40 mm)
were processed and stained in free-floating to detect GFP
signal in the sensorimotor cortex. GFP signal was also
enhanced using chicken anti-GFP antibody (1:500, Abcam).
Sections were also stained with anti-Ctip2 antibody (1:500,
Abcam) to mark layer V neurons.
Immunohistochemistry anti-fibronectin allowed visualizinga-
tion of the core of the lesion site. Immunohistochemistry anti-
GFAP allowed defining the size of the spinal lesions in all of
the experiments performed including treatment versus vehicle.
The GFAP-positive immunolabelling delimiting the lesion site
was measured in triplicate sections centred around the central
canal for each cord. The lesion size was comparable between
experimental and control conditions, therefore not affecting
the assessment of axonal sprouting.
For 5-HT immunostaining we followed a protocol as previ-
ously described (Floriddia et al., 2012). Briefly, spinal cord
sections were post-fixed in 0.1% glutaraldehyde in 4% paraf-
ormaldehyde. Then quenched with ethanol peroxide and trans-
ferred to 0.2% sodium borohydride. They underwent antigen
retrieval in 0.1M citrate buffer, pH 4.5, and microwave irradi-
ation at 98!C for 2min. The sections were incubated with
rabbit anti-5-HT (1:8000, ImmunoStar) in 4% normal goat
serum in 0.3% Tris-buffered saline–TritonTM X-100 for 4
days at 4!C. After that, the sections were further blocked in
avidin and biotin (avidin-biotin blocking kit, Vector Labs),
then were incubated in biotinylated goat anti-rabbit antibody
(1:200, Vector Labs) in 2% normal goat serum in 0.3% Tris-
buffered saline–TritonTM X-100 followed by incubation in
ABC elite complex (Vector Labs). The signal was further
amplified by incubation in biotinylated tyramide and revealed
with diaminobenzidine tetrahydrochloride (Vector Labs). The
sections were dehydrated and coverslipped.
5-HT sprouting
5-HT sprouting was evaluated by quantitative measurement of
5-HT-positive axons caudally to the lesion site. The number of
5-HT-positive fibres was counted live with a #40 objective on
parasagittal sections across the left, middle and right segments
of the cord from at least three representative sections per cord.
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Measurements were conducted blind to the experimental
conditions.
Behavioural assessments
Mice were gently handled daily for five to seven sessions.
Thereafter they were acclimatized to the Basso Mouse Scale
(Basso et al., 2006) open field platform and to the grid walk
apparatus daily for another five to seven sessions. The inves-
tigators that participated in the behavioural ratings were blind
to the pump content (Nutlin-3a or vehicle) or to the solution
the animals were being injected intraperitoneally (picropodo-
phyllin or vehicle). Only animals with a histological proof of
hemisection until the central canal, excluding the ones with
occurrence of spared fibres below the lesion or with a total
hemisection, were taken into account.
Basso Mouse Scale
Briefly, a mouse walked on the platform for 4min during
which its motor behaviour was rated by two investigators in
terms of ankle movement, paw placement, stepping and paw
position of the hindlimbs, coordination, trunk stability and tail
position. The Basso Mouse Scale main score and subscore
were given. Animals were tested 1 day before, then 1, 3, 7,
14, 21, 28 and 35 days after injury.
Grid walk
The grid walk consists of a 50 cm # 3 cm metal grid placed
between two vertical 40 cm high wood blocks. The metal mesh
is formed by 1 cm # 1 cm spaces. Only animals able to fre-
quent or consistently step (Basso Mouse Scale5 5) were also
tested on the grid walk. The mice were video recorded for
3min while running on the grid in both directions. The
videos were later analysed by a blind investigator, who
counted the number of missteps. A misstep occurs when the
animal fails to place the paw on the grid and the paw slips
down in the 1 cm # 1 cm space. Only animals that had at least
three compliant runs were considered for statistical analysis. A
compliant run was defined as a run comprising at least g of
the grid length in consistent speed. The animals were tested in
the grid walk 1 day before the injury and 14, 21, 28 and 35
days afterwards.
To ensure that surgical procedures did not interfere with the
behavioural assessments, animals were tested in the Basso
Mouse Scale and grid walk in the same day but before the
pump was removed (14 days post-injury) and before the tracer
was injected (35 days post-injury).
Experiments were performed by the surgeons blinded to the
content of either the minipumps or the syringes containing
virus or drug. Another researcher organized the groups at
random allowing for equal group sizes on each day of surgery;
however, the order and treatment were withheld from both the
surgeons and the researchers performing behavioural and
histological analysis. The treatment order was randomized at
the level of the animal such that within a day post-injury, drug
treated or control treated animals were interspersed at
random. Animals were excluded from analysis in the case of
spared fibres (see above) or when we observed a total transec-
tion with the fibronectin positive scar spanning the entire
depth of the spinal cord. These animals were rejected from
analysis by someone blinded to their treatment allocation. A
detail description of the experimental designs can be found in
Supplementary Tables 3 and 4, according to ARRIVE guide-
lines and the Minimal Information about a Spinal Cord Injury
Experiment reporting standards.
STRING bioinformatics analysis
STRING functional protein interaction analysis online tool
based upon the work by Jensen et al. (2009) was used to
identify cluster of axonal regeneration regulatory protein cen-
tral to the whole protein network. Fifteen regulatory protein
networks for genes involved in the axonal regeneration pro-
gram within the CNS were included in the analysis. They in-
clude: STAT3, SMAD1, SMAD2, KLF4, KLF7, KLF9, jun,
p53, p300, PTEN, SOCS1, SOCS3, RARB, CREB and
SOX11. The interactions include direct (physical) and indirect
(functional) association. All of the interactions reported have
P-values 50.001, while K-means based clustering was used.
Results
MDM4 conditional deletion stimu-
lates optic nerve regeneration and
corticospinal tract axonal sprouting
Initially, we performed a protein network analysis with
STRING network and protein interaction algorithms to
determine whether ubiquitin ligases and ubiquitin-like
ligases may be linked to known transcriptional and protein
synthesis regulators of axonal regeneration in CNS axons
(see ‘Materials and methods’ section for detail). Given their
central positioning in the protein network, we identified
a protein complex composed of MDM4-MDM2 and p53
potentially restricting the regenerative program
(Supplementary Fig. 1A). To examine our hypothesis in
an in vivo model of non-regenerating axons after injury,
we used the optic nerve crush method in mice, where the
injured optic nerve does not regenerate. First, we
established by co-immunoprecipitation experiments that
MDM4, MDM2 and p53 form a protein complex in the
retina both before and after optic nerve crush
(Supplementary Fig. 1B). Importantly, these three proteins
are highly expressed in retinal ganglia cells (Supplementary
Fig. 2). Next, we asked whether disruption of this complex
would enhance axonal regeneration. To this end, we
performed conditional deletion of MDM4 specifically in
RGCs by intravitreal injection of AAV2-CreGFP virus
in MDM4f/f mice 2 weeks before optic nerve crush, while
an AAV2-GFP vector was used as a control (Fig. 1). AAV2
infects RGCs rather efficiently and specifically due to
the physical proximity (Supplementary Fig. 3A), although
$5–10% of other neuronal populations can also be in-
fected. Following AAV2-cre mediated infection
(Supplementary Fig. 3A) and conditional deletion
we could confirm a strong reduction of MDM4 expression
in infected cells (Supplementary Fig. 3B). Additionally,
AAV-cre mediated genetic deletion of MDM4 in primary
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Figure 1 Conditional deletion of MDM4 in retinal ganglion cells enhances axonal regeneration after optic nerve crush. (A)
Schematic of the experimental design showing AAV-Cre or AAV-GFP intra-vitreal infection of RGC in MDM4f/f mice 14 days before optic nerve
crush. Regenerating axons were traced with CtB. (B) High magnification images of regenerating CtB labelled optic nerve axons 28 days post-crush
(asterisk) in MDM4f/f mice after infection with AAV-Cre or AAV-GFP. Scale bar = 100mm. (C) Quantification of regenerating optic nerve axons
post-crush (shown in B). At least four serial sections were analysed from each animal (Student t-test with ANOVA, *P5 0.05 or **P5 0.01 n = 7,
each group). (D) Anti-Tuj1 immunofluorescence shows surviving retinal ganglion cells (Tuj1 + ) 28 days post-optic nerve crush. Scale bar = 50 mm.
(E) Quantification of surviving RGCs as total percentage of surviving cells as compared to the intact contralateral retina (n = 7, AAV-Cre infected
animals; n = 6, AAV-GFP infected animals). (F) Representative images of CtB labelled optic nerve axons from MDM4f/fp53 f/f mice infected with
AAV-CreGFP/AAV-GFP. No regenerating axons were observed past the lesion site (asterisk). Scale bar = 100 mm. (G) Quantification of CtB-
labelled axons regenerating past the lesion site. At least four serial sections were analysed from each animal (Student t-test with ANOVA, n = 5,
AAV-CreGFP group, n = 4, AAV-GFP).
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retinal cells determined by semi-quantitative PCR con-
firmed MDM4 deletion (Supplementary Fig. 3C).
Significantly, MDM4 deletion promoted axonal regener-
ation of the optic nerve as measured 28 days after optic
nerve crush (Fig. 1); however, it did not affect RGC sur-
vival (Fig. 1).
To confirm the generalization of this regenerative pheno-
type to another clinically relevant CNS fibre tract, we
A
C
D E
B
Figure 2 Conditional deletion of MDM4 in the sensorimotor cortex enhances corticospinal tract sprouting following T9 dorsal
hemisection in MDM4f/f mice. (A and B) Schematic diagrams summarizing the experimental design. AAV-CreGFP/AAV-GFP particles were
injected in the sensorimotor cortex of adult MDM4f/f mice 5 weeks before T9 dorsal hemisection. BDA for corticospinal tract labelling was
injected 14 days before sacrificing the animal. (C) Representative images of sagittal sections from MDM4f/f mice after cortical AAV-GFP/AAV-
CreGFP infection. The corticospinal tract was traced by BDA injection (red) in the cortex. Spinal cord sections were also stained with DAPI
(blue). High magnification images (insets) show the sprouting axons past the lesion site, in the AAV-CreGFP infected mice. Scale bar = 500 mm. (D)
Quantification of the BDA-labelled sprouting corticospinal tract in the spinal cord rostral and distal to the lesion site. (Mann Whitney test,
**P5 0.001, n = 10 for AAV-GFP and n = 9 for AAV-CreGFP, number of cords analysed). (E) Coronal section of a spinal cord 15mm caudal to the
lesion site showing completeness of the lesion with lack of BDA positive corticospinal tract labelling after AAV-cre infection in the sensorimotor
cortex of MDM4f/f mice (5 weeks post-spinal cord injury). Scale bar = 500 mm.
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investigated whether MDM4 conditional deletion may en-
hance axonal sprouting and regeneration of the corticosp-
inal tract after spinal cord injury. To this end, we
performed AAV1-cre-mediated MDM4 conditional deletion
in the sensorimotor cortex of MDM4f/f mice (Fig. 2A and
Supplementary Fig. 4A and B) and subsequently performed
a spinal thoracic T9 dorsal hemisection, which severs the
corticospinal tract in mice. An AAV1-GFP virus was again
used as a control. It is important to note that GFP was
found highly expressed in the sensorimotor cortex includ-
ing in layer V neurons (Supplementary Fig. 4C). In line
with the data from the optic nerve, we found significant
axonal sprouting and regeneration after MDM4 condi-
tional deletion while control-infected mice displayed the
typical collapse of the corticospinal tract before reaching
the lesion site (Fig. 2C and D and Supplementary Fig. 5).
Lack of BDA tracing below the lesion site allowed exclu-
sion of the presence of spared corticospinal tract fibres
(Fig. 2E).
In support of the specificity of the in vivo axonal regen-
eration findings, we investigated neurite outgrowth in cul-
tured RGCs and cerebellar granule neurons on both
outgrowth permissive and myelin inhibitory conditions.
AV-cre or AV-GFP control viruses were employed to infect
RGCs or cerebellar granule neuron at the time of plating
on poly-D-lysine or myelin and neurite outgrowth was
analysed at 72 h and 24 h, respectively. Results
showed that MDM4 deletion enhances neurite
outgrowth in both RGCs and cerebellar granule neurons
on both permissive and inhibitory substrates
(Supplementary Fig. 6).
Together, these data suggest that MDM4 conditional de-
letion significantly lifts the CNS regenerative block
thus enhancing axonal regeneration and sprouting
after optic nerve and spinal injury in sensory and motor
neurons.
MDM4 conditional deletion enhances optic
nerve regeneration via p53 and is phenocopied
by inhibition of the MDM2/p53 interaction
To gain mechanistic insight into the regenerative phenotype
observed with MDM4 conditional deletion, we investigated
the role of the MDM4 associated proteins, p53 and
MDM2. MDM4 typically keeps p53 transactivation
under check (Marine and Jochemsen, 2005), as supported
by our findings in primary neurons where conditional de-
letion of MDM4 (Supplementary Fig. 7A) enhances p53-
dependent gene targets, including axon growth associated
genes (Supplementary Fig. 7B). Therefore, we hypothesized
that MDM4 deletion could enhance the regeneration pro-
gram via p53 transactivation. To this end, we investigated
whether double conditional deletion of MDM4 and p53
would block the regenerative phenotype observed with
MDM4 deletion. We performed AAV2-cre conditional de-
letion of MDM4 and p53 in RGCs simultaneously in
double MDM4f/f /p53f/f mice (Fig. 1) and found that this
abolished axonal regeneration induced by MDM4 deletion
alone as the number of axons past the crush site were now
similar to AAV2-GFP control infected mice (Fig. 1).
This demonstrates that p53 is required for MDM4-
dependent axonal regeneration. Next, we further explored
the central role of ubiquitin ligase related signalling in this
regenerative paradigm. Thus, we asked whether modula-
tion of the MDM4 binding protein and ubiquitin ligase
MDM2, also expressed in RGCs (Supplementary Fig. 2E
and F), would be phenocopying axonal regeneration as
seen upon deletion of MDM4. Given that MDM2 controls
p53 protein levels by ubiquitination and proteasome deg-
radation, we inhibited MDM2/p53 interaction by intravitr-
eous injection of the well-characterized small molecule
MDM2/p53 antagonist Nutlin-3a (Vassilev et al., 2004).
Importantly, Nutlin-3a (100 nM) delivery at the time of
optic nerve crush and 7 days later (Fig. 3A) promoted
axonal regeneration of the optic nerve to a similar extent
as MDM4 deletion without affecting the survival of RGCs
28 days after crush (Fig. 3B, C, E and F). Administration of
Nutlin-3a enhanced p53 protein levels in the retina as ex-
pected (Fig. 3G). To investigate by a genetic approach
whether MDM2/p53 inhibition promotes axonal regener-
ation specifically via p53, we performed an analogous set
of Nutlin-3a experiments, but in p53" / + mice that typically
retain only 25% of p53 expression; however, do not dis-
play aberrant cell metabolism as opposed to p53" /" mice
(Boehme and Blattner, 2009). This would also address
whether a ‘minimum’ threshold p53 expression level is
required for axonal regeneration similar to the p53
dosage effect found in cancer (Boehme and Blattner,
2009). Data analysis revealed that axonal regeneration of
the optic nerve after crush was significantly reduced in
Nutlin-3a p53" / + mice as compared to wild-type (Fig. 3B
and D), further supporting the overall model that the
observed regeneration after either deletion of MDM4 or
inhibition of MDM2 is dependent upon p53 transactiva-
tion. Indeed, Nutlin-3a delivery in primary neurons
enhanced p53 transactivation as shown by quantitative
RT-PCR (Supplementary Fig. 8A), without promoting
apoptosis (Supplementary Fig. 8B). Genes included as
p53-target were previously identified as predicted (pro-
moter analysis correlating with gene expression following
p53 modulation) or fully experimentally confirmed p53 tar-
gets (including with chromatin immunoprecipitation assays)
(Tedeschi et al., 2009; Gaub et al., 2011).
Optic nerve axonal regeneration
after conditional MDM4 deletion
relies upon the IGF1R pathway
The data thus far point to a model where disruption of the
MDM4-MDM2/p53 inhibitory protein complex triggers
axonal regeneration after optic nerve crush. To explore
directly in vivo in RGCs whether disruption of this com-
plex via MDM4 deletion would affect the gene expression
program supporting the regenerative phenotype, we
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Figure 3 Inhibition of MDM2/p53 interaction enhances axonal regeneration after optic nerve crush. (A) Schematic of the ex-
perimental design showing intravitreal injection of Nutlin-3a (100 nm) on the day of optic nerve crush followed by a second application 7 days later.
Regenerating axons were traced with CtB. (B) High magnification images of regenerating CtB-labelled optic nerve axons 28 days post-crush
(asterisk) in Nutlin-treated wild-type mice. Only sporadic regenerating axons were observed 200 mm post optic nerve crush in Nutlin-treated
p53+ /" mice. Scale bar = 100 mm. (C and D) Quantification of regenerating optic nerve axons post-crush (experiment as in B). At least four serial
sections were analysed from each animal (Student t-test with ANOVA, *P5 0.05 or **P5 0.01 for each distance, n = 7, each group). (E) Anti-Tuj1
immunofluorescence shows surviving retinal ganglion cells (Tuj1 + ) 28 days post-optic nerve crush. Scale bar = 50 mm. (F) Quantification of
surviving RGCs as total percentage of surviving cells as compared to the intact contralateral retina (n = 7, Nutlin; n = 6, vehicle). (G)
Immunoblotting from retinae treated with vehicle or Nutlin (100 nM) at the time of optic nerve crush, 3 days post-optic nerve crush. Nutlin
enhances p53 expression. Blots from AV-p53 or control AV-GFP infected primary neurons were used as positive control of p53 expression. (H) Bar
graphs show densitometry analysis (arbitrary units) expressed as fold change. n = 3. Student’s unpaired two-tailed t-test **P5 0.01.
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performed Affymetrix-based genome wide gene expression
arrays from FACS isolated RGCs after optic nerve crush.
DiI-positive retrogradely traced RGCs were sorted 3 days
following optic nerve crush from MDM4f/f mice that
underwent either AAV2-creGFP or AAV2-GFP control
intravitreous injections (Fig. 4A and B). Functional data
analysis of statistically significant differentially regulated
transcripts was performed with the Ingenuity pathway
analysis platform. Unsupervised hierarchical clustering of
the gene expression data showed a clear separation of the
gene expression profiles between AAV2-cre and AAV2-
GFP cells (Fig. 4C). Additionally, Ingenuity pathway ana-
lysis revealed that conditional MDM4 deletion was asso-
ciated with a number of receptor-dependent signalling
cascades involved in cell growth and metabolism (Fig.
4D, Table 1, and Supplementary Tables 1 and 2).
Highly ranked differentially regulated pathways were
p53 and the related GADD45 cascades (Fig. 4D and
Supplementary Table 2), supporting our model. Of special
interest was the MDM4-deletion dependent activation of
insulin and insulin receptor signalling pathways via over-
expression of IGF1R, as insulin-dependent pathways have
a key role in cell growth and are highly neurotrophic.
Careful analysis of IGF1R protein expression in RGCs
revealed that in most cells where MDM4 deletion
occurred, IGF1R levels were particularly elevated, whereas
in control AAV-GFP positive RGCs, IGF1R was lower
(Fig 6E). Next, we asked whether the IGF1R pathway
might be critical for the downstream regenerative signal-
ling elicited by conditional deletion of MDM4. Therefore,
we decided to inhibit IGF1R signalling after MDM4 dele-
tion and optic nerve crush. We chose to use picropodo-
phyllin, a highly selective and potent inhibitor of IGF1R
(IC50 = 6 nM) that efficiently blocks IGF1R activity and
expression in vivo without noticeable toxicity. In prepar-
ation for the in vivo experiment, we performed a dose
response analysis of picropodophyllin in primary neurons
in permissive growth conditions and monitored toxicity
(active cleaved caspase 3-positive neurons) and neurite
outgrowth. This allowed identifying a dose between
10 nM and 1 mM that efficiently inhibited neuronal out-
growth without resulting in significant toxicity
(Supplementary Fig. 9A and B). After AAV2-cre MDM4
conditional deletion in RGCs of MDM4f/f mice (Fig. 5A),
picropodophyllin 1 mM was delivered both intravitreous
and at the site of the nerve crush at the time of optic nerve
crush and optic nerve regeneration was evaluated at 28
days post-injury. Indeed, picropodophyllin delivery
strongly reduced the expression of IGF1R (Fig. 5B) and
drastically inhibited optic nerve regeneration induced by
MDM4 deletion, without affecting RGC survival
(Fig. 5C–F).
In line with IGF1R loss of function, overexpression of
IGF1 in the eye (Fig. 6A and B) led to enhanced axonal
regeneration (Fig. 6C and D), whereas it did not affect
RGC survival (Fig. 6E and F). Together, these data support
a role for IGF1 signalling in axonal regeneration down-
stream of MDM4.
Pharmacological modulation of
MDM2/p53/IGF1R axis enhances
axonal sprouting and functional
recovery after spinal cord injury
Next, we decided to investigate whether pharmacological
modulation of the MDM2/p53/IGF1R axis would enhance
axonal sprouting and functional recovery after spinal cord
injury. To this end, we continuously delivered intrathecally
the small molecule Nutlin-3 via an osmotic minipump at
the time of spinal cord injury in proximity of the injury site
(T9 dorsal hemisection) for 14 days and performed loco-
motor behavioural tests for 5 weeks post-injury.
Importantly, Nutlin-3 triggered the expression of active
p53 and of the well-characterized p53 target gene p21
(now known as CDKN1A), while it did not enhance
active caspase 3, suggesting lack of Nutlin-3 dependent
cell death (Supplementary Fig. 10) After sacrifice, we mea-
sured axonal regeneration and sprouting of supraspinal
descending fibres including the BDA labelled corticospinal
tract and the 5-HT raphe-spinal projections, whose sprout-
ing highly correlates with locomotor recovery
(Trakhtenberg and Goldberg, 2012). Indeed Nutlin-3 deliv-
ery induced significant functional recovery as compared to
vehicle as measured by open field Basso Mouse Scale scores
and subscores as well as by assessing locomotion ability on
a Gridwalk (Fig. 7 and Supplementary Videos 1 and 2).
This was paralleled by enhancement in corticospinal tract
sprouting (Fig. 7 and Supplementary Fig. 11) and most
remarkably in 5-HT fibre sprouting below the lesion site
(Fig. 8). No spared fibres below the lesion were found in all
the cords included in the analysis. Finally, inhibition of
IGF1R signalling via intraperitoneal delivery of picropodo-
phyllin together with Nutlin-3 mini-pump administration
strongly reduced sprouting of 5-HT tracts (Fig. 8) as well
as Nutlin-3 dependent functional recovery (Fig. 8).
Together these data support a novel role for MDM2/p53/
IGF1 axis in axonal sprouting and functional recovery after
spinal cord injury.
Discussion
The reasons underlying the lack of a neuronal intrinsic re-
generative potential after CNS axonal injury seem to be
found in an inhibitory molecular network, which either
exists prior to axonal injury or is elicited by it. The present
work defines MDM4-MDM2/p53 as a protein complex re-
stricting axonal sprouting and regeneration, whose disrup-
tion activates p53 and the axonal regenerative program via
IGF1 signalling. Although the effect of MDM4 deletion
upon functional recovery after spinal cord injury has not
been tested, inhibition of MDM2/p53 interaction led to
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Figure 4 Genome-wide gene expression analysis in RGCs after conditional MDM4 deletion and sorting by FACS. (A) Schematic
of the experimental design. MDM4f/f animals were infected with AAV-CreGFP/AAV-GFP 14 days before the optic nerve crush. DiI was injected in
the superior colliculus 7 days before crushing the optic nerve. DiI + RGCs were sorted by FACS 3 days following optic nerve crush, and RNA
extracted from these samples were used to perform gene expression analysis (Affymetrix). (B) Whole mount retina showing highly efficient DiI
tracing in the RGC layer. Scale bar = 20 mm. (C) Heatmap showing clear-cut separation of gene expression levels (green: low; red: high) between
AAV-GFP and AAV-creGFP infected RGCs. (D) Differentially regulated signalling pathways upregulated in MDM4-deleted RGCs analysed with
Ingenuity Pathways Analysis (IPA). These include p53, Gadd45 and IGF1-IGFR signalling pathways. Blue bars represent the relative representation
of genes in each pathway. Lack of blue bar shows poorly represented pathways. y-axis: P-value: significant below threshold (dotted yellow line). (E)
Immunofluorescence micrographs showing high IGF1R expression level 3 days after optic nerve crush in retinal ganglion cells (Tuj1*) infected with
AAV-CreGFP, whereas a faint signal was observed in AAV-GFP + RGCs in MDM4f/f mice. Retinal ganglion cells are counterstained with Tuj1. Scale
bar = 20um. Arrowheads indicate IGF1r positive cells.
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significant functional recovery after spinal injury.
Therefore, the discovery of the MDM4-MDM2/p53-IGF1
axis clarifies a cause for failed regeneration and provides a
target for regenerative therapy after nerve and spinal injury.
MDM4 was first identified as a p53 binding protein in
selected cancers where it inhibits p53 transcriptional activ-
ity thus promoting tumour progression (Markey, 2011).
Similarly, MDM4 regulates cell cycle, survival and
apoptosis by forming an inhibitory complex with a selected
set of proteins that include MDM2, ASPP1, ASPP2, p300,
SMAD1 and SMAD2 (Sabbatini and McCormick, 2002;
Wade et al., 2010; Gaub et al., 2011). However, a role
for MDM4 and MDM2 in axonal regrowth has, until
now, been missing. Here, we show that conditional deletion
of MDM4 enhances axonal regeneration and sprouting
after optic nerve crush and spinal cord injury, respectively
and co-deletion of p53 significantly diminishes the MDM4-
deletion dependent regenerative phenotype, while inhibition
of MDM2/p53 interaction mimics it. Moreover, pharmaco-
logical small molecule mediated disruption of the MDM2/
p53 complex enhances axonal sprouting of long spinal des-
cending tracts and promotes significant neurological
recovery after spinal cord injury.
We have recently shown that the tumour suppressor
and transcription factor p53 is required for neurite out-
growth, axonal sprouting and regeneration both after facial
nerve injury and spinal cord hemisection in mice (Di
Giovanni et al., 2006; Tedeschi and Di Giovanni, 2009;
Tedeschi et al., 2009a, b; Floriddia et al., 2012).
Specifically, transcriptionally active acetylated p53 at
K372-3-82 and the acetyltransferases CBP/p300 and P/
CAF form a transcriptional complex that occupies
promoters of selected pro-regenerative genes, driving neur-
ite outgrowth (Di Giovanni et al., 2006; Tedeschi et al.,
2009). p53 integrates numerous stress signals including
following axonal injury and it undergoes tight regulation
of its protein levels, subcellular localization and of its tran-
scriptional activity by several factors, including the well-
defined negatively regulators MDM2 and MDM4 (Lavin
and Gueven, 2006). MDM2, an E3 ubiquitin ligase, targets
p53 for degradation via the ubiquitin proteasome pathway
and negatively regulates p53 cytoplasmic-nuclear shuttling
(Toledo and Wahl, 2007). MDM4, although structurally
similar to MDM2, is devoid of ubiquitin ligase activity,
and rather regulates with MDM2 p53 cytoplasmic-nuclear
shuttling and it occupies the p53 transcriptional activation
domain thereby inhibiting p53 transactivation (Toledo and
Wahl, 2007). MDM4 prevents p53 nuclear translocation
in association with MDM2 and competes with the
acetyltransferases CBP and p300 for binding to lysines on
p53 C-terminus, overall hindering p53 transcriptional
activity.
Given the pro-neurite outgrowth and axon regeneration
function of the MDM4 interacting proteins p300 and
Table 1 List of selected differentially regulated genes from RGCs after optic nerve crush in MDM4fl/fl mice- AAV Cre
versus GFP.
Functional class Fold change (Cre versus GFP) P-value Function
Axonal signalling
IGF1R 2.12 0.0122 Intracellular signalling
CXCR2 2.18 0.0222 Chemoattraction
Klf11 1.764 0.0391 Axonal transport
Cited4 1.69 0.0324 Transcription co-activator
Sprr2b 1.866 0.004 Axon growth
Neuronal morphology and cytoskeleton organization
DCC "2.031 0.0476 Axon guidance
GAD1 1.569 0.0365 Glutamate/GABA metabolism
Arf1 3.505 0.02 GTP-bind protein
FCER1A 1.71 0.018 IgE rec
NKX2-2 "1.66 0.014 NeuroD1-cofactor
Nrg1 "1.84 0.006 Neuronal differentiation
Rab23 1.516 0.01 GTPase
Rin2 1.797 0.029 GTPase
Mast3 "1.797 0.043 Microtubule associated kinase
Neuronal development
GAD1 1.569 0.0365 Glutamate/GABA metabolism
CAMKK2 1.595 0.004 CREB activator
ZIC1 1.632 0.0385 Transcription Activity-Neurogenesis
ZNF423 1.762 0.0226 Smad coactivation-Neurogenesis
LYNX1 2.222 0.0004 Synaptic plasticity
ST8SIA2 1.683 0.02704 NCAM1 binding protein-receptor
DCC "2.031 0.0476 Axon guidance
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Smads (Zou et al., 2009; Gaub et al., 2011; Parikh et al.,
2011), it is plausible that p300-dependent acetylation of
regenerative promoters as well as TGFb-Smad signalling
may also contribute to axonal regeneration induced by
MDM4 deletion. In support of this, we have recently
shown that p300 acetylates p53 in RGCs after
optic nerve crush during p300-dependent axonal regener-
ation, supporting the presence of this signalling network
during axonal regeneration (Gaub et al., 2011). Given the
axon regenerative/sprouting function of p21 (Tanaka et al.,
2004), the previously described inhibitory MDM4 protein
complex with p21 (Markey, 2011), which is also a
classical p53-target gene, may also play a role in axonal
regeneration. Interestingly, we found that MDM4
deletion in primary neurons enhanced p21 gene
expression levels along with other classical regeneration
associated genes, supporting the inhibitory role for
MDM4 in repressing the regenerative gene expression
program.
An extranuclear and non-transcriptional role for p53
in growth cone remodelling and axonal outgrowth
has also been described. For example, inhibition of p53
phosphorylation causes growth cone collapse in primary
neurons via RhoA kinase activation (Qin et al., 2009).
Additionally, when active phosphorylated p53 is truncated
by calpain activity following semaphorin 3A-induced
growth cone collapse, it results in cytoskeleton
reorganization by activating Rho Kinase (ROCK), therefore
enhancing growth cone retraction (Qin et al., 2010). This
highlights how inhibition of MDM2 and MDM4 may also
promote axonal outgrowth via p53 localization and
activation in axons and at the growth cone.
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Figure 5 Regeneration elicited by MDM4 deletion is reduced by inhibition of IGF1R signalling. (A) Schematic of the experimental
design. Conditional MDM4 deletion in MDM4f/f mice was followed by optic nerve crush and pharmacological inhibition of IGF1R with the
antagonist picropdophyllin (PPP). Axonal tracing was performed with CtB. (B) Immunoblotting from retinas 3 days after optic nerve crush and
administration of picropodophyllin or vehicle. Shown is a strong reduction in the expression of IGF1R. (C) Bar graphs show densitometry analysis
(arbitrary units) expressed as fold change of picropodophyllin versus vehicle (n = 3). Student’s unpaired two-tailed t-test **P5 0.01. (D)
Representative images of optic nerves showing regenerating CtB-labelled axons of MDM4f/f animals after MDM4 conditional deletion and vehicle.
Not a significant number of regenerating axons were found after picropodophyllin administration post-optic nerve crush (asterix). Scale
bar = 100 mm. (E) Quantification of regenerating optic nerve axons post-crush (shown in D). At least four serial sections were analysed from each
animal (Student t-test with ANOVA, P5 0.05 for each distance, n = 6, each group). The number of regenerating axons was significantly hampered
following AAV-cre-PPP treatment versus AAV-cre-veh. (F) Anti-Tuj1 immunofluorescence shows surviving retinal ganglion cells (Tuj1 + ) 28 days
post-optic nerve crush. Scale bar = 50mm. (G) Quantification of surviving RGC as total percentage of surviving cells as compared to the intact
contralateral retina (n = 6).
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Further, genome-wide analysis from FACS sorted RGCs
after optic nerve crush revealed that MDM4 conditional
deletion was associated with the enhancement of transcripts
involved in cytoskeleton remodelling, axonal development
and signalling, including genes involved in neuronal matur-
ation (Table 1). This pattern of gene expression
changes suggests that MDM4 deletion modulates develop-
mentally regulated pathways, which may support axonal
regrowth.
Additionally, here we show that IGF1R signalling is
required for axonal regeneration of the crushed optic
nerve induced by MDM4 deletion and it is likely down-
stream of the transcriptional complex formed by MDM4-
p53/MDM2. The best-characterized IGF1R targets include
PI3K and JAK/STAT3, which are typically activated by
IGF1R (Staerk et al., 2005; Serra et al., 2007; Subbiah
et al., 2011; Kim et al., 2012). Both PI3K and JAK/
STAT3 activation depends upon the phosphorylation
status that has been shown to be necessary to promote
axonal regeneration following deletion of PTEN or after
JAK binding to IL6, respectively (Cao et al., 2006; Shah
et al., 2006, Teng and Tang, 2006; Hakkoum et al., 2007;
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Figure 6 Overexpression of IGF1 promotes axonal regeneration after optic nerve crush. (A) Schematic of the experimental design
showing AAV-IGF1 or AAV-ctr intra-vitreal infection of RGCs in mice 14 days before optic nerve crush. Regenerating axons were traced with CtB.
(B) Immunofluorescence micrographs showing high IGF1 expression level 3 days after optic nerve crush in retinal ganglion cells (Tuj1*) infected
with AAV-IGF1, while a faint signal was observed in AAV-ctr infected RGCs. RGCs were counterstained with Tuj1. Scale bar = 20 mm. (C) High
magnification images of regenerating CtB labelled optic nerve axons 28 days post-crush (asterisk) in MDM4f/f mice after infection with AAV-IGF1
or AAV-GFP. Scale bar = 100 mm. (D) Quantification of regenerating optic nerve axons post-crush (shown in C). At least four serial sections were
analysed from each animal (Student t-test with ANOVA, *P5 0.05 or **P5 0.01 n = 7, each group). (E) Anti-Tuj1 immunofluorescence shows
surviving retinal ganglion cells (Tuj1 + ) 28 days post-optic nerve crush. Scale bar = 50 mm. (F) Quantification of surviving RGCs as total percentage
of surviving cells as compared to the intact contralateral retina (n = 5, AAV-IGF1 infected animals; n = 4, AAV-ctr infected animals).
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Figure 7 MDM2/p53 inhibition via Nutlin-3 delivery enhances neurological recovery and corticospinal tract regeneration
following T9 dorsal hemisection. (A) Basso Mouse Scale score and subscore (B) show significant improvement in locomotion in Nutlin-3
treated mice (Nutlin-3 or vehicle were delivered via osmotic minipump connected to an intrathecal catheter in proximity of a T9 dorsal
hemisection for 14 days post-injury). (C) Percentage of mice able to walk on a gridwalk is much higher after Nutlin-3 treatment versus vehicle. (D)
Percentage of mice with a Basso Mouse Scale score5 5 from 14 days after injury. (E) Number of missteps on a gridwalk is significantly reduced by
Nutlin-3 treatment (two-way ANOVA with Sidak’s multiple comparisons, ***P5 0.001; **P5 0.01; *P5 0.05, n = 13 (vehicle), n = 13 (Nutlin).
(F) Schematic diagram summarizing the experimental design. BDA for corticospinal tract labelling was injected 10 days before sacrifice.
SCI = spinal cord injury. (G) Representative images of sagittal cord sections of mice treated with Nutlin-3 or vehicle. The corticospinal tracts
were traced by BDA injection (red) in the cortex. Spinal cord sections were also stained with DAPI (blue). Visible are sprouting axons past the
lesion site in the Nutlin-3 treated mice. Scale bar = 500 mm. Inset (i) showing sprouting corticospinal tract fibers at higher power. (H)
Quantification of the BDA labelled sprouting corticospinal tract axons in the spinal cord rostral and distal to the lesion site. (Mann Whitney test,
**P5 0.01 n = 7).
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Park et al., 2008). This suggests a likely cross-talk between
the MDM4-MDM2/p53-IGF1 signalling and these regen-
erative pathways, further supporting our findings.
Last but not least, our work shows that MDM2/p53
inhibition via Nutlin-3, a small molecule, significantly en-
hances axonal sprouting of corticospinal tract and of 5-HT
descending fibre tracts as well as functional recovery after
spinal cord injury. Importantly, inhibition of IGF1R signal-
ling via picropodophyllin blocks axonal sprouting of the
functionally limiting 5-HT tracts as well as Nutlin-3
dependent neurological recovery. This suggests MDM2/
p53-IGF1 as a novel regenerative pathway
following nerve and spinal injury, including the opportun-
ity of a novel therapeutic target for recovery after spinal
trauma.
Given that pharmacological antagonism of MDM2-p53
interaction including with Nutlins have been shown to
induce tumour suppression and are currently being
explored in the clinic for cancer treatment and have been
shown to be safe (Brown et al., 2009), they may represent
viable options for neuroregenerative therapy in the
short-term. The recent discovery of specific small mol-
ecule inhibitors of MDM4 (Reed et al., 2010; Vogel
et al., 2012), which are still awaiting confirmation in mul-
tiple studies, may also expand our regenerative therapeutic
options.
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Supplementary Figure 1. Network pathway analysis and co-immunoprecipitation 
experiments identify MDM4-p53-MDM2 protein complex in the retina  
a. STRING network analysis shows interdependence of a number of key regenerative 
molecules with ubiquitin ligases and ligase-like proteins. However, a hot spot was found 
around MDM4-MDM2-p53, due to their highly ranked connections amongst themselves and 
their central position within the whole network. b. Representative co-immunoprecipitation 
immunoblot and input and co-immunoprecipitation at 72h after optic nerve crush or sham 
showing p53 and MDM2 co-immunoprecipitation with MDM4. Normal mouse IgG and actin 
were used as negative controls of the IP, n = 3.  
 
Supplementary Figure 2.  
a. Representative fluorescent images at 24h and 72h after optic nerve crush showing MDM4 
expression in retinal ganglion cells. Retinal ganglion cells were counterstained with Tuj1. 
MDM4 co-localised with Tuj1. Scale bar 20 µm. b. Quantification of the expression level of 
MDM4 by fluorescence intensity measurement. MDM4 expression level did not change 
significantly at 24h and 72h following optic nerve crush. At least six sections were analysed 
from 3 animals in each group. c. Representative fluorescent images at 24h and 72h after optic 
nerve crush showing p53 expression in retinal ganglion cells. Retinal ganglion cells were 
counterstained with Tuj1. P53 co-localised with Tuj1. Scale bar 20 µm. d. Quantification of 
the expression level of p53 by fluorescence intensity measurement. P53 expression level did 
not change significantly at 24h and 72h following optic nerve crush. At least six sections were 
analysed from 3 animals in each group. e. Representative fluorescent images at 24h and 72h 
after optic nerve crush showing MDM2 expression in retinal ganglion cells. Retinal ganglion 
cells were counterstained with Tuj1. MDM2 co-localised with Tuj1. Scale bar 20 µm. f. 
Quantification of the expression level of MDM2 by fluorescence intensity  
measurement. MDM2 expression level did not change significantly at 24h and 72h following 
optic nerve crush. At least six sections were analysed from 3 animals in each group. 
  
Supplementary Figure 3.  
a. Representative image of a retina infected with AAV-CreGFP showing specific highly 
efficient infection in retinal ganglion cells. Scale bar 50 µm. b. Immunofluorescence of retinal 
ganglion cells infected with AAV-GFP or AAV-CreGFP showing MDM4 deletion 14d after 
infection. MDM4 expression could be detected by immunostaining in control AAV-GFP 
infected samples only (arrowheads). Scale bar 20 µm. c. Semi quantitative PCR from 
dissociated retinal ganglion cell culture 3 days after infection with AAV-GFP/AAV-Cre. 
MDM4 expression was significantly reduced after Cre mediated recombination.  
 
Supplementary Figure 4.  
a. Shown are GFP and BDA labeling of the sensorimotor cortex after stereotaxic delivery of 
AAV-GFP or BDA. Inset shows layer V in the sensorimotor cortex. Scale bar 500 µm. b. 
Shown are cre-positive cells after anti-cre immunostaining in proximity of the injection site 
(asterix) of AAV-cre in the sensorimotor cortex. Scale bar 50 µm. c. Immunostaining for GFP 
and CTIP2 (layer V neurons marker) show AAV-GFP infection of layer V neurons in the 
sensorimotor cortex. Scale bar 20 µm.  
 
Supplementary Figure 5.  
Shown are BDA+ corticospinal tract sprouting axons (arrowheads) past the lesion site (dashed 
line) after AAV-cre delivery in the sensorimotor cortex of MDM4f/f mice (5 weeks pre-
injury). Sagittal section. Scale bar 500 µm.  
 
 
 Supplementary Figure 6.  
a. Dissociated retinal ganglion cells from MDM4f/f postnatal day 7 mice were cultured on 
permissive (PDL) and inhibitory substrate (myelin) for 72h following Ad-Cre/Ad-GFP 
infection. Neurites were traced with Tuj1. b. Quantification of neurite outgrowth 72h after 
AV-GFP/AV-Cre infection. Semi-automatic analysis from more than 500 neurons per 
condition (n = 3) showed a significantly higher outgrowth in the AV-Cre infected group. 
Student’s t-test, p<0.05. c. Cerebellar granule neurons from MDM4f/f mice were plated on 
permissive (PDL) and inhibitory (Myelin) substrate and infected with AV-GFP/AV-Cre. AV-
Cre infected group showed a significantly higher neurite outgrowth 24h after infection. 
Neurites were traced with Tuj1. d. Quantification of neurite outgrowth of cultured cerebellar 
granule neuron . Neurites were traced manually from single neurons that were infected with 
the virus. At least 100 neurons were analysed per condition per group. n = 4. Student’s t-test, 
p<0.05.  
 
Supplementary Figure 7.  
a. Semiquantitative PCR mice from MDM4f/f cerebellar granule neuron (cerebellar granule 
neuron ) cultures after infection with AV-Cre or AV-GFP. MDM4 expression was 
significantly reduced after Cre mediated recombination. b. Real time quantitative PCR from 
MDM4f/f cerebellar granule neuron cultures 24h after infection with AV-GFPor AV-Cre 
showed enhanced expression of several p53-target genes. P53 expression was not altered due 
to MDM4 deletion.  
 
Supplementary Figure 8.  
a. Quantitative RTPCR from cerebellar granule neuron treated with Nutlin-3a or vehicle 
(24h). Shown is enhanced expression of axon growth associated and p53 target genes with 
Nutlin-3a 100nM versus vehicle.18S RNA was used for nomalization. n = 3. (Student t-test, 
*p< 0.05 or **p<0.01). b. Apoptosis was evaluated 24h after administration of Nutlin-3a or  
vehicle in cerebellar granule neuron . Pyknotic cells were identified with DAPI staining. n = 
3. (Student t-test, *p< 0.05 or **p<0.01).  
 
Supplementary Figure 9.  
a. Dose response of picropodophyllin (picropodophyllin, IGF1R antagonist) in cerebellar 
granule neurons was determined by counting the number of Cleaved Caspase 3 positive cells 
in a dose response curve. picropodophyllin 1µM or above showed significant cell death as 
compared to vehicle control. n = 3. Student’s t-test, p<0.05. b. Cells extending neuritis in 
response to picropodophyllin treatment (dose response) were counted. Cells treated with 
picropodophyllin 10nM or above showed reduced number of cells extending neurites. n = 3. 
Student’s t-test, p<0.05.  
 
Supplementary Figure 10.  
a. Representative immunoblotting from a spinal cord 72 hours after Nutlin-3 or vehicle 
delivery with osmotic minipump and spinal cord T9 hemisection. Shown is enhancement of 
active acetylated p53 (p53ac) and of the prototypical p53 target gene p21 after Nutlin-3 versus 
vehicle. Classical cell death pathways were also not induced by Nutlin-3 as shown by cl-
caspase 3 expression. b. Bar graphs show densitometry analysis (arbitrary units) expressed as 
fold change of Nutlin-3 versus vehicle. n = 3. Student's unpaired two-tailed t-test **p< 0.01 or 
***p<0.001.  
 
 
 
 
Supplementary Figure 11.  
Shown are BDA+ corticospinal tract sprouting axons past the lesion site (dashed line) after 
Nutlin-3 administration (for 14 days after T9 spinal cord hemisection) 45 days post-injury. 
Scale bar 250 µm.  
 
Supplementary Table 1.  
List of dysregulated genes. Genes differentially expressed were selected based upon a 2 fold 
change cut-off and significant statistical difference between AAV GFP and AAV cre infected 
RGC (ANOVA with Bonferroni correction).  
 
Supplementary Table 2.  
Ingenuity canonical pathways from dysregulated genes between AAV GFP and AAV cre 
infected RGC. 
  
Supplementary Table 3.  
Details about our spinal cord injury experimental design and criteria according to the Minimal 
Information about a Spinal Cord Injury Experiment reporting standards. 
  
Supplementary Table 4.  
Details about our optic nerve crush experimental design and criteria according to the Minimal 
Information about a Spinal Cord Injury Experiment reporting standards.  
 
Supplementary movies.  
Shown are representative runs on the grid walk 35 days after spinal cord injury and vehicle 
(a) versus Nutlin-3 administration (b). The number and severity of missteps is significantly 
reduced after Nutlin-3 treatment. 
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Supplementary Table 3 Minimum Information About a Spinal Cord Injury experiment*
*Lemmon'VP'et'al.'(2014)'Minimum'Information'about'a'Spinal'Cord'Injury'Experiment:'A'Proposed'Reporting'Standard
for'Spinal'Cord'Injury'Experiments.'J"Neurotrauma"31:1354–1361.
ORGANISM Nutlin.experiments Nutlin.+.PPP.experiment MDM4.f/f.experiments
Binomial'systematic'name'(genus'and'
species)'
Mus'musculus Mus'musculus Mus'musculus
Phenotype Wild'type Wild'type Wild'type
Genotype None None Mdm4'f/f
How'was'genotype'confirmed? Not'applicable Not'applicable PCR'(primer'sequences'in'MM)
Source/Vendor Charles'River,'Sulzfeld,'Germany Charles'River,'Sulzfeld,'Germany Obtained'from'J.C.'Marine'Lab
Organism'Vendor'Cat'# B6NSIMA B6NSIMA
Strain C57BL/6 C57BL/6 C57BL/6
Number'of'generations'backcrossed Not'applicable Not'applicable
Sex Male Male M&F
PubMed'Reference Not'applicable Not'applicable Not'available
Het'vs.'homozygote Not'applicable Not'applicable Homozygote
Propagation'strategy Not'applicable Not'applicable
Age'at'sacrifice 19'weeks 19'weeks 13'weeks
Weight'at'surgery 24b30'g 25b30'g 19b29'g
Was'Tamoxifen'administered? No' No' No'
If'yes,'at'what'age? Not'applicable Not'applicable Not'applicable
If'yes,'when'relative'to'injury? Not'applicable Not'applicable Not'applicable
HOUSING
Group'vs.'Single Group Group Group
Light/Dark'Cycle 12b12 12b12 12b12
When'tested'relative'to'Light/Dark'cycle? Light'(morning) Light'(morning) Not'applicable
Enrichment Yes Yes Yes
Exercise'opportunities Nestlets Nestlets Nestlets
Food Milk+moistured'food+dry'food'until'3rd'
DPO,'moistured'food+dry'food'until'
recovery'of'surgery'weight,'fruit'crunchies'
ad'libitum
Milk+moistured'food+dry'food'until'3rd'
DPO,'moistured'food+dry'food'until'
recovery'of'surgery'weight,'fruit'crunchies'
ad'libitum
Moistured'food+dry'food'ad'libitum
Supplemental'Nutrical Yes,'daily'until'sacrifice Yes,'daily'until'sacrifice No
SURGERY Nutlin-experiments Nutlin-+-PPP-experiment MDM4-f/f-experiments
Anesthetics
Systemic-Anesthetics
Anesthetic)1 Ketamin-10% Ketamin-10% Ketamin-10%
Source/Company WDT WDT WDT
Catalogue)number F0637@04 F0637@04 F0637@04
Amount 100)mg/Kg 100)mg/Kg 100)mg/Kg
Solvent 0,9%)saline 0,9%)saline 0,9%)saline
Delivery)method Intraperitoneal) Intraperitoneal) Intraperitoneal)
Anesthetic)2 Sedaxylan-(Xylazin-20-mg/ml) Sedaxylan-(Xylazin-20-mg/ml) Sedaxylan-(Xylazin-20-mg/ml)
Source/Company WDT WDT WDT
Catalogue)number Ch.)B.)EM43 Ch.)B.)EM43 Ch.)B.)EM43
Amount 10)mg/Kg 10)mg/Kg 10)mg/Kg
Solvent 0,9%)saline 0,9%)saline 0,9%)saline
Delivery)method Intraperitoneal) Intraperitoneal) Intraperitoneal)
Local-Anesthetics Xylocain-2% Xylocain-2% Xylocain-2%
Source/Company Astra)Zeneca Astra)Zeneca Astra)Zeneca
Catalogue)number PZN#1313764 PZN#1313764 PZN#1313764
Amount 1)drop 1)drop 1)drop
Solvent not)diluted not)diluted not)diluted
Delivery)method local)on)the)dura)mater local)on)the)dura)mater local)on)the)dura)mater
Surgical/details
Concealed)allocation:)were)experimenters)
blinded)to)treatments?
Yes Yes Yes
Does)the)phenotype)of)a)transgenic)animal)
make)its)genetic)status)obvious?
Not)applicable Not)applicable No
Injury)Level T9 T9 T9
SURGERY Nutlin-experiments Nutlin-+-PPP-experiment MDM4-f/f-experiments
Surgery)duration 1)hour 1)hour 20)minutes
Surgery)time)of)day Morning)and)afternoon Morning)and)afternoon Morning)and)afternoon
Batching)method)/)method)of)
randomization
Randomized Randomized Randomized
Number)of)surgeons)in)project 1 1 1
Injury/Method
Contusion No No No
Hemisection Yes Yes Yes
If)yes,)provide)details T9)dorsal)hemisection)until)the)central)
canal
T9)dorsal)hemisection)until)the)central)
canal
T9)dorsal)hemisection)until)the)central)
canal
Neurochemical No No No
Crush No No No
Compression No No No
Vascular)occlusion No No No
Transection No No No
Reporters/
Axon)labeling)method BDA)anterograde)tracing)and)5@HT)
immunostaining
5@HT)immunostaining BDA)anterograde)tracing
Post/Surgery/Care
Analgesic-1 Buprenorphine-(Temgesic)-0,3-mg/ml-
injection-solution
Buprenorphine-(Temgesic)-0,3-mg/ml-
injection-solution
Source Schering@Plough Schering@Plough
Catalogue)number PZN)345928 PZN)345928
Amount 0,05@0,1)mg/Kg)12/12)h)until)3rd)DPO 0,05@0,1)mg/Kg)12/12)h)until)3rd)DPO
Solvent 0,9%)saline 0,9%)saline
Delivery)method Subcutaneous Subcutaneous
SURGERY Nutlin-experiments Nutlin-+-PPP-experiment MDM4-f/f-experiments
Analgesic-2 Carprofen-(Carprieve)-50-mg/ml-injection-
solution
Carprofen-(Carprieve)-50-mg/ml-injection-
solution
Source Norbrook Norbrook
Catalogue)number VM#10999/102/1 VM#10999/102/1
Amount 5)mg/Kg)once)day,)4th@7th)DPO 5)mg/Kg)once)day,)4th@7th)DPO
Solvent 0,9%)saline 0,9%)saline
Delivery)method Subcutaneous Subcutaneous
Hydration
Solution 0,9%)saline 0,9%)saline 0,9%)saline
Volume 2)ml)or)1)ml 2)ml)or)1)ml 2)ml)or)1)ml
Delivery)method Subcutaneous Subcutaneous Subcutaneous
Frequency 1)ml)12/12)h)until)2nd)DPO,)1)ml)once)daily)
3rd@5th)DPO.)1)ml)daily)if)signs)of)bladder)
infection)(i.e.)purulent)or)bloody)urine)
1)ml)12/12)h)until)2nd)DPO,)1)ml)once)daily)
3rd@5th)DPO.)1)ml)daily)if)signs)of)bladder)
infection)(i.e.)purulent)or)bloody)urine)
1)ml)12/12)h)until)2nd)DPO,)1)ml)once)daily)
3rd@5th)DPO.)1)ml)daily)if)signs)of)bladder)
infection)(i.e.)purulent)or)bloody)urine)
Antibiotics Enrofloxacin-(Baytril)-2,5%-injection-
solution
Enrofloxacin-(Baytril)-2,5%-injection-
solution
Source Bayer Bayer
Catalogue)number PZN)3543238 PZN)3543238
Volume 5)mg/Kg)(prophylactic))or)10)mg/Kg)
(therapeutic))
5)mg/Kg)(prophylactic))or)10)mg/Kg)
(therapeutic))
Delivery)method Subcutaneous Subcutaneous
Frequency Prophylactic:)once)daily)at)surgery)day)and)
1st@5th)DPO.)Therapeutic:)10@14)days)at)
chronic)phase)(+8)DPO))if)signs)of)bladder)
infection)(i.e.)purulent)or)bloody)urine))
Prophylactic:)once)daily)at)surgery)day)and)
1st@5th)DPO.)Therapeutic:)10@14)days)at)
chronic)phase)(+8)DPO))if)signs)of)bladder)
infection)(i.e.)purulent)or)bloody)urine))
SURGERY Nutlin-experiments Nutlin-+-PPP-experiment MDM4-f/f-experiments
Bladder-expression
Frequency Twice)a)day Twice)a)day Twice)a)day
Timing)relative)to)behavioral)testing Always)before Always)before Not)applicable
Animal/Attrition
Exclusion)criteria Animals)were)excluded)from)analysis)in)
the)case)of)spared)fibers)or)when)we)
observed)a)total)transection)with)the)
fibronectin)positive)scar)spanning)the)
entire)depth)of)the)spinal)cord.)These)
animals)were)rejected)from)analysis)by)
someone)blinded)to)their)treatment)
allocation.))))))))))))))))))))))))))))))
Animals)were)excluded)from)analysis)in)
the)case)of)spared)fibers)or)when)we)
observed)a)total)transection)with)the)
fibronectin)positive)scar)spanning)the)
entire)depth)of)the)spinal)cord.)These)
animals)were)rejected)from)analysis)by)
someone)blinded)to)their)treatment)
allocation.)
Animals)were)excluded)from)analysis)in)
the)case)of)spared)fibers,)poor)CST)tracing)
or)when)we)observed)a)total)transection)
with)the)fibronectin)positive)scar)spanning)
the)entire)depth)of)the)spinal)cord.)These)
animals)were)rejected)from)analysis)by)
someone)blinded)to)their)treatment)
allocation.)
Were)exclusion)criteria)established)before)
the)study)was)initiated
Yes
Health/Outcomes
Number)of)animals)excluded)for)any)
reason
7 0 6
Why)were)animals)excluded? Total)transection CST)tracing)was)poor
Survival)time)after)surgery 45)days 35)days 28)days
PERTURBAGEN Nutlin/experiments Nutlin/+/PPP/experiment MDM4/f/f/experiments
Adapted/from/MIACA/080404
Perturbagen*Name*1 NutlinC3a NutlinC3a Virus
Perturbagen*Type Drug Drug AAV12GFP*and*AAV12Cre2GFP
Perturbagen*Sequence/Composition:*of*
cDNA/siRNA/shRNA;*
structure/’smile’/CHEBI*if*compound
Not*applicable Not*applicable Not*applicable
Perturbagen*manufacturer Cayman Cayman SignaGen*Laboratories
Perturbagen*Catalogue*# 18585 18585 SL100803*(AAV12GFP)*and*SL100805*
(AAV12Cre2GFP
Perturbagen*Lot*# Batch#044170527 Batch#044170527 AAV616714*(AAV12GFP)*and*AAV616731*
(AAV12Cre2GFP)
Perturbagen*Target*Species:*e.g.*if*siRNA Not*applicable Not*applicable Not*applicable
Perturbagen*Stock*Concentration 2*mM 2*mM
Perturbagen*Solvent 100%*pure*ethanol 100%*pure*ethanol
Solvent*Final*concentration 8,6%*(in*PBS) 8,6%*(in*PBS)
Stock*storage*condition 220*∘C 220*∘C 280*∘C
If*perturbagen*is*a*compound,*is*any*
information*available*about*its*
biodistribution?
Yes*(Zhang*F*et*al.*Drug*Metab*Dispos.*
39:15221,*2011)
Yes*(Zhang*F*et*al.*Drug*Metab*Dispos.*
39:15221,*2011)
If/Perturbagen/1/is/part/of/a/library
Library*Name PubChem PubChem
Library*Type Compound Compound
Library*manufacture U.S.*National*Library*of*Medicine U.S.*National*Library*of*Medicine
Library*Catalogue*# CID*11433190 CID*11433190
PERTURBAGEN Nutlin/experiments Nutlin/+/PPP/experiment MDM4/f/f/experiments
Perturbagen*Name*2 Picropodophyllin
Perturbagen*Type Drug
Perturbagen*Sequence/Composition:*of*
cDNA/siRNA/shRNA;*
structure/’smile’/CHEBI*if*compound
Not*applicable
Perturbagen*manufacturer Medkoo*Biosciences
Perturbagen*Catalogue*# 205812
Perturbagen*Lot*# BP40711
Perturbagen*Target*Species:*e.g.*if*siRNA Not*applicable
Perturbagen*Stock*Concentration 100*mM
Perturbagen*Solvent DMSO
Solvent*Final*concentration 10%*(in*cottonseed*oil)
Stock*storage*condition 220*∘C
If*perturbagen*is*a*compound,*is*any*
information*available*about*its*
biodistribution?
Yes*(Yin*S*et*al.*Neuro*Oncol.*12(1):19227,*
2010)
If/Perturbagen/2/is/part/of/a/library
Library*Name PubChem
Library*Type Substance
Library*manufacture U.S.*National*Library*of*Medicine
Library*Catalogue*# SID*53787335
If*Perturbagen*is*virus:
Virus*Type AAV
Virus*isotype AAV1
Virus*Titer 4,4*x*109*GC/µl*(AAV12GFP)*and*3,1*x*109*
GC/µl*(AAV12Cre2GFP)
Titration*method Real2time*PCR
Promoter*driving*protein/miRNA*
expression
CMV
IRIS/2A*peptide/Dual*Promoter Not*applicable
PERTURBAGEN Nutlin/experiments Nutlin/+/PPP/experiment MDM4/f/f/experiments
Transfection*Reagents Not*applicable
Timing*of*perturbagen*1*delivery*relative*
to*injury
Immediately*after Immediately*after 5*weeks*prior*to*injury
Timing*of*perturbagen*2*delivery*relative*
to*injury
At*the*surgery*day*(≤*8*hours*after*surgery)
Treatment*Delivery*(Perturbagen*1) NutlinC3a NutlinC3a AAV/
Rate 0,5*µl/h 0,5*µl/h
Location Minipump*subcutaneous,*catheter*
intrathecal**
Minipump*subcutaneous,*catheter*
intrathecal**
Right*sensorimotor*cortex
Method*&*route*(i.p.,*i.v.,*minipump) Alzet*minipump*(model*2002,*Lot#102852
12)+intrathecal*catheter*(polyethylene,*
32G,*ReCathCo)
Alzet*minipump*(model*2002,*Lot#102852
12)+intrathecal*catheter*(polyethylene,*
32G,*ReCathCo)
Stereotaxic2coordinated*micro2injections*
with*5*µl*Hamilton*syringe
Dosage*(mg/kg) 0,04*mg/Kg/day*(14*days) 0,04*mg/Kg/day*(14*days) 0,32*µl
Acute*/*chronic Acute*and*chronic Acute*and*chronic
Convection*based Not*applicable Not*applicable Not*applicable
Treatment*Delivery*(Perturbagen*2) Picropodophyllin
Rate Not*applicable
Location Not*applicable
Method*&*route*(i.p.,*i.v.,*minipump) I.P.
Dosage*(mg/kg) 20*mg/Kg*12/12*h*(14*days)
Acute*/*chronic Acute*and*chronic
Convection*based Not*applicable
HISTOLOGY Nutlin/experiments Nutlin/+/PPP/experiment MDM4/f/f/experiments
Fixation/Method
Method Pump Pump Pump
Anesthetic Ketamine+Xylazine Ketamine+Xylazine Ketamine+Xylazine
Prerinse Yes Yes Yes
Buffer PBS PBS PBS
Volume 10?ml 10?ml 10?ml
Temperature 0?∘C 0?∘C 0?∘C
Fixative 4%?PFA 4%?PFA 4%?PFA
Buffer PBS PBS PBS
Volume 10?ml 10?ml 10?ml
Temperature 0?∘C 0?∘C 0?∘C
Tissue/Processing
Sectioning?method Cryostat,?embedded?in?OCT,?18?µm Cryostat,?embedded?in?OCT,?18?µm Cryostat,?embedded?in?OCT,?18?µm
Normalization?method?for?shrinkage None None None
Lesion?volume/size ≅2mm?(length)?X?1?mm?(wide)?x?0,5?mm?
(depth)
≅2mm?(length)?X?1?mm?(wide)?x?0,5?mm?
(depth)
≅2mm?(length)?X?1?mm?(wide)?x?0,5?mm?
(depth)
White?matter/Gray?matter?sparing Both Both Both
Axonal/tracing/methods
Traditional?tracer BDA No BDA
Genetic?tracer No No No
Viral?tracer No No No
Where?tracer?injected Sensorimotor?cortex Sensorimotor?cortex
When?tracer?injected?relative?to?injury 5?weeks?after?injury 2?weeks?after?injury
Survival?time?after?injection?of?tracer 10?days 14?days
Histology Nutlin/experiments Nutlin/+/PPP/experiment MDM4/f/f/experiments
Characterization/of/injury
Measures?of?sprouting Yes Yes Yes
Measures?of?regeneration No No No
Measures?of?spanning No No No
Clearing?method None None None
Cell?counts No No No
IMMUNOHISTOCHEMISTRY Nutlin2Experiments Nutlin2+2PPP2experiment MDM42f/f2experiments
Neurons2identified No No Yes
Marker*used Ctip2*(Brain)
Neurites2identified No No
Axons2identified Yes Yes Yes
Marker*used BDA*and*59HT 59HT BDA
Dendrites2identified No No No
Growth2Cones2identified No No No
Synapses2identified No No No
Astrocytes2identified Yes No Yes
Markers*used GFAP GFAP
Oligodendrocytes2identified No No No
Schwann2cells2identified No No No
Microglia2identified No No No
Immunohistochemistry Nutlin2Experiments Nutlin2+2PPP2experiment MDM42f/f2experiments
Primary2antibodies
Antigen*/*Target Fibronectin 59HT Ctip2
Vendor Sigma9Aldrich Immunostar Abcam
Catalogue*number F3648 20080 AB18465
Species Rabbit Rabbit Rat
Clonality Polyclonal Polyclonal Monoclonal
lot*# 1131001
Antigen*/*Target GFAP GFAP
Vendor Millipore Millipore
Catalogue*number AB5804* AB5804*
Species Rabbit Rabbit
Clonality Polyclonal Polyclonal
lot*# NG1817590 NG1817590
Antigen*/*Target 59HT
Vendor Immunostar
Catalogue*number 20080
Species Rabbit
Clonality Polyclonal
lot*# 1131001
IMAGING Nutlin+experiments Nutlin+++PPP+experiment MDM4+f/f+experiments
Live%Cell%Imaging No No No
Immunostaining Yes Yes Yes
Imaging%Format: .zvi .zvi .zvi
Imaging%method:% Fluorescence%and%bright%field Fluorescence%and%bright%field Fluorescence
Microscope+Manufacture Zeiss Zeiss Zeiss
Microscope%Name Axioplan%2%with%Axiophot%2 Axioplan%2%with%Axiophot%2 Axioplan%2%with%Axiophot%2
Microscope%model Light%microscope Light%microscope Light%microscope
Were%constant%image%acquisition%standards%
used
Yes Yes Yes
Camera+Manufacture+1 Zeiss Zeiss Zeiss
Camera%type% CCD CCD CCD
Camera%Model AxioCam%MRm AxioCam%MRm AxioCam%MRm
Pixel%binning Yes Yes Yes
Camera+Manufacture+2 MBF+Bioscience MBF+Bioscience
Camera%Type Legacy%with%IIDC%interface%protocol Legacy%with%IIDC%interface%protocol
Camera%Model MBF%CX9000 MBF%CX9000
Pixel%binning No No
Microscope+Incubator Not+applicable Not+applicable Not+applicable
IMAGING Nutlin+experiments Nutlin+++PPP+experiment MDM4+f/f+experiments
Imaging
Observer%blinded%to%treatment? Yes Yes
Image+Analysis+1 AxioVision AxioVision AxioVision
Software%Vendor Zeiss Zeiss Zeiss
Software%Package%Name AxioVision%4.8.1%(11X2009) AxioVision%4.8.1%(11X2009) AxioVision%4.8.1%(11X2009)
Software%Package%release%Number AxioVs40%V%4.8.1.0 AxioVs40%V%4.8.1.0 AxioVs40%V%4.8.1.0
Parameters%Captured CSTXlabelled%and%5HTXstained%axons%and%
sprouts/GFAP%labelled%
astrocytes/amorphous%substance%labelled%
with%fibronectin%at%the%injury%site%
5HTXstained%axons%and%sprouts% CSTXlabelled%axons%and%sprouts
Features%studied Axons%and%sprouts/injury%site%area%and%
morphology
Axons%and%sprouts/injury%site%area%and%
morphology
Axons%and%sprouts
Neurite%length,%#,%branching,%density Not%applicable Not%applicable Not%applicable
Velocity%of%neurite%growth%or%retraction No No No
Varicosities%in%synapse%formation No No No
Neurite%thickness No No No
Criteria%of%cell%selection/analysis Morphology:%axons%above%the%lesion%are%
homogeneous%and%run%parallel%to%each%
other%in%the%tract;%sprouts%follow%an%
irregular%and%random%course.
Biased/unbiased Unbiased Unbiased
Sholl%Analysis No No No
Are%neurites%touching? Not%applicable Not%applicable Not%applicable
Image+Analysis+2 Stereo+Investigator Stereo+Investigator
Software%Vendor MBF%Bioscience MBF%Bioscience
Software%Package%Name Stereo%Investigator%7 Stereo%Investigator%7
Software%Package%release%Number Stereo%Investigator%7.50.4 Stereo%Investigator%7.50.4
Parameters%Captured CST%axons%and%sprouts% CST%axons%and%sprouts%
Features%studied Axons%and%sprouts%counted%live Axons%and%sprouts%counted%live
IMAGING Nutlin+experiments Nutlin+++PPP+experiment MDM4+f/f+experiments
Neurite%length,%#,%branching,%density Not%applicable Not%applicable
Velocity%of%neurite%growth%or%retraction No No
Varicosities%in%synapse%formation No No
Neurite%thickness Not%applicable Not%applicable
Criteria%of%cell%selection/analysis Morphology:%axons%above%the%lesion%are%
homogeneous%and%run%parallel%to%each%
other%in%the%tract;%sprouts%follow%an%
irregular%and%random%course.
Morphology:%axons%above%the%lesion%are%
homogeneous%run%and%parallel%to%each%
other%in%the%tract;%sprouts%follow%an%
irregular%and%random%course.
Criteria%of%cell%selection/analysis
Biased/unbiased
Biased/unbiased Unbiased Unbiased
Sholl%Analysis No No
Are%neurites%touching? Not%applicable Not%applicable
BEHAVIOR Nutlin/experiments Nutlin/+/PPP/experiment
History(of(Training Animal(handling(once(a(day(for(7(days.(Animal(
acclimatization(once(a(day(for(another(7(days.
Animal(handling(once(a(day(for(7(days.(Animal(
acclimatization(once(a(day(for(another(7(days.
Frequency(of(testing 1(day(before(injury,(then(1,(3,(7,(14,(21,(18(and(35(
days(after(injury
1(day(before(injury,(then(1,(3,(7,(14,(21,(18(and(35(
days(after(injury
Devices Basso(open(field(platform(for(BMS,(grid(walk Basso(open(field(platform(for(BMS
Time(of(day Morning Morning
Observers(blinded(to(treatments? Yes Yes
Analgesics Yes Yes
Kind(of(analgesic Opioid(or(NSAID Opioid(or(NSAID
Dose 0,05S0,1(mg/Kg(or(5(mg/Kg,(respectively 0,05S0,1(mg/Kg(or(5(mg/Kg,(respectively
Frequency 12/12(h(or(once(day,(respectively 12/12(h(or(once(day,(respectively
When(relative(to(testing Always(after(testing Always(after(testing
Hydration/administered/during/behavioral/testing Yes Yes
Kind 0,9%(saline(solution 0,9%(saline(solution
Amount 1(ml 1(ml
Frequency 1(ml(12/12(h(until(2nd(DPO,(1(ml(once(daily(3rdS5th(
DPO.(1(ml(daily(if(signs(of(bladder(infection((i.e.(
purulent(or(bloody(urine)
1(ml(12/12(h(until(2nd(DPO,(1(ml(once(daily(3rdS5th(
DPO.(1(ml(daily(if(signs(of(bladder(infection((i.e.(
purulent(or(bloody(urine)
When(relative(to(testing Always(after(testing Always(after(testing
Antibiotics Yes Yes
Kind Fluoroquinolone Fluoroquinolone
Amount 5(mg/Kg((prophylactic)(or(10(mg/Kg((therapeutic)( 5(mg/Kg((prophylactic)(or(10(mg/Kg((therapeutic)(
Frequency Once(a(day Once(a(day
When(relative(to(testing Always(after(testing Always(after(testing
Behavior Nutlin/experiments Nutlin/+/PPP/experiment
Motor
Basso,/Beattie,/Bresnahan/Locomotor/Rating/Scale/
(BBB)/for/rats No No
Basso/Mouse/Scale Yes Yes
BMS(subscore Yes Yes
Raters
Paired Yes Yes
Discussion Yes Yes
Interrater(correlation Not(calculated Not(calculated
Training(certification Yes Yes
If(certified,(when(relative(to(testing One(year(before(the(tests(were(started One(year(before(the(tests(were(started
Gait(Analysis No No
Sensory No No
Cognitive No No
Autonomic No No
EXPERIMENTAL+DESIGN,+DATA+
ANALYSIS,+STATISTICS
Nutlin+experiments Nutlin+++PPP+experiment MDM4+f/f+experiments
How$and$when$were$investigators$blinded$
to$experimental$treatments?
The$surgeon,$the$behavior$raters$and$the$
researchers$that$performed$histological$
analysis$were$blinded$to$the$pump$content$
(i.e.$Nutlin?3a$or$vehicle)
The$surgeon,$the$behavior$raters$and$the$
researchers$that$performed$histological$
analysis$were$blinded$to$the$syringe$
content$(i.e.$PPP$or$vehicle)$
Number+of+independent+experiments+for+
a+study
3 3 2
What$does$independent$mean? Different$days Different$days Different$days
Technical+replicates 1 None 1
What$is$a$technical$replicate? Different$animals$and$days Different$animals$and$days
Was$primary$outcome$measure$set$prior$to$
start$of$study?
Yes Yes Yes
Describe$the$prospective$analysis$plan To$study$a$continuous$response$variable$
such$as$behavioral$testing$(BMS$and$grid$
walk)$from$matched$pairs$with$prior$data$
indicating$a$standard$deviation$1,$we$will$
need$to$study$13$pairs$of$subjects$to$be$
able$to$reject$the$null$hypothesis$that$this$
response$difference$is$zero$with$
probability$(power)$0,9$and$a$$significant$p?
value$of$0,05$for$a$mean$difference$of$1.$
Performed$with$the$software$PS$Power$
and$Sample$Size$Calculations$3.1.2$
(http://biostat.mc.vanderbilt.edu/$
PowerSampleSize).
To$study$a$continuous$response$variable$
such$as$behavioral$testing$(BMS)$from$
matched$pairs$with$prior$data$indicating$a$
standard$deviation$1,$we$will$need$to$study$
7$pairs$of$subjects$to$be$able$to$reject$the$
null$hypothesis$that$this$response$
difference$is$zero$with$probability$(power)$
0.9$and$a$$significant$p?value$of$0.05$for$a$
mean$difference$of$1.5.$Performed$with$
the$software$PS$Power$and$Sample$Size$
Calculations$3.1.2$
(http://biostat.mc.vanderbilt.edu/$
PowerSampleSize).
To$study$a$variable$such$as$histological$
sprouting$from$matched$pairs$with$prior$
data$indicating$a$standard$deviation$0,75,$
we$will$need$to$study$4$pairs$of$subjects$to$
be$able$to$reject$the$null$hypothesis$that$
this$response$difference$is$zero$with$
probability$(power)$0,9$and$a$$significant$p?
value$of$0,05$for$a$mean$difference$of$2.$
Performed$with$the$software,$PS$Power$
and$Sample$Size$Calculations$3.1.2$
(http://biostat.mc.vanderbilt.edu/$
PowerSampleSize).
Experimental+Design,+Data+
Analysis,+Statistics
Nutlin+experiments Nutlin+++PPP+experiment MDM4+f/f+experiments
Statistical$tests:$what$tests$were$used$ Two?way$ANOVA$with$Sidak$multiple$
comparison$post?tests$(behavior)$and$One?
way$ANOVA$with$multiple$comparison$
Tukey$post?tests$(histology/sprouting$
fibers).$
Two?way$ANOVA$with$Sidak$multiple$
comparison$post?tests$(behavior)$and$One?
way$ANOVA$with$multiple$comparison$
Tukey$post?tests$(histology/sprouting$
fibers).$
One?way$ANOVA$with$multiple$comparison$
Tukey$post?tests$(sprouting$fibers).$
Normalization$methods The$number$of$corticospinal$tract$sprouts$
was$normalized$to$the$number$of$labeled$
axons$rostral$to$the$lesion.
The$number$of$corticospinal$tract$sprouts$
was$normalized$to$the$number$of$labeled$
axons$rostral$to$the$lesion.
Positive$and$negative$controls Negative$controls:$8,6%$pure$ethanol$in$
PBS
Negative$controls:$10%$DMSO$in$
cottonseed$oil
Negative$controls:$AAV1?GFP$virus$injected$
in$the$sensorimotor$cortex
 1 
 
Primers sequences 
 Gene Primer forward Primer Reverse 
p21 CGGTGGAACTTTGACTTCGT  AGAGTGCAAGACAGCGACAA 
GADD45 CAGGGGAGGGACTCGCACTT CGGGGTCTACGTTGAGCAGC 
GAP43 AAGCTACCACTGATAACTCCCC CTT CTTTACCCTCATCCTGTCG 
SCG10 AGACTCCTCTCTCGCTCTCTCCGC AGCCTCTTGAGACTTTCTTCGCTCCTC 
CAP23 GGCGGCAGCGCTCCAACTCG CCGCCTGGGGTTCGCTCTCC 
p53 AGAGACCGCCGTACAGAAGA  CTGTAGCATGGGCATCCTTT 
MDM4 CAGCTAGGAGGGGGAGCGACT GCAGTTTTGGCCGCACCTGACTAA 
β-actin CTCTCSGCTGTGGTGGTGAA AGCCATGTACGTAGCCATCC 
L1CAM ATGCTGCGGTACGTGTGGCCCT CCACTTGGGGGCACCCTCGG 
BDNF AGTCTCCAGGACAGCAAAGC TCGTCAGACCTCTCGAACCT 
Sprr1a CCCCTCAACTGTCACTCCAT CAGGAGCCCTTGAAGATGAG 
18S RNA CTCAACACCGGGAAACCTCAC CGCTCCACCAACTAAGAACG 
β-actin CTCTCSGCTGTGGTGGTGAA AGCCATGTACGTAGCCATCC 
RPL13a GGCTGAAGCCTACCAGAAAG TTCTCCTCCAGAGTGGCTGT 
   Supplementary Table 5. List of primer sequences 
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PCAF-dependent epigenetic changes promote
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Axonal regenerative failure is a major cause of neurological impairment following central
nervous system (CNS) but not peripheral nervous system (PNS) injury. Notably, PNS injury
triggers a coordinated regenerative gene expression programme. However, the molecular link
between retrograde signalling and the regulation of this gene expression programme that
leads to the differential regenerative capacity remains elusive. Here we show through
systematic epigenetic studies that the histone acetyltransferase p300/CBP-associated factor
(PCAF) promotes acetylation of histone 3 Lys 9 at the promoters of established key
regeneration-associated genes following a peripheral but not a central axonal injury.
Furthermore, we find that extracellular signal-regulated kinase (ERK)-mediated retrograde
signalling is required for PCAF-dependent regenerative gene reprogramming. Finally, PCAF is
necessary for conditioning-dependent axonal regeneration and also singularly promotes
regeneration after spinal cord injury. Thus, we find a specific epigenetic mechanism that
regulates axonal regeneration of CNS axons, suggesting novel targets for clinical application.
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The regenerative response initiated following axonal injuryin the peripheral nervous system (PNS) versus the centralnervous system (CNS) leads to differential growth
capacities and repair. In fact, the lack of pro-neuroneal growth
gene expression and glial inhibitory signals leads to regenerative
failure following CNS but not PNS injury1–4. Immediately after a
peripheral nerve injury, rapid ion fluxes increase, followed by a
rise in cAMP levels, axonal translation occurs, phosphorylation
retrograde cascades activate transcription factors, gene expression
is induced and finally regeneration occurs5,6. However, the final
link between axonal injury-induced retrograde signalling and the
regulation of essential regenerative gene expression remains
elusive. The dorsal root ganglia (DRG) sensory neurone system
has a central as well as a peripheral axonal branch departing
from a single cell body. This allows for bimodal injury inputs
with differing regenerative capacities into one central
transcriptional hub. Interestingly, the lack of regeneration of
injured ascending sensory fibres in the spinal cord can be partially
enhanced by an injury to the peripheral branch (conditioning
lesion) of DRG neurones7. In search of key regulatory
mechanisms that may clarify the molecular nature of this
regenerative gene expression programme, we hypothesized that
as an ‘orchestrator of gene regulation’ epigenetic changes would
direct expression of genes crucial for regeneration only in the
presence of pro-regenerative signalling following peripheral but
not central damage.
Identification of a specific regulatory mechanism shared by
several essential genes may lead to novel molecular strategies
recapitulating the conditioning effect, thus non-surgically enhan-
cing axonal regeneration in the CNS. To this end, we employed the
first systematic approach to understand the epigenetic environ-
ment in DRG neurones. We examined both DNA methylation and
various key histone modifications with regards to gene regulation
following axonal injury. We found that p300/CBP-associated factor
(PCAF)-dependent acetylation of histone 3 lysine 9 (H3K9ac),
paralleled by a reduction in methylation of H3K9 (H3K9me2),
occurred at the promoters of select genes only after PNS axonal
injury. In addition, we observed that extracellular signal-regulated
kinase (ERK) axonal retrograde signalling is required for PCAF-
dependent acetylation at these promoters and for their enhance-
ment in gene expression. Finally, we established that PCAF is
required for regeneration following a conditioning lesion and
PCAF overexpression promotes axonal regeneration similar to that
of a conditioning lesion after CNS injury in spinal ascending
sensory fibres. Our results show the first evidence of immediate
retrograde signalling leading to long-term epigenetic reprogram-
ming of gene expression of select genes whose modulation leads to
axonal regeneration in the hostile spinal environment.
Results
Histone codes are shaped by a peripheral not by a central
lesion. Given that epigenetic changes are a rapid and dynamic
way to translate external stimuli into targeted and long-lasting
gene regulation, such has been observed in learning and memory,
seizures, stroke and neuroneal differentiation8–11, we
hypothesized that retrograde signals following axonal injury
could lead to an epigenetic environmental shift facilitating the
expression of genes critical to regeneration. We believed that a
positive retrograde signal initiated by PNS injury could relax the
chromatin environment surrounding specific promoters and
allow for gene expression; however, a negative signal following
CNS injury may restrict promoter accessibility and inhibit gene
expression. Following equidistant CNS (dorsal column axotomy,
DCA) or PNS (sciatic nerve axotomy, SNA) axotomies, from
L4-L6 DRG we assessed both high-throughput promoter
and CGI DNA methylation (DNA methylation microarrays)
and histone modifications (quantitative chromatin immuno-
precipitation (ChIP) assays) at the proximal promoters of genes
previously established to be critical to regeneration such as
growth-associated protein 43 (GAP-43)12, Galanin13 and brain-
derived neurotropic factor (BDNF)14,15 (Fig. 1a).
DNA methylation arrays showed a modest number of genes
differentially methylated between injuries (Supplementary
Fig. 1a–e); however, none of the genes associated with regenera-
tion displayed significant levels of methylation nor were they
differentially methylated between SNA and DCA (Supplementary
Fig. 2a). More importantly, and as opposed to a recent study
investigating folate and its DNA methylation after sciatic and
spinal injury16, quantitative RT–PCR analysis of the differentially
methylated genes, and DNA methyltransferases did not show a
consistent correlation between DNA methylation levels and gene
expression (Supplementary Figs 2b–e and 3). Therefore, promoter
and CGI DNA methylation does not appear to be a key factor in
the differential regenerative response between CNS and PNS
injuries in the DRG system.
Next, we investigated whether key histone modifications
would be specifically enriched on established critical genes for
the regenerative programme in DRG neurones. Of all histone
modifications that correlate with active gene transcription
(H3K9ac, H3K18ac, H3K4me2)17 or gene repression (H3K9me2
and H3K27me3)17 that were screened, H3K9ac, H3K9me2 and
H3K27me3 were enriched compared with IgG on most
promoters; however, only H3K9ac and H3K9me2 were found
to be differentially enriched at GAP-43, Galanin and BDNF
promoters, consistently correlating with early and sustained
increased expression following SNA (1–7 days; Figs 1b,c and 2a–d;
Tables 1 and 2). Additionally, these three genes presented
common promoter motifs in CpG content as well as
transcription-binding sites that together with increased H3K9ac
at their promoters suggest common transcriptional regulation
(Fig. 1b,c). H3K9ac and the H3K9ac-specific acetyltransferase,
PCAF, are typically found in the proximity of transcriptional start
sites of actively transcribing genes17, and accordingly PCAF was
also enriched at these promoters (Fig. 1c). Interestingly,
H3K9me2, which is associated with gene silencing17, was found
to be decreased at these promoters and inversely correlated to
gene expression following SNA (Fig. 1c). In contrast, SCG-10,
whose gene expression is unaltered after 24 h and only modestly
increased following 3- and 7-day SNA (Fig. 1b), did not show an
enhancement of H3K9ac or PCAF at its promoter (Fig. 1c). Given
that a preconditioning lesion (SNA preceding DCA) activates the
regenerative capacity of the CNS7, we questioned whether a PNS
epigenetic signal overrides a CNS signal. We observed an increase
in the gene expression of these genes following preconditioned
DCA versus DCA alone, which correlated with an increase in
PCAF at these promoters (Fig. 1d,e). Furthermore, a broader
picture of post-axotomy gene expression profiles and H3K9ac
promoter enrichment is depicted by regeneration-associated
(Chl1, L1cam, SPRR1a)18, axonal growth (ATF3 and Bcl-xL)19,20
housekeeping (ribosomal unit 18S) genes and axonal structure
(NF-L) genes21 (Fig. 2a,b). Importantly, these experiments show
that H3K9ac, a marker of actively transcribing genes, is selectively
enriched on the promoters of GAP-43, Galanin and BDNF, but not
on the promoters of other SNA-induced genes such as SPRR1a,
ATF3 and HSP27 (Fig. 2a–d; Table 1), suggesting that their
common regulation maybe linked to their importance in
regeneration.
NGF-MEK-ERK signalling regulates PCAF and H3K9ac. Next,
we turned our attention to understanding whether retrograde
signalling following SNA plays a role in this positive chromatin
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remodelling. Immediately following peripheral injury, pERK
levels rise in the injured axon and ERK signalling modules are
retrogradely transported to the DRG cell body22,23, where we
show that global PCAF and H3K9ac levels rise (Fig. 3a–c). In
adult primary DRG neuroneal cultures, nerve growth factor
(NGF), an activator of ERK signalling and neurite outgrowth24,
increased the expression of PCAF and H3K9ac, while the ERK
kinase (MEK) inhibitor, PD98059 (PD), prevented PCAF and
H3K9ac induction25 (Fig. 4a,b). NGF induces PCAF expression,
nuclear localization and activation of acetyltransferase activity
specifically by threonine phosphorylation at its histone
acetyltransferase domain26. In L4-L6 DRG, SNA induced the
expression of nuclear PCAF and PCAF threonine but not serine
phosphorylation (Fig. 4c,d). This correlated with an increase in
pERK in DRG, as well as nuclear PCAF translocation and
acetylation of H3K9, all of which are dependent on ERK
activation following SNA (Fig. 4e–i). As predicted, inhibition of
ERK activation following SNA decreased gene expression as well
as PCAF and H3K9ac at the promoters of GAP-43, Galanin and
BDNF (Fig. 4j–l). However, in conjunction with our theory of
specificity of regulation, H3K9ac did not correlate with gene
expression at other promoters following inhibition of ERK
activation (Supplementary Fig. 4a,b). Remarkably, cAMP
signalling in adult DRG neuroneal cultures did not induce
nuclear PCAF translocation (Supplementary Fig. 5), suggesting
that cAMP-mediated mechanisms only partially supporting
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Figure 1 | H3K9ac and PCAF involvement in the regulation of regeneration genes. (a) Schematic diagram of SNA and DCA injury models used for
epigenetic screens involving DNA methylation arrays and quantitative ChIP assays from L4-L6 DRG. Scale bar, 100mm. (b) Fold change increases
observed in GAP-43, Galanin and BDNF gene expression at 1, 3 and 7 days post SNA but not DCA and at 3 and 7 days for SCG-10. (c) Increased
gene expression, H3K9ac, PCAF and decreased H3K9Me2 at GAP-43, Galanin and BDNF, but not SCG-10 (SCG-10 had decreased H3K9me2 enrichment
to a lesser extent) promoters following 1 day post-SNA versus DCA. (d) A preconditioning lesion performed 1 week before DCA still induced 24 h
later gene expression of GAP-43, Galanin and BDNF but not SCG-10. (e) This correlated with an increase in PCAF at the promoters of activated regeneration
genes. Q-PCR. (b,c) N¼ 3 per group; ChIP assays (c–e) N¼6 per group, Student’s t-test, error bars, s.e. *Po0.05, **Po0.01, ***Po0.001.
All experiments were performed in triplicate.
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conditioning-dependent axonal regeneration27 operate inde-
pendently from pERK-induced epigenetic PCAF-mediated
long-term mechanisms. These data present the first link
between retrogradely transported PNS-injury-related signals and
epigenetic modifications at the promoters of specific established
regenerative genes.
PCAF supports axonal regeneration mimicking a conditioning
lesion. As a preconditioning lesion is able to induce neurite
outgrowth in primary adult DRG neurones cultured on permis-
sive (laminin) or non-permissive (myelin) substrates28, we tested
whether increased PCAF expression by adeno-associated virus
Table 1 | Correlation between gene expression and H3K9ac ChIP data.
H3K9ac at promoters
Increase No change Decrease
Gene expression Increase BDNF, Galanin, GAP-43 ATF3, HSP27 Sprr1a
No change CAP-23 SCG-10, Chl1, L1cam, 18S, Lgals
Decrease NF-L Bcl-xL
BDNF, brain-derived neurotropic factor; ChIP, chromatin immunoprecipitation; H3K9ac, acetylation of histone 3 lysine 9.
A table displaying our gene expression data for genes associated with regeneration or known data for control genes and our H3K9ac ChIP data at their promoters, showing a clear correlation between
increased gene expression and H3K9ac at the promoters of the genes BDNF, Galanin and GAP-43.
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Figure 2 | Histone modifications that do not correlate with gene expression. (a) Gene expression of genes associated with regeneration found to be
induced (Sprr1a and Chl1) or not changed (Lgals, L1cam and CAP-23) at various timepoints. (b) H3K9ac ChIP assays at the promoters of several genes
previously found to be either induced (Sprr1a, HSP27 and ATF3), unchanged (Chl1 and 18S) or repressed (Bcl-xL and NF-L) in gene expression 24 h post SNA
only showed a correlation between expression and H3K9ac promoter occupancy for Bcl-xL. No enrichment to IgG was found for L1cam promoter.
(c) ChIP assay for H3K9me2 24 h post SNA and DCA compared with Shams shows no correlation with 24-h gene expression time point for Sprr1a,
Chl1, Lgals and CAP-23, but for L1cam there is no change observed, which is in agreement with no change in gene expression. (d) No consistent pattern
of correlation with gene expression was found with H3K27me3 24 h post SNA by ChIP assay. No enrichment was found compared with IgG for L1cam
and Galanin. (ChIP assays, N¼6 per group, performed in triplicate). Error bars, s.e. (a,c,d) Student’s t-test, *Po0.05, **Po0.001 and ***Po0.001.
Table 2 | Enrichment of histone modifications over IgG.
Histone modifications Enrichment compared with IgG
H3K9ac Yes
H3K18ac No
H3K4me2 No
H3K9me2 Yes
H3K27me3 Yes
Of the histone modifications examined, those shown in the table in white are inducers and those
in grey are repressors of gene expression. Two of the histone modifications screened for this
study, H3K18ac and H3K4me2, did not show enrichment compared with IgG for any of the genes
examined.
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(AAV, Supplementary Fig. 6a–c) could also drive neurite
outgrowth. Indeed, neurite outgrowth increased on laminin and
myelin by PCAF overexpression in DRG (Fig. 5a,b) as well as
another CNS primary culture, cerebellar granule neurones (CGN,
Supplementary Fig. 7a). In CGN (employed for its ease of culture
and greater cell number for use in immunobloting, ChIP and
transfections for luciferase assays) there was a significant decrease
in H3K9ac when plated on myelin (Supplementary Fig. 7b,c) and
a reduction of H3K9ac at select promoters, which was reverted to
permissive levels with overexpression of PCAF (Supplementary
Fig. 7d). Likewise, PCAF overexpression reversed myelin
repression of select genes in DRGs (Fig. 5c). Furthermore, the
drug Garcinol (5 mM), which inhibits PCAF acetyltransferase
activity29, reduced neurite outgrowth in DRG (Fig. 5d,e)
and CGN (Supplementary Fig. 7e,f), decreased the luciferase
expression of a GAP-43 promoter luciferase construct in CGN
(Supplementary Fig. 7g) and decreased select gene expression
in DRG (Fig. 5f). In ex vivo experiments, the inhibition of
PCAF activity by Garcinol was able to significantly limit neurite
outgrowth on both laminin and myelin as well as repress H3K9ac
induced by SNA (Fig. 5g–i). Correspondingly, PCAF! /! mice
provided full abolishment of neurite outgrowth induced by SNA
in ex vivo cultured DRG neurones (Fig. 5j,k). Additionally,
SNA-dependent neurite outgrowth in ex vivo cultured DRG
neurones was blocked by ERK inhibition via delivery of PD at the
nerve stump (Fig. 6a–c), phenocopying PCAF loss of function
experiments.
Thus far our data suggest that PCAF is integral to the signalling
involved following PNS injury leading to regeneration by altering
the epigenetic landscape and stimulating intrinsic competence
through crucial gene expression. To validate these observations
in vivo, we studied regeneration of ascending sensory fibres
following a preconditioning lesion (SNA 7 days before DCA) in
the absence of PCAF and found that PCAF is required for
regeneration induced by a conditioning lesion and for the
expression of GAP-43, Galanin and BDNF in DRG (Fig. 7a–g).
Importantly, axonal tracing in SCI experiments in a cohort of
PCAF-/- mice and strain-matched controls showed that PCAF-/-
mice did not display any abnormalities or overt phenotype in
axonal tracing or regarding the lesion site (Fig. 7a).
Next, we wondered whether PCAF overexpression alone would
mimic regeneration induced by a conditioning lesion and
enhance regeneration of ascending sensory fibres in the spinal
cord following dorsal column lesion. Indeed, similar to that
previously reported for a preconditioning lesion7,30, PCAF
overexpression (Supplementary Fig. 8) significantly increased
the number of regenerating fibres across the lesion and up to a
distance of 1mm rostral of the lesion site (Fig. 8a–c and
Supplementary Fig. 9). Important to note, the depth of the lesion
(Supplementary Fig. 10) and lack of tracing rostral to the lesion
site (Supplementary Fig. 11) allowed excluding the presence
of spared fibres. Furthermore, the introduction of the AAV
directly into the sciatic nerve is in and of itself a PNS injury
that does induce minimal sprouting towards the lesion in the
GFP control.
Discussion
Our work demonstrates that PCAF is required for conditioning-
dependent spinal regeneration and that PCAF overexpression
alone is able to promote regeneration of sensory fibres across the
injured spinal cord and beyond similarly to previously established
conditioning paradigms. Furthermore, PCAF-induced regenera-
tion correlated with a significant increase in the expression of
H3K9ac, GAP-43, Galanin and BDNF in the L4-L6 DRG. The
definition of regeneration-associated genes (RAGs) is genes
differentially induced between the regenerating PNS and non-
regenerating CNS systems; however, this does not validate the
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entire class of genes as essential for immediate and sustained
axonal regeneration. In support of this, our data show that PCAF-
dependent regulation of GAP-43, Galanin and BDNF is at the
essential core of the regenerative programme.
An immediate response to the external stimulus of a peripheral
axonal injury is to seal the wound. This is followed by electrical
impulses and calcium fluxes that are the first messages relayed
from the lesion site to the cell body requesting assistance. Next, is
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a rise in cAMP levels and phosphorylation signalling by multiple
players involved in transmitting further information to the cell
body5,6. Recently, it has been shown that calcium influx ejects
histone deacetylase 5 (HDAC5) from the DRG nucleus correlating
to increased global H3ac and gene expression31. It has been
hypothesized that merely shifting the balance from a deacetylated
to a globally acetylated chromatin environment by inhibition of
HDACs could recapitulate the conditioning lesion and could lead
to regeneration. However, recent experimental evidence32 and our
own work using HDAC class I and HDAC class I and II
inhibitors33 has proven this to be insufficient in producing post-
lesion regeneration of sensory fibres following a spinal or optic
nerve injury and therefore unlikely the key to unlocking the
molecular mechanisms of regeneration. While our work here
describes that specific epigenetic codes are induced endogenously
following a conditioning lesion that leads to CNS regeneration, it
is also consistent with previous findings from our laboratory that
showed the presence of a transcriptional complex formed by p53,
p300 and PCAF in the proximity of several RAGs including GAP-
43, Coronin 1b and Rab13 in primary neurones as well as facial
motor neurones in a PNS facial nerve axotomy model34–36.
Additionally, we found that the histone acetyltransferase p300
(which may form a complex with PCAF) is developmentally
regulated in retinal ganglion cells and whose overexpression drives
axonal regeneration of the injured optic nerve33.
While it is known that signals are sent via retrograde transport
machinery23,37–39, how they are decoded into the gene expression
of key axonal regeneration players for growth towards re-
innervation of the lost target has not been known until now. Here,
we have shown the first systematic study of various epigenetic
modifications revealing specifically that increased H3K9ac
and PCAF as well as decreased H3K9me2 at the promoters of
GAP-43, Galanin and BDNF are due to retrogradely induced
pERK activation of PCAF leading to essential gene activation,
which is sufficient to mimic the regenerative response assembled
by a conditioning lesion, thus driving regeneration in the CNS.
The fundamentals of decoding the regenerative retrograde
signal by understanding the specific epigenetic changes that occur
to chromatin surrounding essential genes is paramount in our
ability to recapitulate this mechanism when the signal is lacking,
such as after spinal cord injury (SCI). Here we take the first steps
in this understanding that may lead to the design of epigenetic-
related regenerative therapies for SCI patients.
Methods
Reagents. PD 98059 (Calbiochem), Garcinol (Sigma-Aldrich), NGF (BD
Biosciences) and dbcAMP (Enzo Life Sciences) were purchased from respective
companies. The following antibodies were purchased and utilized, rabbit anti-
PCAF (ab12188, Abcam), mouse anti-PCAF (E8, sc-13124, Santa Cruz Bio-
technology), rabbit anti-AcH3K9 (no. 9671, Cell Signalling), rabbit anti-H3K9me2
(no. 9753, Cell Signalling), mouse anti-H3K27me3 (ab6002, Abcam), mouse
anti-H3K4me2 (no. 9726, Cell Signalling), rabbit anti-H3K18ac (ab15823, Abcam),
mouse anti-NeuN (MAB 377, Millipore), rabbit anti-phospho-Erk 1/2 (no. 9101,
Cell Signalling), mouse anti-!III tubulin (no. G712A, Promega), mouse b-actin
(A2228, Sigma), rabbit anti-Phospho-Threonine (no. 600-403-263, Rockland),
rabbit anti-Phospho-Serine (no. ADI-KAP-ST2103-E, Enzo Life Sciences), rabbit
anti-MAP2 (sc20172, Santa Cruz Biotechnology), rat anti-Glial fibrillary acidic
protein (GFAP) (no. 13-0300, Invitrogen), rabbit anti-BDNF (sc-546, Santa Cruz
Biotechnology), rabbit anti-Galanin (T-4334, Bachem Peninsula Laboratories) and
sheep anti-GAP-43 (no. NBP1-41123, Novus Biologicals).
Mice. All mice used for this work were treated according to the Animal Welfare
Act and to the ethics committee guidelines of the University of Tu¨bingen. Equally
distributed male and female C57Bl6/J (bred from Charles River Laboratories), CD1
or CD1 PCAF! /! (generated in Dr Boutillier´s laboratory) mice ranging from
6 to 8 weeks of age were used for all experiments. C57Bl6/J were used for all studies
except those specifying PCAF null mice. For surgeries, mice were anesthetized with
ketamine (100mg kg! 1 body weight) and xylazine (10mg kg! 1 body weight).
For all experiments, we employed a target for the appropriate expected power
calculation linked to an ad hoc statistical test.
Dorsal column axotomy. Surgeries were performed as previously reported40.
Briefly, mice were anesthetized and a T10 laminectomy was performed (B20mm
from the L4-L6 DRGs), the dura mater was removed, taking care of not damaging
the spinal cord. A dorsal hemisection until the central canal was performed with a
microknife (FST). For the control laminectomy surgery, the dura mater was
removed but the dorsal hemisection was not performed.
Sciatic nerve axotomy. Mice were anesthetized. At B20mm far from L4-L6
DRG, a 10-mm incision was performed on the gluteal region and muscles were
displaced to expose the sciatic nerve for a complete transection with spring
micro-scissors. For the PD study 30 s before transection, 2.5 ml of 100% DMSO
or 2.0 ml of PD 98059 were slowly pipetted on the nerve. Finally, skin was closed
with two suture clips. The nerve fibre was left uninjured in sham surgery.
Methylated DNA immunoprecipitation from DRG ex vivo. For each of the three
time points (1, 3 and 7 days post SNA or DCA and naive), L4-L6 DRG were
collected from two mice per time point and condition in triplicate for injury
samples and naive, and in duplicate for shams. Frozen tissue was ground and
digested with 0.2mgml! 1 Proteinase K. The lysate was then sonicated to average
size of 700 bp and cleared of remaining tissue by centrifugation. Genomic DNA
was extracted from the lysate via standard phenol–chloroform extraction and
DNA precipitation protocols. MeDIP was then performed according to the
manufacturer’s protocol for the ChIP Kit from Upstate/Millipore. A total of 10 mg
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of genomic DNA and 5 mg of a 5-methyl-Cytosine antibody (Eurogentec, BI-
MECY-0100) were added to immunoprecipitate methylated DNA fragments. The
Whole Genome Amplification Kit (Sigma-Aldrich) was applied to amplify 20 ng of
genomic samples to a maximum yield of 3–7 mg, followed by subsequent column
purification using the GenElute PCR Clean-Up Kit (Sigma). MeDIP efficiency was
tested with previously published primers for methylated H19 ICR41.
DNA methylation microarray. Whole-genome amplified, high-quality42 samples
(input genomic DNA, immunoprecipitated methylated DNA or no-antibody
control) were sent to Roche/NimbleGen for DNA methylation microarray analysis.
NimbleGen processed the samples as described in its ‘NimbleChip Arrays User’s
Guide for DNA Methylation Analysis’. A ‘2007-02-27 MM8 CpG Island Promoter
(385K RefSeq)’ tiling microarray, covering proximal promoter regions and CGIs by
close-set oligonucleotide probes. Fluorescence intensity raw data were obtained
from scanned images of the tiling arrays using the NimbleScan extraction software.
For each spot on the array, Cy5/Cy3 ratios were normalized and calculated to
obtain log2 values. Then, the bi-weight mean of log2 ratios of a certain region was
subtracted from each data point; this procedure is similar to mean normalization of
each channel.
Promoter CGI analysis. Several known RAGs and of differentially methylated
genes that emerged from the DNA methylation microarray analysis within this
study were analyzed for CpG islands (CGIs). The complete genomic region,
together with the promoter region (5,000 bp upstream of the transcription start site
(TSS)), was analysed with the EMBOSS CpGPlot online tool from EMBL-EBI.
Characteristic parameters of reported CGIs were used.
Gene-regulatory region bioinformatics analysis. We performed a Matinspector
(Genomatix) and UCSD genome browser-based bioinformatics analysis of the
regulatory regions of RAG genes (GAP-43, Galanin, BDNF, SCG-10, Sprr1a, Chl1,
Lgals, L1cam and CAP-23) spanning 1,000 bp upstream and 1,500 bp downstream
of the TSS. These regions overlap and further extend what we studied for DNA
methylation (500 bp upstream and 1,500 bp downstream of the TSS). Significant
transcription-binding sites displayed at least two of the three classically required
criteria: a P-value o0.05, matrix similarity 40.8 and core similarity 40.8.
Additionally, CGI and DNA methylation were examined in these regions for all of
the RAGs investigated with the EMBO DNA methylation analysis online software.
Results of the combined analysis suggested that GAP-43, Galanin and BDNF had
common gene regulatory regions with low levels of DNA methylation and absence
of typical CpG islands, presented transcriptional-binding sites for transcription
factors that are typically acetylated and active in the proximity of acetylated
histones, including, Klf, NFkB, SRF, p53, YY1, CREB and c-jun.
Quantitative real-time RT–PCR analysis. RNA was extracted using PeqGOLD
TriFast reagent (peqlab), cDNA was synthesized from 1 mg of total RNA using both
oligodT and random hexamers from the SuperScript II Reverse Transcriptase kit
(Invitrogen) and a real time RT–PCR was performed using Absolute QPCR SYBR
low ROX master mix (Thermo Scientific). Quantities and fold changes were
calculated following the manufacturer’s instructions (ABI 7,500) and as previously
reported35,43. Primer sequences are shown in Supplementary Table 1. RPL13A,
GAPDH or b-actin were used for normalization.
Quantitative chromatin immunoprecipitation. The SimpleCHIP Enzymatic
Chromatin IP Kit with magnetic beads (Cell Signalling) was used according to
previously published methods44. Antibodies used were H3K9ac, PCAF (rabbit),
H3K9me2, H3K27me3, H3K4me3 and H3K18ac. Real-time Q-PCR was run using
Absolute QPCR SYBR low ROX master mix (Thermo Scientific). Quantities and
fold changes were calculated following the manufacturer’s instructions (ABI 7,500)
and as previously reported35,43. Primers were designed in proximity (within 500 bp
upstream) of the TSS. Primer sequences are shown in Supplementary Table 2.
Immunohistochemistry. DRG were fixed in 4% paraformaldehyde (PFA)
and transferred to 30% sucrose. The tissue was embeded in OCT compound
(Tissue-Tek), frozen at ! 80 !C and sectioned at 10-mm thickness. DRG sections
underwent antigen retrieval with 0.1M citrate buffer (pH 6.2) at 98 !C and were
incubated with 120 mgml! 1 goat anti-mouse IgG (Jackson Immunoresearch).
They were blocked for 1 h with 8% BSA, 1% PBS-TX100 or 0.3% PBS-TX100,
respectively, and then incubated with NeuN (1:100), PCAF (mouse, 1:500) and
AcH3K9 (1:500) antibodies or phospho-Erk 1/2 (1:500) and !III tubulin (1:1,000)
antibodies O/N. This was followed by incubation with Alexa Fluor 568-conjugated
goat anti-mouse and Alexa Fluor 488-conjugated goat anti-rabbit or Alexa Fluor
568-conjugated goat anti-rabbit and Alexa Fluor 488-conjugated goat anti-mouse
(1:1,000, Invitrogen), respectively. Slides were counterstained with DAPI (1:5,000,
Molecular Probes). Photomicrographs were taken with an Axio Imager.Z1/
Apotome (Zeiss) microscope as 0.800 mm Z-stacks at " 40 magnification and
processed with the software AxioVision (Zeiss). In order to determine the nuclear
intensity density (ID) of pixels, Image J (Fiji) was used. Each neuroneal nuclear
area was selected in the DAPI channel (about 25 nuclei/picture). The same
selection was then used to delineate the nuclei in the other channels. The threshold
of the nuclear area was set for each different channels, and based on that the pixel
ID of the nucleus was determined and divided by its nuclear area. Triplicates of
each treatment were analysed.
Immunoblotting and immunoprecipitation. For whole-cell extract immuno-
blotting, DRG or CGN were collected, lysed on ice in RIPA lysis buffer containing
protease inhibitors (Complete Mini; Roche Diagnostics), sonicated briefly,
centrifuged and the supernatant collected. The NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Thermo Scientific) was used according to the manufacturer’s
instructions for nuclear enriched fractions. H3K9ac (1:1,000), PCAF (rabbit,1:500),
b-actin (1:1,000) and bIII Tubulin (1:1,000) were employed as primary antibodies.
Quantitation of protein expression was performed by densitometry (Image J) of
the representative bands of the immunoblots and normalized to the respective
levels of loading controls.
For immunoprecipitation, the nuclear enriched fractions were bound to rabbit
PCAF antibody (8mg), pulled down with Protein G magnetic beads, washed with
low and high salt buffers (ChIP kit, Cell Signalling) and was eluted with loading
buffer (Thermo Scientific). The IP was stained with PCAF (rabbit, 1:500),
Phospho-Threonine (1:1,000) or Phospho-Serine (1:1,000).
DRG culture. Adult DRG were dissected and collected in Hank’s balanced
salt solution on ice. DRGs were transferred to a digestion solution (5mgml! 1
Dispase II (Sigma), 2.5mgml! 1 Collagenase Type II (Worthington) in DMEM
(Invitrogen)) and incubated at 37 !C for 35min with occasional mixing. Following
which DRGs were transferred to media containing 10% heat-inactivated fetal
bovine serum (Invitrogen), 1" B27 (Invitrogen) in DMEM:F12 (Invitrogen) mix
and were briefly triturated with a Sigma-cote (Sigma) fire-polished pipette to
manually dissociate the remaining clumps of DRG. After which the single cells
were spun down, resuspended in media containing 1" B27 and Penicillin/
Streptomycin in DMEM:F12 mix and plated at 4,000–5,000 per coverslip. The
culture was maintained in a humidified atmosphere of 5% CO2 in air at 37 !C.
Neurones were infected with either AAV-GFP or AAV-PCAF (1" 10e12ml! 1) a
few hours post-plating and fixed with 4% PFA 48 h later. For the Garcinol study,
cells were exposed to Vehicle (5% EtOH) or Garcinol (5 mM per well, Sigma-
Aldrich) for 24 h and fixed. For the ERK/PD study, the day following plating DRG
were exposed for 1 h to PD 98059 (50 mM per well), then to NGF (100 ngml! 1) for
3 h and fixed.
CGN culture. CGNs were prepared from the cerebellum of 7-day-old C57Bl6/J
mice following standard procedures45. These disassociated CGNs were plated on
either PDL (with or without 5 mM Garcinol) or myelin for 24 h in a humidified
atmosphere of 5% CO2 in air at 37 !C. Neurones were infected at the time of
plating with a CMV promoter AV-GFP or AV-PCAF (1" 10e10ml! 1).
Immunocytochemistry. Glass coverslips were coated with 0.1mgml! 1 PDL,
washed and coated with mouse Laminin (2 mgml! 1; Millipore). For myelin
experiments, they were additionally coated with 4 mg cm! 2 rat myelin. Cells were
plated on coated coverslips for 24 or 48 h, at which time they were fixed with 4%
PFA/4% sucrose. Immunocytochemistry was performed as previously reported45
using bIII Tubulin (1:1,000), MAP2 (1:100), PCAF (mouse, 1:400), AcH3K9
(1:1,000) or pErk1/2 (1:500). This was followed by incubation with Alexa Fluor
568-conjugated goat anti-mouse and Alexa Fluor 488-conjugated goat anti-rabbit
(1:1,000, Invitrogen). To visualize the nucleus, we stained the cells with DAPI
(1:5,000, Molecular Probes).
Image analysis for immunocytochemistry. DRG pictures were taken at " 20
magnification with an Axioplan 2 (Zeiss) microscope and processed with the
software AxioVision (Zeiss). Using Image J, a threshold was set. On the basis of the
threshold, for each picture the ID of pixels was calculated in each channel and then
divided by its respective number of cells (about 225 cells per picture). This was
carried out in triplicate.
Neurite length analysis. Immunofluorescence was detected using an Axiovert 200
microscope (Zeiss) and pictures were taken as a mosaic at " 10 magnification
using a CDD camera (Axiocam MRm, Zeiss). Neurite analysis and measurements
were performed using the Neurolucida software (MicroBrightField) in triplicate
with 50 cells per triplicate.
Luciferase assays. Experiments were performed in CGN using electroporation
with the rat neurone nucleofactor kit (Amaxa Biosystems) according to the
provided protocol. Briefly, five million neurones were used for each cuvette, with
2–4 mg of total DNA (GAP-43-Luc reporter46 and 25 ng of pRL-TK-Renilla-
luciferase (Promega)). Neurones were plated in 24-well plates at a density of
0.4 million cells per well with or without 5 mM Garcinol and incubated for a total
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of 24 h. Cells were harvested and lysed with 100ml of passive lysis buffer, and
luciferase activities were determined using the Dual-Luciferase kit (Promega).
Ex vivo DRG culture. Intrathecal (i.t.) injection was performed using the Wilcox
technique47. Mice were briefly anaesthesized with isofluorane (2%), and a lumbar
cutaneous incision (1 cm) was made. I.t. injections were performed with 30-gauge
15-mm needles mated to a 5-ml luer tip syringe (Hamilton, Reno, NV, USA). The
needle was inserted into the tissue between the L5 and L6 spinous processes and
inserted B0.5 cm with an angle of 20!. Vehicle (10% DMSO in 0.9% NaCl) or
Garcinol (80 mM) was slowly injected in a final volume of 5 ml. Directly after i.t.
injection of Vehicle or Garcinol, mice underwent Sham or SNA surgeries. Twenty-
four hours after surgery, mice were killed and L4–L6 DRG were collected and
cultured for 24 h, and were then fixed and stained. We used three animals per
group and plated in triplicate. L4–L6 DRG were also collected for total protein
extraction for western blot analysis of H3K9ac.
For PCAF null ex vivo study, WT or PCAF! /! mice (generated in Dr
Boutillier’s laboratory) underwent Sham or SNA surgeries. Twenty-four hours after
surgery, mice were killed and L4–L6 DRG were collected and cultured for 18 h, and
were then fixed and stained. We used three animals per group and the DRG were
plated in triplicate.
SCI study
AAV-GFP/PCAF injection. All experimental procedures were performed in
accordance with protocols approved by the Univeristy of Tu¨bingen. PCAF
expression plasmid was obtained from Addgene (Plasmid 8941). AAVs were
prepared as described previously48. Mice were anaesthetized and the left sciatic
nerve was injected with 1.5–2ml of either AAV-GFP or AAV-PCAF
(1" 10e12ml! 1) using a glass-pulled micropipette. Standardized randomization
and blinding strategies were adopted. Randomization of samples was performed by
random assignment and labelling of control and test groups while between one to
three experimenters were blind to the groups for each experiment performed.
Spinal cord injury. Two weeks after AAV injection, a T9–10 laminectomy was
performed and the dorsal half of the spinal cord was crushed with no. 5 forceps
(Dumont, Fine Science Tools) for 2 s (ref. 49). The forceps were deliberately
positioned to severe the dorsal column axons completely. Four weeks after the
spinal cord lesion, dorsal column axons were traced by injecting 2 ml of Microruby
tracer (3,000 molecular weight, 10%, Invitrogen) into the left sciatic nerve50. Mice
were kept for an additional 2 weeks before termination. CD1 WT and PCAF! /!
mice underwent the same spinal cord surgery as above. Additionally, they received
a conditioning sciatic nerve lesion 1 week before the spinal surgery. One week after
the spinal cord lesion, dorsal column axons were traced by injecting 2 ml of
Microruby tracer (3,000 molecular weight, 10%, Invitrogen) into the left sciatic
nerve50. These mice were kept for an additional 2 weeks before termination.
Animals were deeply anaesthetized and were perfused transcardially. Spinal cords
were dissected and post-fixed in 4% PFA in phosphate-buffered saline (PBS) at 4 !C
for 2 h and 30% sucrose O/N. Then the tissue was embedded in Tissue-Tek OCT
compound, frozen at ! 80 !C and cut in 18-mm-sagittal and coronal sections
(3mm caudal and 5mm rostral to the lesion were taken to confirm the
completeness of the lesion and to quantify tracing efficiency among experimental
groups). Brain stem from each cord was also dissected, and sections of the nuclei
gracilis and cuneatus were generated to monitor tracing from spared fibres. Mice
with incomplete lesions were excluded. Staining for GFAP (1:2,000) was performed
following the standard protocols40. Confocal laser scanning microscopy was
performed using a Zeiss LSM700. Semi-automatic skeletonization of regenerating
axons was performed on confocal scans using the three-dimensional (3D) imaging
software Amira (FEI Visualization Sciences Group). An isosurface was applied to
the GFAP signal.
Quantification of axonal regeneration. For each spinal cord after dorsal column
crush, the number of fibres caudal to the lesion and their distance from the lesion
epicentre were analysed in four to six sections per animal with a fluorescence
Axioplan 2 (Zeiss) microscope and with the software StereoInvestigator 7 (MBF
bioscience). The lesion epicentre (GFAP) was identified in each section at a " 40
magnification. The sum total number of labelled axons rostral to the lesion site was
normalized to the total number of labelled axons caudal to the lesion site counted
in all the analysed sections for each animal, obtaining an inter-animal comparable
ratio considering the individual tracing variability. Sprouts and regrowing fibres
were defined following the anatomical criteria reported by Steward et al.51 Samples
falling short of standard quality for each specific experiment or altered by clear
experimental flaw were excluded from the analysis.
DAB immunostaining. Peroxidase activity was blocked in 0.3% H2O2, followed by
incubation in 8% bovine serum albumin (BSA) and 0.3% TBS-TX-100. BDNF
(1:500), Galanin (1:2,000) or GAP-43 (1:500) antibodies in 2% BSA and 0.2%
TBS-TX100 were used. Labelled cells were visualized using the ABC system
(Vectastain Elite; Vector Laboratories) with DAB as chromogen. The sections then
were counterstained with haematoxylin (Vector Laboratories).
Statistical analysis. Data are plotted as the mean±s.e. All experiments were
performed in triplicate. Asterisks indicate a significant difference analysed using
analysis of variance with Bonferroni post hoc tests, Student’s t-test, Welch’s t-test or
two-way analysis of variance as indicated (*Po0.05; **Po0.01; ***Po0.001).
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Supplementary Figure 1 Promoter and CpG island DNA methylation arrays   
a, Schematic diagram summarizing the experimental design of promoter and CpG island 
DNA methylation arrays from L4-L6 DRGs after SNA and DCA. b, Pie chart summarizing 
the overall number of methylated genes irrespective of injury, showing only a minority of 
methylated genes. c, Pie charts showing the number of fully hypermethylated or 
hypomethylated genes (3/3) after either SNA or DCA in comparison with Shams. e, Pie 
charts showing the limited number and respective functional classes of differentially 
methylated genes (comparison to Shams) after SNA and DCA. 
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Supplementary Figure 2 Methylation of genes and correlation with expression 
a, Table shows a selection of differentially methylated genes belonging to chromatin 
remodelling and retrograde signalling functional classes and the lack of methylation of RAGs 
after axonal injury. Relative mRNA expression fold changes upon SNA or DCA for a subset 
of differentially methylated genes do correlate with methylation status, but not as a general 
rule. b-e, For each differentially methylated gene, mRNA levels were detected for the 
relevant time point for SNA and DCA samples (injury and sham). Most differentially 
hypermethylated genes upon SNA exhibit decreased mRNA expression levels (injury/sham 
fold change, in orange), while levels upon DCA varied (blue). In contrast to the hypothesis, 
most differentially hypomethylated genes upon SNA are downregulated, except for Rbpjl (b). 
Upon DCA, some differentially hypomethylated genes are upregulated while differentially 
hypermethylated genes were marginally upregulated as well (c). To investigate the 
correlation between gene expression and DNA methylation, the SNA/DCA FC ratio was 
calculated, showing lack of correlation between promoter and CpG island methylation and 
gene expression (d, e). Error bars, s.e.m. 
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Supplementary Figure 3 DNMT 1 and 3a gene expression after SNA and DCA 
Quantitative RT-PCR shows a modest change in gene expression for DNMT1 and DNMT3a 
after SNA and DCA. All values are fold changes to Shams, N = 3, triplicate experiments. 
Error bars, s.d. 
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Supplementary Figure 4  Inhibition of ERK on gene expression and promoters  a, One 
day following SNA with PD treatment showed a decrease in gene expression of most genes 
tested compared to SNA with DMSO (Quantitative RT-PCR, N = 3 per group). b, No 
correlation with H3K9ac at the promoters of these genes was found except for Lgals (ChIPs). 
N = 6 per group, performed in triplicate. Error bars, s.e.m. (a,b) Student’s t-test, *P<0.05, 
**P<0.001 and ***P<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
 
 
 
Supplementary Figure 5  dbcAMP does not alter PCAF in cultured DRG neurons  
a, dbcAMP (1 mM) delivered at the time of plating enhances pCREB  expression as expected 
(24 h), but does not alter expression level nor localization of PCAF. N = 3. Arrow head 
shows selected cell and nuclear localization.  (Scale bar: 10 μm) 
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Supplementary Figure 6 AAV overexpression leads to enhanced PCAF levels   
a, HEK cells infected with AAV-GFP or AAV-PCAF for 48 h. Scale bar, 100 μm. b, 
Cultured DRG neurons from adult mice were infected with AAV-GFP or AAV-PCAF for 48 
h. Scale bar, 100 μm. c, High magnification of numbered PCAF positive cells in (b) showing 
nuclear accumulation after PCAF overexpression. Scale bar, 25 μm. 
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Supplementary Figure 7 PCAF overexpression in CGN  
a, CGN electroporated with PCAF for 24 h showed an increase in neurite length on PDL and 
myelin. b, c, Immunoblot (b) shows decreased H3K9ac expression in CGN following 24 h of 
plating on myelin, intensity analysis (c). d, Myelin significantly decreases H3K9ac at the 
promoters of RAGs, which is restored by AV-PCAF overexpression (24 h) in CGN. e, f, 
CGN plated for 24 h and treated with 5 µM of the PCAF inhibitor Garcinol showed a 
decrease in neurite outgrowth on PDL, ICC (e) and neurite length analysis (f). Scale bars, 50 
µm. g, GAP-43 proximal promoter luciferase construct shows decreased expression after 24h 
treatment with 5 µM Garcinol. Error bars, s.e.m., (a, d) P<0.0001, ANOVA, Bonferroni post-
hoc tests, *P<0.05, **P<0.001 and ***P<0.001 (c, f, g) Student’s t-test, *P<0.05, **P<0.001 
and ***P<0.001, N = 3-6, performed in triplicate. Original immunoblot images are shown in 
Supplementary Figure 15. 
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Supplementary Figure 8 Infection efficiency of AAV in DRGs from SCI study  
a, AAV injected in the sciatic nerve specifically targets DRG neurons (8 weeks post-
infection) as seen by the overlap in GFP expression and NeuN staining. Scale bars, 250 and 
100 µm respectively. b, Sciatic nerve injected AAV-GFP and AAV-PCAF shows infection 
and expression of PCAF protein levels in the L4-L6 DRGs (8 weeks post-infection). Scale 
bar, 250 µm. 
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Supplementary Figure 9 3D visualization of regenerating axons 
Amira 3D reconstruction of regenerating dorsal column axons and glial scar in a sagittal 
projection (~25 µm) of the spinal cord after PCAF overexpression. * Lesion site. cc: central 
canal. Scale bars, 200 µm (top panel), 100 µm (1), 50 µm (2) and 10µm (3). 
 10 
 
 
 
Supplementary Figure 10 Lesion sites after SCI  
Micrographs show spinal cord lesion sites from individual mice (#1,2, etc...) after SCI as 
indicated in Figure 8. Asterisk indicates the lesion site. Scale bar, 250 µm. 40X Scale bar: 
250 μm 
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Supplementary Figure 11 Tracer in the dorsal columns after SCI  
Micrographs show tracing in representative coronal sections of the dorsal columns after SCI 
cord. The dotted line indicates dorsal columns. Tracer is visible 3 mm caudal to the lesion 
site (right panel), but not 5 mm rostral to it (left panel). Scale bar, 150 µm.  
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Supplementary Figure 12 
 
 
Supplementary Figure 12 Full scan images of western blot data in Figure 4 
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Supplementary Figure 13 Full scan images of western blot data in Figure 5i 
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Supplementary Figure 14 
 
 
 
Supplementary Figure 14 Full scan images of western blot data in Figure 6c 
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Supplementary Figure 15 
 
 
 
Supplementary Figure 15 Full scan images of western blot data in Supplemental Figure 
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Supplementary Table 1 
Quantitative-RT-PCR Primers 
Gene  Forward Primer Reverse Primer 
GAP-43 5’-CTTCTTTACCCTCATCCTGTCG-3’ 5’- CAGGAAAGATCCCAAGTCCA-3’ 
Galanin 5’- GTGACCCTGTCAGCCACTCT -3’ 5’- GGTCTCCTTTCCTCCACCTC-3’ 
BDNF 5’- AGTCTCCAGGACAGCAAAGC-3’ 5’- TCGTCAGACCTCTCGAACCT -3’ 
SCG-10 5’- GCAATGGCCTACAAGGAAAA -3’ 5’- GGTGGCTTCAAGATCAGCTC-3’ 
L1cam 5'-GGGTGAGTGGAATCTGGCTA-3' 5'- TGGCTCTAGCACATGGTGTC-3' 
Sprr1a 5'-CCCCTCAACTGTCACTCCAT-3' 5'-CAGGAGCCCTTGAAGATGAG-3' 
CAP-23 5'-GGGAGAGAGAGAGCCTTTGC-3' 5'-CTTCGGCCTTCTTGTCTTTG-3' 
Lgals 5'-TCAAACCTGGGGAATGTCTC-3' 5’-ATGCACACCTCTGTGATGCT-3' 
Chl1 5'-ATTGCGGCTAACAATTCAGG-3' 5'-GAGGGTTGCAGGGTAAGACA-3' 
Bcl-xL 5'- CTGGTGGTTGACTTTCTCTCC-3' 5'- CAAGGCTCTAGGTGGTCATTC-3' 
18S 5'-CGGCTACCACATCCAAGGAA-3' 5'-GCTGGAATTACCGCGGCT-3' 
Dnmt1 5’- GTGGTGTCTGTGAGGTCTGTC-3’ 5’- AAGTTAGGACACCTCCTCTTGAG-3’ 
Dnmt3a 5’- AGGGAGGCTGAGAAGAAAGC-3’ 5’- GGCTGCTTTGGTAGCATTCT-3’ 
Dnmt3b 5’- AGTTTCCGGCTACCAGGTCT-3’ 5’- TGTGCTGTCTCCATCTCTGC -3’ 
RPL13A 5’-CCCTCCACCCTATGACAAGA-3’ 5’-CCTTTTCCTTCCGTTTCTCC-3’ 
GAPDH 5'-ACCCTGTTGCTGTAGCCGTATCA-3' 5'- TCAACAGCAACTCCCACTCTCCA-3' 
β-actin 5’-GAACGGAACATTGCACACAC-3’ 5’-ACAGCTTCACCACCACAGCTGA-3’ 
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Supplementary Table 2 
ChIP Primers 
Gene Forward Primer Reverse Primer 
GAP-43 5’- CTGCGCGTAAAATCTAATGG-3’ 5’- TGGAGAGATTGGATGGAACA-3’ 
Galanin 5’- TACACCTCCGGTCCTGAGAC-3’ 5’- GGTAGGGAAGCTGCAGTCAC-3’ 
BDNF 5’- GGAGACTAGCGCCGATCTTC-3’ 5’- CGAGCCACTAGTTGCCCACA-3’ 
SCG-10 5’- AAGGAGGCTTCCAGGCTAAG-3’ 5’- GCTCAAGCAGATTGGCTCTC-3’ 
CAP-23 5'-GTCCCCCAACTTCTCTCCAC-3' 5'-GGGCGTGTAAGGAGGGAATA-3' 
Sprr1a 5'-TCCCCTAGTTCACCCTCTGA-3' 5'-AGGACCACTTCAACCCTCCT-3' 
Lgals 5'-CTGACTGGTCACCTCTGCTC-3' 5'-CAGTCAGAAGACTCCACCCGA-3' 
Chl1 5'-TGTCCCCTTTCGCGGTTTTC-3' 5'-TGAAGGCTCGATGCCCAAGT-3' 
L1cam 5'-GCTGCACCATCCACTCTCTT-3' 5'-TCACGACCATCTTGCTGTCAG-3' 
Bcl-xL 5'- CGACATCGAAAGGAAAAAGC -3' 5'-ATCGAGACATGGGAGAGCAG-3' 
NF-L 5'-CAGGGAAGTTATGGGGGTCT -3' 5'-TTATACGCCGGGACTCTGAC-3' 
HSP27 5'-TTGCTCCCCAGGAGATACAC-3' 5'-GATTCCCACTGTCGGGTTTA-3' 
ATF3 5'-GCTGGTCAAAGAAGGCACAT-3' 5'-ATCTCTCCCTCCGCTAGGTT-3' 
18S 5'-GGCCGAACCGGAAGTTATAG-3' 5'-AAGAGAGAGCGGAAGTGACG-3' 
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APPENDIX – Calculations of Nutlin-3a mass rate infusion and concentration !
 
The calculation of the concentration of Nutlin-3a to be infused daily was based on 
the manufacturer instructions, available at  
http://www.alzet.com/products/guide_to_use/formulating.html. Accordingly, the mass rate 
of drug infusion is governed mathematically by: 
 !0 = !!×!!d, 
 
where K0 = mass delivery rate (µg/hr), Q = volume delivery rate (µl/hr) of the solution from 
the pump, Cd = concentration (µg/µl) of the agent in the vehicle. Considering that for the 
osmotic pump Alzet model 2002, Lot.#10285-121, Q = 0,43 µl/hr and the mean fill volume 
is 242,8 µl (considered as 240 µl for practical purposes); taking also in account that the sol-
ubility of Nutlin-3a is 0,1 mg/ml in 1:10 ethanol:PBS (Catalog#18585, Cayman, USA), then 
the maximum Nutlin-3a mass (!) per pump is:  
 0,1!"!" = 1001000 !!!! = !240 !!!! ! 
 ! = !"!!! 
  
With 24 µg of Nutlin per pump: 
 !d = 24#!240$! = 0,1!!!/!! 
 !0 = 0,43 !!ℎ !×!0,1 !!!! = 0,043!!!/ℎ!! 
  
In 24h: 0,043 !!ℎ !×!24ℎ = !,!"#!!!/!"# !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Q and the mean fill volume vary among pumps from different production lots. To rule out variabil-
ity, I always employed the same lot of pumps for all experimental groups. 
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Having in account that the pump content diffuses into the cerebrospinal fluid (CSF) 
of the mouse, we need to consider the total volume of CSF produced daily to determine the 
concentration of Nutlin-3a that is going to be daily delivered into the CSF. According to the 
pump manufacturer, the CSF production rate in the mouse is 18 µl/h, therefore in 24 hours it 
produces a total of 432 µl. 1,032 µg of Nutlin-3a (molecular weight = 581,5 g/mol) in 432 
µl of CSF corresponds to: 
 !"#$%#&'(&)"#! !"#! = ! !"##!(!)!"#$%&! ! !×! "#$%&#'(! "#$ℎ!! !!"#  
 !"#$%#&'(&)"# = ! 0,0010320,000432!×!581,5 
 !"#$%#&'(&)"# = 0,0041! ≈ !!!! 
 
Because of the limited Nutlin-3a solubility (0,1mg/ml), the maximal concentration we 
could reach with an osmotic minipump, considered all the available models for mice that 
deliver for two weeks, was about 4 µM daily.  
Finally, considering that the concentration of Nutlin-3a in the stock solution in pure 
ethanol is 2mM, the volume of stock solution to have 24 µg of Nutlin-3a was calculated by: 
 !"#$%&! ! = ! !"##! !!"#$%#&'(&)"#! !"#! ×! "#$%&#'(! "#$ℎ!! !!"#  
 !"#$%&! = ! 0,0000240,002!×!581,5 
 !"#$%& = 0,0000206!! = !",!!!! 
 
Therefore, 20,6 µl Nutlin-3a in pure ethanol were diluted in 240 µl PBS or 8,6% eth-
anol/PBS. 
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